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Abstract
Early studies aimed at producing a reversible contraceptive for men involved
treatments with injectable testosterone esters which induce azoospermia in only a
proportion of subjects. Androgens remain a central part of any hormonal
contraceptive for men although understanding the heterogeneity of the suppression
response within populations may be pivotal and require consideration of other
hormonal regulatory systems. Development of minimally invasive, long acting
androgen formulations is also necessary to provide an acceptable, convenient and
reliable form of androgen delivery which men themselves can administer. The first
study describes a clinical trial employing a wholly subject administered, non-invasive
hormonal contraceptive regime which combined transdermal T patches with the oral
progestin desogestrel (DSG). The study shows that oral DSG combined with
transdermal T produces suppression of gonadotrophins and spermatogenesis but is
less effective than regimens incorporating injectable T and serves to further
emphasise the critical role of T delivery. Studies in animals have established prolactin
as a progonadal hormone in the testis and accessory glands. To explore the role of
prolactin in men we first investigated the localization of prolactin receptor expression
in the human testis and accessory tissues by immunohistochemistry and found it to be
localized to the Leydig cells and differentiating cells of the testis, the epithelium of
vas deferens, epididymis, prostate and seminal vesicles. Expression of prolactin
receptor mRNA was identified in human testis and vas deferens by RT-PCR.
Functional activation of prolactin receptor was demonstrated in human vas deferens
by examination of the Janus Kinase/Signal Transducer and Activator of Transcription
and Mitogen Activated Protein kinase and Extracellular signal-Regulated Kinase
signalling pathways. The demonstration of function and localization of the prolactin
receptor presented here suggests multiple roles for prolactin in the human male
reproductive tract. The final study investigated whether concomitant suppression of
PRL with the non-ergot, dopamine receptor agonist quinagolide (Q) in healthy male
volunteers , would enhance spermatogenic suppression by testosterone (T). The
results suggest that inhibition of PRL does not confer additional efficacy in spermatic
suppression by T although difficulty in consistently suppressing PRL in eugonadal
men did not allow unequivocal testing of the hypothesis. It is hoped that these studies
address some of the challenges in this area and contribute toward the ambition of a
safe, reversible contraceptive for men.
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Introduction
The female combined oral contraceptive pill is widely recognized as one of the
pivotal scientific and cultural developments of the modern era.l Developed in the
middle of last century by Gregory Pincus and Carl Djerrassi it allowed many women
to reliably control their fertility for the first time and arguably to gain fuller control
over their lives.
Developments in the sphere of human male reproductive biology have been less
marked: the most widely used male-directed methods today (condoms and vasectomy)
were developed in the 16th and 19th century respectively. However, recent estimates
indicate that some 45 million men have had a vasectomy with similar numbers using
condoms, which together with the substantial number still relying on withdrawal,
constitute at least one-third of total contraceptive usage in the world today 2 It is clear
that, despite contrary perceptions in some quarters, men are active and willing
participants in the practice of contraception, whose needs and demands are not met by
current methods.
Discussions on the subject of male hormonal contraception inevitably turn to the twin
issues of whether men would use it and whether women would trust them to. The
definitive answer will have to wait until such products are a commercial reality but
recently published data suggests support for the concept and that a market for such a
product exists 3,4. Questionnaire based surveys have been carried out to ascertain the
attitudes of both men and women to male contraception in four culturally and
economically diverse cities: Edinburgh, Cape Town, Hong Kong and Shanghai. The
principal finding of these studies was that the majority of men would look favourably
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on new hormonal methods of contraception with 44-83% adding they would
definitely or probably use a male pill. The women surveyed were similarly positive
with over 84% in the four centres agreeing that availability of a hormonal preparation
for men would facilitate sharing of responsibility for contraception.
Spermatogenic suppression following testosterone administration was first reported in
the first half of last century and administration of exogenous androgen remains a
universal feature of effective prototype regimes examined to date. Despite progress in
the half century which has passed since the first studies, a commercially available,
safe, effective, reversible hormonal contraceptive for men remains elusive.
In the review that follows, the published data in the field of male hormonal
contraception will be examined in some detail. Three recurring themes emerge:
• Finding a means of effective, sustained, non-invasive androgen
delivery
• Need for combination therapies to lower the dosage of exogenous
testosterone without compromising efficacy
• Need to improve efficacy such that treatment is consistently, reliably
and absolutely effective - with the female combined oral contraceptive
pill as the yardstick.
The following studies attempt to address one or all of these difficulties. The
consistent, reproducible finding that a cohort ofmen fail to suppress spermatogenesis
to azoopsermia in the absence of gonadotrophins challenges current concepts of
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testicular regulation in the human. Prolactin is a recognised progonadal hormone in
many animals and receptor localisation and activation is becoming more clearly
understood. In seasonal animals following experimental withdrawal of
gonadotrophins, persistent, prolactin driven testicular cycles are found suggesting a
facilitatory role for prolactin in conjunction with the established gonadotrophins FSH
and LH. Clinical data supports a similar progonadal role for prolactin in humans. It is
postulated that experimental manipulation of prolactin in conjunction with the
classical gonadotrophins will result in more effective suppression of spermatogenesis.
The following studies describe the localization and distribution of the prolactin
receptor in human male reproductive tract using histochemical and molecular biology
laboratory methods. These studies have established the presence and distribution of
the prolactin receptor in key structures in the human male reproductive tract and
provide a sound foundation for the subsequent clinical trail. The clinical trial that
followed was conducted over 18 months to explore the effects on spermatogenesis of
combining a prolactin inhibitor, quinagolide with testosterone implants: a well
established, effective method of androgen replacement in contraceptive research and
clinically proven in androgen replacement in hypogonadal men. The final study
describes a clinical trial which employs a wholly subject administered combination
contraceptive drug regimen. Transdermal androgen replacement offers the hope of
simple, non-invasive androgen replacement in combination with desogestrel - a
highly effective progestagen whose efficacy had already been established in earlier
studies where, in combination with injectable testosterone, complete azoospermia was
achieved in all subjects. If such regimes are to become a commercial and scientific
reality, they must be able to withstand the rigours of testing "in the field" with the
attendant problems of subject compliance and reliability. An effective regime will
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have tolerances in-built to allow a margin of safety i.e. that efficacy remains
uncompromised when subjects are outwith the laboratory setting and compliance may
on occasions be less than optimal. This study uses a downward dose finding regime of
desogestrel to find the minimum effective dose of progestagen in combination with
transdermal testosterone.
The following studies hope to offer novel approaches to established biological
problems in the area of male hormonal contraceptive research.
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Review of male contraception
The world's population currently stands at around 6 billion and, unless global fertility
rates are curtailed, will more than triple to 19 billion by 2100 (Population Studies,
1990). Such growth is unsustainable in natural resource terms as well as its projected
impact on issues of global poverty and pollution. This realization is a key factor
underpinning research efforts directed towards the regulation of human fertility,
which began in the second half of the twentieth century. In the last two decades this
field has enjoyed a broader perspective, with agreement through the Cairo Programme
of Action that a shift in emphasis was warranted (Cairo Programme of Action, 1994).
Thus, research efforts initially directed at the control of processes in the female were
expanded to include regulation of male fertility in general and male hormonal
contraception in particular with drug industry interest showing a parallel increase.
In order to appreciate the challenges inherent in producing an effective male hormonal
contraceptive, it is appropriate to review our understanding of the physiological
regulation of the male reproductive axis.
Physiological basis for a male hormonal contraceptive
Spermatogenesis and steroidogenesis
Spermatogenesis in the testis is dependent on intratesticular testosterone
concentrations 100-fold in excess of those in peripheral blood. Testosterone
production is activated by the action of LH from the anterior pituitary on the Leydig
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cells of the testis and acts in conjunction with pituitary FSH on the Sertoli cell to
promote normal spermatogenesis within the seminiferous tubules. FSH and LH
release is regulated by hypothalamic GnRH which is in turn regulated by negative
feedback from testosterone which also feeds back on FSH and LH at the level of the
anterior pituitary. Inhibition of both FSH and LH is mandatory to achieve maximal
suppression of spermatogenesis but the parallel fall in testosterone production results
in diminished libido, mood changes and fatigue, with decreased bone and muscle
mass and disruption to haemopoiesis as longer term effects. Androgen replacement is
thus a central component to all contraceptive regimes of this type. Exogenous
testosterone at sufficient doses provides effective suppression of FSH and LH via
classical negative feedback pathways but when such supraphysiological doses are
employed there may be unwanted extragonadal effects e.g acne, changes in libido and
excesss sebum production. The challenge for any contraceptive drug regimen is thus
to achieve a testosterone dose which will suppress gonadotrophins whilst avoid
symptoms of hypogonadism. Combination therapies may allow the simultaneous
achievement of these apparently conflicting objectives.
Testosterone mediates a number of peripheral, extra gonadal actions on bone , liver,
muscle and prostate either directly or following 5a-reduction to dihydrotestosterone
(DHT) or following aromatisation to oestradiol.
5cc-reductase
The enzyme 5a-reductase converts testosterone to DHT, a steroid with a greater
potency of action than testosterone. It is highly expressed in some peripheral tissues
such as the prostate and has been demonstrated in human testis (Payne et al., 1973,
Rivarola et al., 1973). Under normal circumstances, DHT is not thought to make a
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significant contribution to maintenance of spermatogenesis, but following
experimental suppression of endogenous testosterone by a hormonal contraceptive
regimen, conversion to DHT may become a more important factor in supporting
spermatogenesis. The enzyme has two isoforms and in the rat testis, the type 1
isoform predominates. In humans, characterization of the isoforms, and their
regulation are less clearly understood: activity and mRNA levels are said to be low
but it is thought that humans may bear the type 2 isoform (Russel et al., 1994).
Variation in suppression of spermatogenesis between and within population groups
has been ascribed to differences in 5a-reductase activity and clinical studies based on
this postulate are described later. Peripheral tissue conversion to DHT may underlie
some of the unwanted effects of exogenous testosterone therefore synthetic androgens
which do not undergo 5a-reduction may offer the advantage of fewer extra-gonadal
effects e.g. prostatic hypertrophy.
Aromatase and oestrogens
A role for oestrogen in support of spermatogenesis has begun to emerge in the last
decade. Testosterone is converted to oestradiol by the enzyme aromatase. Estrogen
receptor a (ERa) knockout mice are found to have dysfunctional seminiferous
tubules and epididymis and impaired fertility as a consequence (Lubhan et al., 1998.
Hess et al., 1997, Korach et al., 1996). Individual humans with rare mutations in the
gene coding for aromatase and for the oestrogen receptor showed similar impaired
fertility (Smith et al., 1994, Morishima et al., 1995, Carani et al., 1997). Combined
oestradiol and testosterone implants have been shown in the rat (Ewing et al., 1977)
and the monkey (Lobl et al., 1988) to very effectively suppress spermatogenesis
without affecting mating behaviour suggesting oestrogen blockade as a potential
target for contraception. Conversely, aromatisation of testosterone to oestrogen has
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also been fund to be highly important in the mediation of the feedback effect of
testosterone on FSH secretion (Hayes et al., 2000). Improved FSH negative feedback,
and consequently, spermatogenic suppression through addition of low dose oestradiol
has been demonstrated in animal studies. Similar contraceptive studies in men are
described below.
Although incomplete, our knowledge ofmale reproductive physiology has developed
significantly in recent years. In addition to the classical gonadotrophins, regulation by
other hormone systems may play an important role in the development of an effective
hormonal contraceptive for men.
Extragonadal effects ofandrogen administration
Intramuscular testosterone has been shown to produce markedly fluctuating levels of
testosterone with repeated high peaks which lead to weight gain, effects on lipid
metabolism (lowering of high-density lipoprotein-cholesterol (HDL-C)), skin
(increased sebum production leading, in some cases, to acne), liver (raised
transaminases) (Wu et al., 1996) and haemopoiesis (raised hemoglobin, red cell count,
and haematocrit) (Anderson et al., 1995). All changes proved to be transient and had
returned to normal within 3 months of discontinuing treatment. Such changes have
been reported in the great majority of studies of this kind in the last decade regardless
of the agents employed.(Wu et al., 1999)
HDL-C has an important role in removal of cholesterol to the liver and is controlled
by physiological levels of sex steroids via their effect on hepatic triglycerides lipase
activity. Low concentrations of HDL-C have been epidemiologically linked to
coronary artery disease although there is no established link between testosterone
concentrations and cardiovascular disease. (Barrett-Connor, 1999)
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SHBG concentrations also change following administration of exogenous sex steroids
showing a decline following administration of either testosterone or progestins and
may be useful as a marker of unwanted hepatic steroid effects on the liver.
(Handelsman 1992)
It is also well known that androgens are stimulators of erythropoiesis manifest by
increases in haematocrit and haemoglobin concentrations following TE
administration. (Wu et al., 1996) Antiandrogens such as CPA produce the opposite
effect. (Meriggiola et al., 1998) Clearly, the availability of improved methods for the
delivery of testosterone at doses that more closely resemble physiological values and
awareness of the extra-gonadal effects of other agents in the combination regimes
described below is crucial for the continued development of safe hormonal
contraceptives that are acceptable to healthy young men.
Male contraception
Three broad approaches to male fertility regulation are currently being pursued: (i)
interruption of sperm transport (ii) disruption of sperm maturation and/or function
and, (iii) suppression of sperm production.
Vasectomy and Condoms
Interruption of sperm transport by physical barriers such as vasectomy and condoms
or by coitus interruptus have been the mainstay of male contraceptive methods thus
far and are the contraceptive method of choice for a third of users worldwide. These
are the only two reliable methods currently available to men (condoms and
vasectomy) are based on historical practices developed from the 16th and 19th
centuries respectively. Since the 1960s, vasectomy has played an increasingly
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important role as the principal method for male contraception in men who have
completed their family. Some 45 million men are estimated to have undergone
vasectomy. The single most important advantage of the method is the very high
efficacy (1-2 failures per 1000 procedures). Complications include haematoma or
infection in 5%, recanalisation in up to 3% and sperm granulomata varying from 3 -
75%, with no reported mortality. Vasectomy has at various times been linked to
increased disease risks (atherosclerosis, diabetes, immunological disorders) but has
generally been shown to be a reassuringly safe (Nienhuis et al., 1992). Retrospective
surveys have suggested a modest increased predisposition to prostatic (Giovannuci et
al., 1993) and testicular tumours in vasectomised men in the USA. However, the
reported relationships were weak and have not been universally observed. On the
basis of current data, no changes in vasectomy practice are warranted although
ongoing prospective studies should further clarify this situation (Farley et al., 1993).
Results of vasectomy reversal are highly variable depending on the time interval since
the original procedure, the skill and experience of the operator and the type of
procedure. In general, much more favourable results are obtained with microsurgical
techniques within 2 years after vasectomy. Potential patients should expect to achieve
patency rates of 80% and pregnancy rates of 60% if reversal is within 5 years after
vasectomy. Two main factors limit the wider acceptability of surgical vasectomy: the
need for skin incisions and the uncertainty of reversibility. New techniques such as
no-scalpel vasectomy and percutaneous transluminal vas occlusion have been or are
being developed to make the procedure simpler, less invasive as well as more
predictably reversible (Xiaozhang and Sunqiang, 1993).
Barrier contraception has been employed in ancient Greece, Egypt and China in form
of animal bladder, intestines and silk paper sheaths during sexual intercourse. But in
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more recent times, it is disease prevention that promoted the use of sheath-type
barriers. The condom is the only male contraceptive method effective in protecting
against sexually transmitted diseases (STDs) and should have a pre-eminent role in
men who have multiple, short-term or irregular sexual partners. However, despite the
danger ofHIV infections, poor user compliance and low consumer acceptability have
continued to produce high failure rates and undermine the potential usefulness of
condoms. Currently available condoms made from vulcanised latex rubber are further
hampered by high slippage/breakage rates, incompatibility with oil-based lubricants,
latex allergy and limited shelf life. These factors have prompted efforts to develop
non-latex polyurethane condoms that have higher tensile strength and provide greater
transmission of heat and tactile sensations. They are less susceptible to degradation
and are unaffected by oil-based lubricants. Several polyurethane products are
currently undergoing clinical testing and some are commercially available.
Epididymal agents
The epididymis would appear to be a promising target for a contraceptive agent, by
preventing the acquisition ofmotility and fertilizing potential through disruption of
epididymal function. Loss of sperm motility through interference with energy
metabolism, or disruption of sperm surface protein chemistry causing impaired
sperm-ovum binding, acrosome reaction and fertilizing capacity are all possible
modes of action for prototype contraceptive drugs.
A few compounds which inhibit the oxidative metabolism of spermatozoa, and hence
inhibit motility, have been evaluated. a-Chlorohydrin and 6-chloro-6-deoxyglucose
are metabolised to 3-chlorolactaldehdye, a compound with the same stereochemistry
as R-glyceraldehyde - a key substrate in the glycolytic pathway. Administration of
these compounds results in competitive inhibition of the key enzyme, glyceraldehyde-
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3-phosphate dehydrogenase, and glycolysis (and therefore sperm motility) is
inhibited.
Evaluation of these and other novel compounds as potential post-testicular
contraceptive agents in rats and mice remains an active area of enquiry. (Bone et al.,
2002, Jones et al., 2002, Cooper 2001). However, given the effects on a core
biochemical process (i.e. glycolysis), many of these compounds have serious systemic
side effects, particularly on the nervous system and bone marrow which may limit
further exploration of their contraceptive potential in humans (Ford and Waites 1986).
The antifungal agent ketoconazole is known to accumulate in seminal plasma and
inhibit sperm motility post-ejaculation. This property has been ascribed to the
imidazole ring structure in ketoconazole and consequently, a variety of substituted
imidazole compounds were evaluated as orally-administered, rather than topical,
inhibitors of sperm motility (Vickery et al., 1986). There have been no studies using
these compounds reported in the last decade.
Nitroimidazole derivatives, often used as antibiotics and anti-protozoan treatments
suppress fertility by inhibiting sperm maturation in the epididymis though once again,
its broad side-effect profile makes long-term use in contraception impractical
(Nieschlag et al., 1997).
Hormonal Methods
Hormonal methods of suppressing spermatogenesis have shown the most promise as
adjuncts to existing barrier based methods and merit review in detail.
Injectable androgen-only regimes and alternative androgen delivery
methods
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From studies in the 1970's it was found that supraphysiological doses of testosterone
alone can consistently and reliably suppress spermatogenesis to azoospermia in 40 to
70% of Caucasian males (Schearer et ah, 1978). The most effective regimen was
intramuscular testosterone enanthate (TE), 200 mg weekly. This was chosen as the
prototype candidate for subsequent male hormonal contraceptive trials because of its
well-documented safety over many years in the treatment of hypogonadal men,
despite its suboptimal pharmacokinetics.
Testosterone enanthate
Between 1986 and 1990, the first ever study to examine the contraceptive efficacy of
testosterone-induced azoospermia was conducted by the World Health Organization
(WHO) in 271 healthy volunteers in 7 countries using TE, at a dose of 200 mg weekly
(WHO, 1990). There were 157 men who achieved azoospermia, and these men
entered the 12-month efficacy phase, in which the weekly testosterone injections were
the only form of contraception used. Only 1 pregnancy occurred during the 1486
months of exposure, giving a Pearl rate of 0.8 (95% CI 0.02 to 4.5). This established
that hormonal suppression to azoospermia yielded an efficacy rate comparable to
female injectables, slightly better than female oral contraception and substantially
better than the condom.
While azoospermia has been confirmed to be the logical target for inducing infertility,
a substantial minority ofmen remained oligospermic despite maximal sex steroid
suppression. It is interesting to note that even when men are severely oligospermic,
the remaining sperm are functionally normal (Wang et ah, 1997).
A second WHO trial was conducted to investigate the contraceptive efficacy of TE-
induced oligospermia (WHO, 1995). In this study, 349 out of 358 (98%) healthy men
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in 9 countries were suppressed to azoospermia or oligospermia (< 5xl06/ml) using TE
at 200 mg i.m, weekly. They accumulated 283.5 years of exposure during which there
were 9 pregnancies. It became clear that pregnancy was related to sperm
concentrations below 5xl06/ml, which enabled a threshold sperm density of below
3xl06/ml to be identified, above which the failure rate was deemed unacceptably high
compared to existing reversible contraceptive methods. Thus a total of 4 pregnancies
during 49.5 years of exposure contributed by men with sperm densities between 0.1
and 3xl06/ml yielded a Pearl rate of 8.1 (2.2 to 20.7 per 100 person years). This study
yielded a Pearl rate for the method as a whole of 1.4 per 100 person years for those
men with sperm densities below 3xl06/ml (i.e., azoospermia to 3xl06/ml) which is
comparable with the failure rate of current female reversible contraceptives
(combined pill, injectables and medicated intrauterine devices) and is superior to the
condom (12 per 100 person years).
These trials became the benchmark against which future contraceptive studies may be
compared.
Testosterone implants
Testosterone implants are small cylindrical pellets of crystalline testosterone which
are implanted surgically, usually under local anesthesia, into the subcutaneous fat of
the anterior abdominal wall. This form of T delivery was the earliest means of
providing effective, long lasting steroid replacement in hypogonadal men and have
been in use since the 1950's. Kinetics approximate to first-order release, yielding 0.65
mg/day for 100 mg pellets and 1.5 mg/day for 200 mg pellets, with near complete
bioavailability (Handelsman et al., 1990). A 600 mg dose of implants will give
physiological replacement over a period of 4 to 6 months (Cantrill et al., 1984,
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Conway et al., 1988). However, a supraphysiological dose of 1200 mg is required to
produce azoospermia in 65% ofmen although fewer androgenic side-effects than
weekly injections of TE were reported (Handelsman et al., 1992). Implants are
relatively inexpensive to produce and despite the fact that a minor surgical procedure
is required, this is a popular method of androgen replacement although the method is
complicated by an extrusion rate of around 7% which in recent studies remains
unchanged by presoaking with antibiotics or varying insertion trajectory (Kelleher et
al., 2001, Kelleher et al., 2002).
Testosterone buciclate
Testosterone-17p-trans-4-n-butyl-cyclohexylcarboxylate (testosterone buciclate) is a
long-acting ester of testosterone developed jointly by the WHO and the National
Institute for Child Health and Human Development, USA, for specific use as a male
contraceptive. The ester is formulated as finely milled crystals (10 to 15 jam particle
size) and is administered as an aqueous suspension by i.m injection. Single-dose
injections of 600 mg and 1000 mg raised plasma testosterone in hypogonadal men
into the low/normal range and maintained a stable concentration for 16 and 20 weeks
respectively (Behre et al., 1992). A single dose of 1200 mg testosterone buciclate
produced azoospermia in 3 out of 8 volunteers whose plasma testosterone levels
remained within the normal range (Behre et al., 1995). At the time ofwriting it is
unavailable due to persistent formulation difficulties.
Testosterone undecanoate (TU)
TU has a long aliphatic side chain, which increases its lipid solubility. It was initially
formulated as a capsule in arachis oil which facilitates oral absorption (vide infra). In
a castor oil or tea seed oil base, it may be given intramuscularly, and has been shown
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to have a significantly longer half-life (f/2) than TE (Partsch et al., 1995). These
initial studies in orchidectomized monkeys have more recently been extended to
androgen replacement in hypogonadal men (Zhang et al 1998). TU kinetics show both
a long duration of effectiveness (up to 8 weeks from a single i.m injection of 1000
mg), plus the absence of the initial supraphysiological peak seen with TE, thereby
reducing the likelihood of androgenic side-effects.
In a clinical study in China, 11 out of 12 volunteers became azoospermic after
receiving TU injections at a dose of 500mg every 4 weeks with all 12 subjects
achieving azoospermia at the higher dose of 1000mg/4weekly (Zhang et al., 1999).
Increasing the dosage interval to 6 weeks in a recent study in Caucasians receiving
1000mg/6weekly resulted in poorer rates of azoospermia (Kamiscke et al., 2001).
However the same authors, employing TU in combination with long acting injectable
progestin NET enanthate, found 13 out of 14 subjects became azoospermic with the
remaining subject suppressing to a sperm concentration of less than 1 million/ml
(Kamischke et al., 2002).
Methyl-nortestosterone
7a-methyl-19-nortestosterone (MENT) is a highly potent synthetic androgen which,
like testosterone, is a free steroid rather than an ester and consequently is usually
formulated as a subdermal implant. MENT is not 5a-reduced to dihydrotestosterone
(DHT), and in the rat has been found to be 12-fold more potent than testosterone in
suppression of gonadotrophins, whilst it is 4-fold more potent in the maintenance of
prostate and seminal vesicle weight and 10-fold more potent in maintaining muscle
weights (Kumar et al., 1992). It is resistant to 5a-reduction but aromatises to
oestrogen (Kumar et al., 1992, Lamorte et al., 1994). As a result of its increased
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potency and tissue selectivity, this compound has, theoretically, the potential
advantage of being able to suppress gonadotrophin production and maintain adult
sexual function and muscle mass at relatively low doses that would not stimulate the
prostate (Sundaram et ah,1993).
Recent studies in non-human primates have been encouraging in this respect: MENT
was found to be 10-fold more potent than testosterone in the suppression of
gonadotrophins but only twice as potent in stimulating prostate growth (Cummings et
al., 1998). However, it was also found to be 10-fold more potent than testosterone in
its effects on lipids, causing decreases in both HDL-C and total cholesterol. Phase I
pharmacokinetic studies in healthy men using micronized MENT (2 to 8 mg), given
as a single i.rn injection have recently been completed showing effective suppression
of gonadotrophins without reported side-effects (Suvisaari et al., 1997). MENT
acetate implants in healthy men have resulted in dose dependent suppression of
gonadotrophins and testosterone (Noe et al., 1999). Dose-finding contraceptive studies
with MENT in men have recently been reported using implants left in situ for 180
days. Rates of azoospermia using 4 x 135mg MENT acetate implants alone are
comparable with those obtained for weekly TE injections or 6-weekly TU injections
(von Eckardstein et al., 2001). These implants may prove useful as part of a future
combination regimen.
19-Nortestosterone (19-NT)
19-NT (See Fig 1) or nandrolone, is one of a group of non-aromatisable anabolic
steroids which have been in clinical use for over 30 years. Given that 19-NT
possesses a higher affinity for the androgen receptor and is 10-fold more
progestagen^ than testosterone, it is a potentially attractive antifertility drug, either as
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a single agent or in combination with another progestagen. 19-NT alone (Knuth et al.,
1985) or in combination with depot of the progestagen medroxy-progesterone acetate
(Knuth et al., 1989) induced suppression of gonadotrophins and testosterone for 12
weeks and achieved azoospermia in 6 and 8 out of 12 volunteers, respectively. 19-NT
may, therefore, have a role as a single-agent contraceptive, providing it is able to
maintain essential androgen-dependent functions without producing undesirable
metabolic, prostatic and behavioral effects which have not been studied to date.
Reports of its action in combination with GnRH antagonists are described later.
Table 1 below summarises and evaluates the androgens described thus far.
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Tabic 1: Evaluation of commonly used androgens in male contraception
Androgen Advantages Disadvantages
Testosterone enanthate Effective suppression of
gonadotrophins.
Moderately high rates of
azoospermia when given
alone.
Short acting. High peak
levels and extragonadal
effects e.g. on lipids








Testosterone undecanoate Longer half-life than TE.
Lower post injection peaks
than TE (fewer androgenic
side effects)
Ester given by injection.
Poor oral bioavailability.
19-NT Established use for 30
years in hypogonadal men.
Eligher affinity for T
receptor than T itself.
Progestational properties
may be useful in
contraception.
Optimal suppression lasts
less than 12 weeks.
MENT Free steroid not subject to
5oc-reduction. 12 times




Aromatises to oestrogen -
may be beneficial in
contraceptive regimes.
Potent adverse effects on
lipids.
Testosterone implants Good pharmacokinetics.






still too short (12 weeks).
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Other androgen delivery Systems
Transdermal testosterone
Delivery of testosterone via the transdermal route is a more recent development.
Compared to transdermal estrogen delivery in female hormone replacement therapy
which requires 50 to 100 pg of steroid daily, much higher amounts - around 3 to 10
mg of testosterone - are required to maintain androgen-dependent physical functions.
The rich vascular network of the scrotal skin is particularly suited to rapid drug
absorption and is able to facilitate the increased delivery of steroid required (Sitruke-
Ware et al., 1989).
Scrotal Systems
This method was initially employed in the treatment of hypogonadal men using
Testoderm - testosterone transdermal system (TTS, ALZA Corporation, Palo Alto,
California, USA) (Place et al., 1990). This system contains testosterone incorporated
in a layer of self-adhering ethylene vinyl acetate co-polymer with a soft flexible
bonded polyester backing which is applied to shaved scrotal skin and proximal penile
shaft and worn for 22 h before it is replaced. Two sizes are available delivering 2.4
mg and 3.6 mg testosterone per day, which allows testosterone levels to be maintained
in the adult physiological range over a 24 h period without fluctuations outside this
normal range, representing an improvement over injectable testosterone. DHT levels
in these patients are elevated - up to three times the normal range, yielding a
DHT/testosterone ratio of 0.5 (normal range 0.1 to 0.2) which is a reflection of the
rich 5a-reductase activity within scrotal skin. The consequences regarding unwanted
effects on DHT-dependent tissues are not yet known.
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Non-Scrotal Systems
More recently, non-scrotal transdermal delivery systems have been developed for use
in androgen replacement therapy in hypogonadal men (Miekle et ah, 1998).
Androderm Testosterone Transdermal Systems (SmithKline Beecham) is one such
system containing testosterone in a permeation-enhancing vehicle composed ofwater,
ethyl alcohol, glycerine, glycerol mono-oleate, methyl laurate and pharmaceutical
gelling agents (Miekle et al., 1992). Two types of system are available, delivering 2.5
mg or 5 mg of testosterone. For adult hypogonadal men, 2 of the lower strength
patches or 1 of the higher strength provides adequate androgen replacement without
alteration of the DHT/testosterone ratio. Flowever, the alcoholic excipients employed
have caused considerable problems. A recent study reported adverse effects in 84% of
hypogonadal men receiving androgen replacement by this method, most commonly
dermatological problems and of these, 72% elected to return to injected depot
preparations (Parker et al., 1999). This system, marketed as Andropatch in Europe,
has been recently evaluated as part of a contraceptive study (Hair et al., 2001) and
will be described in detail in this thesis.
A similar study in Europe using LNG has also been reported with broadly similar
findings (Buchter et al.,1999). Other systems producing a more physiological,
pulsatile release of testosterone are under development (Misra et al., 1997).
A hydroalcoholic gel containing a 2.5% solution of 5a-DHT (Andractim, Besins
Iscovesco, France) is currently in use in Europe for androgen replacement. If applied
over a sufficiently large surface area, e.g., chest and abdomen, adequate androgen
substitution is achieved (Sitruk-Ware et al., 1989). Phase 1 trials of a 2.5%
testosterone gel have very recently been reported with satisfactory replacement after
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daily application of only 5g of gel and may find later use in contraceptive studies
(Rolf et al., 2002).
Testosterone microspheres
Testosterone encapsulated into biodegradable polylactide-glycolide co-polymer
microspheres can be administered as a depot injection, yielding a biphasic pattern of
testosterone release over 11 weeks (Burris et al., 1998). By varying the particle size, a
second-generation microsphere system containing 315 mg testosterone has recently
been shown to provide approximately zero-order testosterone release at physiological
levels for 70 days (Bahsin et al., 1992). Recent animal studies have confirmed that the
microspheres are completely degraded in this particular study after a period of 10
weeks (Kobayashi et al., 1998). There have been no recent developments employing
this approach in human subjects.
Orally-active testosterone
Orally administered free testosterone is efficiently absorbed from the intestine but
undergoes virtually complete hepatic first-pass metabolism. Avoiding first-pass
metabolism, orally administered TU (see above) is absorbed into lymph and enters the
thoracic duct and thence to the systemic circulation via the subclavian vein. TU (40
mg) dissolved in arachis oil (Restandol, Organon NV) is available in capsule form.
However, its variable reabsorption coupled with a short ti/2 and duration of action
requires that patients take two to four capsules per day to achieve adequate androgen
substitution (Schaison et al., 1998).Testosterone complexed with an oligosaccharide
ring can, when administered sublingually, give rise to short-lived (2 h) peaks in
testosterone. However, once again, multiple (3-times/daily) administrations are
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required for adequate androgen replacement and this will limit their practical use
(Salehian et al., 1994).
Inhaled preparations
Using a new type of aerosol characterized by particles of small mass and large size, it
has been shown (Edwards et ah, 1997) that inhalation of such particles complexed
with testosterone yielded high systemic bioavailability of the hormone and avoids
first-pass metabolism. This system offers a potential non-invasive means of androgen
replacement as part of a hormonal contraceptive regime though, as yet, no such
studies have been reported.
Combined hormonal regimes
Experience with androgen-only regimes indicates that supraphysiological levels of
testosterone are required for maximal suppression of gonadotrophins. Due to the
direct stimulatory action of testosterone on spermatogenesis, especially at high doses,
the ability of these regimes to suppress spermatogenesis remains sub-optimal. Dose-
dependent, androgen-related side effects already described, provide further impetus to
lower the testosterone content of future male contraceptives. In addition, until
unequivocal long-term safety data is available with regard to the effect of testosterone
on conditions such as benign and malignant disease of the prostate, cardiovascular
disease and behavioral disturbance, it seems prudent to pursue alternative regimens
which mimic physiological levels as closely as possible. Combination regimes have
been examined with the dual objectives of improving efficacy and lowering the dose
of testosterone or androgen required to minimize extra-gonadal steroid effects.
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Progestogen and androgen combinations
Progestogens are potent inhibitors of gonadotrophin secretion in men (Kjeld et al.,
1979) and may also directly suppress spermatogenesis (Goldzieher et al 1984). By
acting synergistically or additively with androgens they permit lower doses of each
steroid to be used. Synthetic steroids such as levonorgestrel (LNG), desogestrel,
gestodene and norgestimate and medroxyprogesterone acetate (DMPA) are highly
potent progestational compounds that are effective in microgram quantities with only
moderate androgenic properties. Structural modification of the parent molecules from
which they are derived namely, 19-nortestosterone and 17-hydroxyprogesterone, has
allowed the development of these orally active hormones. The comparatively low
mass of drug required has also allowed the successful development of long-acting
subdermal implants such as Norplant (levonorgestrel, Wyeth) and Implanon (3-
ketodesogestrel, Organon NV).
DMPA and testosterone
A single depot injection of the progestin DMPA, in combination with testosterone
(800 mg) implants (Handelsman et al., 1996) showed that the addition of the DMPA
markedly increased the rate of azoospermia compared to testosterone alone although
did not reduce the time course over which this was achieved. Indonesian men
receiving DMPA combined with testosterone undecanoate injections showed rates of
azoospermia of 80% compared with 0% in the testosterone alone group (Moeloek et
al., 2001).
LNG and testosterone
Initial studies using LNG (Foegh et al., 1980) in combination with subreplacement
doses of testosterone produced results that did not improve on those expected for
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androgen alone. Similar results were obtained using DMPA (Schearer et al., 1978),
danazol (Skoglund et al., 1973) and Norethisterone (Soufir et al., 1983).
Later studies are more encouraging; Bebb reports a study (Bebb et al., 1996) in which
volunteers received 500 jug LNG in combination with higher doses of TE (100
mg/week). With this regime they found significantly greater and faster suppression of
spermatogenesis than with the same dose of testosterone alone. However, HDL-C
levels were significantly reduced in those patients receiving LNG plus testosterone
though not in the control group receiving androgen alone.
Combining LNG implants (Norplant II) with transdermal T patches (lOmg/day)
yielded poor results with only 35% of subjects achieving azoospermia compared to
93% when the implants were combined with lOOmg weekly TE injections (Gonzalo et
al., 2002). Poor results have also been reported in a dose study finding using up to
four LNG implants with transdermal DHT gel with none of the subjects achieving
azoospermia (Pollanen et al., 2001). These studies confirm our earlier findings that, as
yet, transdermal T delivery is not sufficiently effective for contraception regardless of
the progestin with which it is combined.
Desogestrel and testosterone
Studies have recently been completed showing oral desogestrel (DSG) (300 pg/day)
in combination with low-dose testosterone (50 mg/weekly i.m injection) provides
effective suppression of gonadotrophins and rates of spermatogenesis superior to
androgen only regimes and earlier studies using progestin/androgen combinations
(Wu et al., 1999). The rate of azoospermia for this regime (100% in the above
treatment group) also compares very favourably with more recent studies using
progestin/androgen combinations, described above: LNG (67% azoospermia) (Bebb
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et al., 1996); and, DMPA (90%) (Handelsman et al., 1996). As with LNG, there was a
significant reduction in HDL-C levels in those patients receiving desogestrel. It
remains to be seen whether employing lower doses of desogestrel or newer
progestagens can minimize these lipid effects without compromising contraceptive
efficacy.
A novel feature of this study was the phased treatment regimen in which testosterone
treatment was initiated after 3 weeks of pre-treatment using desogestrel alone. By
virtue of the phased introduction of androgen the authors were able to demonstrate the
relative contributions made by each drug to suppression of spermatogenesis and
gonadotrophins.
Interestingly, it was found that desogestrel alone, even at maximal dose, suppressed
the hypothalamo-pituitary-testicular axis only partially and that the addition of
testosterone was crucial in achieving maximal suppression. This demonstrates that
testosterone is not only essential for maintenance of androgen-dependent
physiological functions but also to achieve optimal suppression of gonadotrophins.
Two recent studies in Edinburgh have further evaluated the DSG/T combination. In
the first, subjects received implants containing etonogestrel (the active metabolite of
DSG) in combination with 400mg T implants (Anderson et al., 2002). Thirteen of the
fourteen subjects displayed suppressed sperm concentrations to less than
0.1million/ml with 75% of the group achieving azoospermia. The second study
evaluated oral DSG at a dose of 150pg or 300pg in combination with 400mg T
implants administered at 12 week intervals for 24 weeks (Kinniburgh et al., 2002).
Azoospermia was achieved by all subjects in the higher dose DSG group. A large (but
not complete) cohort ofmen in 150pg DSG group also attained azoospermia and were
recruited to a extended treatment arm of the study lasting a further 24 weeks. All
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subjects who completed the treatment remained azoospermic until they discontinued
the study medication. These results are encouraging insofar as they demonstrate
effective long term suppression of spermatogenesis but both studies are still
confounded by marked heterogeneity of response within the subject groups.
The combination studies reviewed thus far have employed a number of permutations
with respect to progestagen, androgen and modes of delivery. Table 2 overleaf
summarises the principal studies and suggests desogestrel as optimal progestagen.
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Table 2: Summary of androgen/progestin combinations employed in recently
published male contraceptive studies and reported rates of azoospermia.







Wu et al.,1999. Daily oral DSG and weekly 100% (300pg DSG +TE
injected TE 50mg)
Kinniburgh et al., 2002 Daily oral DSG and 12- 100% (300pg DSG+400mg
weekly T implants T)
Elair et al., 2001 Daily oral DSG and daily 57% (300pg DSG+5mg T)
transdermal T patches.
Anderson et al., 2002 Once only ENG implants 75% (136mg ENG +400mg
and T implants T)
* These rates are for individual treatment arms of each study and not the overall rates
of azoospermia for the study as a whole
Abbreviations: T testosterone, TE testosterone enanthate, TU Testosterone
undecanoate, DE1T dihydrotestosterone, DSG desogestrel, ENG etonogestrel, DMPA
depot medroxyprogesterone acetate, LNG levonorgestrel, NET norethisterone.
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Table 2: Continued.









Buchter et al., 1999 Oral LNG daily and daily 18% (T 5mg+LNG 500mg)
transdermal T patches




Gonzalo et al., 2002 Once only LNG implants
and weekly TE injections
93% (Norplant II+TE
lOOmg)




Abbreviations: T testosterone, TE testosterone enanthate, TU Testosterone
undecanoate, DHT dihydrotestosterone, DSG desogestrel, ENG etonogestrel, DMPA
depot medroxyprogesterone acetate, LNG levonorgestrel, NET norethisterone
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Other combined contraceptive regimens
As well as androgen/progestin combinations, a number of other combined steroid and
non-steroid regimens have been evaluated.
Anti-androgen/androgen combination
Cyproterone acetate (CPA) is a synthetic steroid which blocks testosterone effects on
the testis, through competitive binding at the androgen receptor, as well as
suppressing gonadotrophin production by the pituitary. It has been used in Europe for
the treatment of hirsuitism in females (Dianette, Schering) and prostatic malignancy
in males (Cyprostat, Schering). When CPA alone is orally administered to men in
doses from 5 mg to 20 mg daily, disruption of sperm motility and morphology occurs,
but with associated symptoms of androgen deficiency (Wang et al., 1980, Foegh et al.,
1979, Roy et al., 1976, Molz et al., 1980). More recent studies have combined low-
dose CPA with androgen supplementation to good effect (Merrigiola et al., 1996).
Initial studies employed a regime of CPA (50 or 100 mg/day) and weekly injections
of TE (100 mg/week), which caused complete azoospermia in the small number of
volunteers treated with either dose of CPA. In a more recent study by the same group,
an oral regime was employed for the first time (Merrigiola et al., 1997). Using a lower
dose of oral CPA (25 mg/day) in combination with oral capsules of TU (160 mg/day),
however, produced much lower rates of azoospermia (only 12.5% of subjects). Also
of note is the significant decrease in haemoglobin and haematocrit seen in subjects
treated with CPA in all studies so far reported, which in the long-term may produce
anaemia. It remains to be seen whether lower doses of CPA may elicit the desired




In man, the counterbalancing effects of small amounts of estrogens on lipid and bone
metabolism as well as on improved gonadotrophin suppression may, theoretically,
produce an ideal formulation for the suppression of spermatogenesis. Such studies
have recently been reported evaluating a combination of implants of oestradiol and
testosterone in men (Handelsman et ah, 2000). Whilst oestradiol was indeed found to
augment the suppressive qualities of testosterone, the narrow therapeutic index and
dose limiting side effects of oestrogen as well as safety concerns regarding
thromboembolism make it highly unlikely that such regimes will have a practical
future.
5a-Reductase inhibitor/steroid regimes
The enzyme 5a-reductase converts testosterone to DHT, a steroid, which, in some
tissues exhibits a greater potency than testosterone, e.g., prostate, seminal vesicles,
and hair follicles. Within-group variation in 5a~reductase (described below) activity
was thought to account for the incomplete suppression of spermatogenesis in some
individuals via residual DHT activity. Studies to evaluate the effects of the (type 2)
5a-reductase inhibitor finasteride (Merck & Co) in conjunction with
androgen/progestins however showed no enhancement of the rate of spermatogenesis
in the finasteride group (Kinniburgh et ah, 2001). Similarly disappointing results
have also been reported in men receiving testosterone implants and finasteride raising
doubts over the extent to which 5a-reductase supports spermatogenesis in man
(Mclachlan et ah, 2000). A fuller understanding of the 5a-reductase isoforms and
their regulation in men may yet lead to improved suppression, perhaps through the use
of specific type 1 inhibitors.
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Gonadotrophin-releasing hormone (GnRH) agonists
Abolition of gonadotropin secretion and therefore of spermatogenesis can be
produced by GnRH agonists. They achieve this by down regulation of pituitary GnRH
receptors and have the advantage that this is a highly specific action, thereby
eliminating unwanted actions on metabolism, haemostasis, and the cardiovascular
system.
A number of studies have explored the potential ofGnRH agonists in suppressing
sperm production (Cummings et al., 1994). In total, only 23% of subjects achieved
azoospermia. These results are clearly disappointing, although it may be argued that
the dose of agonist employed was not adequate or that there may have been
persistence (or escape) of FSH activity during GnRH agonist suppression (Pavlou et
al., 1988, Santen et al., 1984). The GnRH agonist leuprolide has recently been found
to produce effective reversible azoospermia in dogs (Inaba et al., 1996) though as yet,
no human studies have been reported. Further studies are required to more fully
evaluate the true potential ofGnRH agonists.
GnRH antagonists
These are capable of reversibly suppressing gonadotrophins completely and rapidly
(Bagatell et al., 1989). They have higher affinity and slower dissociation rates than
either GnRH itself or any of the GnRH agonists (Heber et al., 1982, Pavlou et al.,
1989). The principal drawback of GnRH antagonists is low potency, necessitating
milligram amounts to be administered systemically via complex delivery systems and
low oral bioavailability (Pavlou et al., 1991). Given that most are produced by
substitution of the natural decapeptide with unnatural, synthetic amino acids (Karten
et al., 1986), they are also extremely expensive to produce, have low solubility and
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are difficult to formulate, which currently limits their potential for large-scale clinical
trials. Despite these constraints, the effects of daily, subcutaneous injections ofNal-
Glu GnRH antagonist given in combination with weekly injections of low-dose TE
(50 mg i.m/weekly) were examined in men and showed greater suppression of
gonadotrophins than with T alone (Bagatell et al., 1995, Tom et al., 1992).
More recent studies using the same antagonist showed that azoospermia was achieved
more rapidly and at higher incidence than TE alone (Swerdloff et al., 1998). In
addition, having suppressed spermatogenesis during the combination induction phase,
it remained suppressed when maintenance treatment of TE alone (100 mg/week) was
continued. This reduction of lag time between treatment and response addresses
criticisms of earlier regimes in which maximal suppression of spermatogenesis took
up to 3 months to achieve.
Combining the novel GnREl antagonist Cetrorelix with the androgenic steroid 19-
Nortestosterone produced azoospermia in all subjects over the 3 month period of
combination therapy but was not sustained by 19 NT alone following cessation of the
Cetrorelix (Behre et al., 2001). Future developments in pharmaceutical technology
may allow more economical production of these compounds as well as orally active
non-peptide GnRH antagonists, making them more attractive prospects for use in
male fertility regulation.
Selective FSH suppression
Selective action against gonadotrophins has been explored but with disappointing
results.
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Monkey studies in which inhibition of FSH alone (achieved by raising antibodies
against FSH) causes reduction in sperm concentration but not azoospermia (Nieschlag
1985). Further evidence may be found in studies ofmen with mutations of FSH
receptors. The authors report that although sperm production was quantitatively
impaired, absence of FSH activity in these men did not abolish spermatogenesis
(Tapanainen et al., 1997). Accordingly, peptides such as inhibin and follistatin, which
selectively suppress FSH production, are not considered promising candidates as male
contraceptives.
Heterogeneity of response to hormonal suppression of
spermatogenesis
A striking finding from the studies described thus far is the marked difference both
between and within population groups in the degree of steroid-induced suppression of
spermatogenesis.
Variation between population groups
One of the surprising findings from the WHO trials was that Asian (Chinese,
Indonesian and Thai) men showed a consistently higher rate of spermatogenic
suppression (89.9%) when compared with European or American (74.3%) men (p <
0.001) [30], Given the much greater efficacy of testosterone-alone regimes in these
countries, the national authorities of China, Indonesia and India have initiated large-
scale phase III trials evaluating testosterone as a single-agent contraceptive. The
source of this heterogeneity has been extensively investigated, though the underlying
reasons remain unclear. Characteristics such as body size, mass, serum biochemistry,
as well as baseline endocrine and semen parameters do not explain the observed
differences (Handelsman et al., 1995).
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A recent study examining the comparative rates of androgen production and
metabolism in Caucasian and Chinese subjects showed increased levels of 5a-reduced
metabolites in Caucasians (Santner et ah, 1998). However, this was not found to be
due to a difference in 5a-reductase activity or testosterone to dihydrotestosterone
conversion ratios in the two groups. The study did show, however, raised levels of
androgenic steroid precursors, which serve as substrates for these metabolites in the
Caucasian group, and interestingly, in Chinese men resident in the USA. The authors
postulate that this is indicative of an environmental or dietary origin to these
population differences. Differences in the gonadotrophin negative feedback response
to exogenous testosterone in Asian and Caucasian men have also been reported
(Wang et ah, 1998).
Differences in testicular structure between Asian men and Caucasians have also been
observed (Johnson et ah, 1998). Histological examination of testes taken from post¬
mortem examination of previously healthy Asian males dying from sudden traumatic
injury has demonstrated that Asian males have fewer spermatogonia, smaller diameter
seminiferous tubules and fewer Sertoli cells per man than do Caucasians. This
variation in testicular structure results in differences in spermatogenic potential
between the two groups, and is tendered by the authors as a potential explanation as to
why Asian men exhibit more complete suppression of testicular function in response
to exogenous testosterone administration.
Recent studies in African men have also yielded interesting results with one treatment
group (n=18) who received oral DSG plus T implants for a whole year achieving
azoospermia in all subjects suggesting perhaps enhanced efficacy in African males
(Anderson et ah, 2002).
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Variation within population groups
It is known that supraphysiological doses of testosterone induce rates of azoospermia
ranging from 40% to 70% in Caucasian men, with the remainder becoming
oligospermic (WHO 1990). The reasons for this variation in spermatogenic
suppression are not entirely understood although it has been shown recently that it is
not accounted for in differences or daily fluctuations in gonadotrophins or circulating
testosterone concentrations (Amory et al., 2001). It is thought by many that a fuller
understanding of this variation is a key step towards perfecting male hormonal
contraceptive regimens.
Earlier studies have shown that men who become oligospermic during testosterone
treatment exhibit a higher 5<x-reductase activity than those who develop azoospermia
which may cause altered intratesticular androgen levels (Anderson et al., 1996). This
higher residual androgenic action on the seminiferous tubules may cause resistance to
complete suppression of spermatogenesis although the apparent failure of the
combined steroid/5a-reductase inhibitor studies (vide supra) suggests a more complex
relationship.
Other studies report the histological evaluation of the effects of testosterone treatment
on spermatogenesis using open testicular biopsy material from healthy males awaiting
vasectomy pre-treated with weekly doses of intramuscular testosterone enanthate TE
(Zhengwei et al., 1998). This study demonstrates that the most consistent lesion
induced by TE treatment was in the reduction in formation of type B spermatogonia -
the germ cells that enter meiosis. Studies in the rat support the view that the
development ofA to B spermatogonia is androgen dependent and can be impaired by
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a 5a-reductase inhibitor and that the extent of 5a reduction may be an important
determinant of the extent of spermatogenic suppression induced by exogenous
testosterone based contraceptives (O'Donnel et al., 1999). Studies from the same
group comprehensively assessed a group men awaiting vasectomy who received an
experimental hormonal contraceptive regimen (testosterone ± DMPA). These
subjects provide a very useful experimental model offering the opportunity of detailed
histological evaluation of cellular responses from testicular biopsy material taken
prior to vasectomy, analysis of intratesticular hormone levels from testis homogenates
as well as established parameters such as sperm concentration in the ejaculate and
peripheral blood hormone measurements.
Recently published data demonstrated more rapid onset of gonadotrophin secretion in
subjects treated with T+DMPA than those with T alone with a more marked
impairment of spermatogonial development although germ cell numbers and sperm
count did not differ. (McLachlan et al., 2002). Testicular DHT and androstendione
levels were maintained despite markedly reduced levels of T, FSH and LH. The
authors postulate up-regulation of 5a-reductase activity and the mechanism and inter-
subject differences in this ability as a possible determinant of the differential response
to contraceptive regimens.
Despite disappointing results from clinical studies using 5a-reductase inhibitors, these
recent data suggest that 5a-reductase and variations in its activity play an important
role in within (and perhaps between) group variation. A fuller understanding of the
distribution of the isoforms of this enzyme and careful choice of appropriate inhibitors
may yet resolve this issue although very recently published animal data from
independent groups challenges the concept. Both studies, performed in cynomolgus
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monkeys contend that variation in T induced inhibition of spermatogenesis is more
closely related to FSH suppression than to intratesticular androgen and, by
implication, intratesticular 5a-reductase activity (Weinbauer et al., 2001, Narula et
al.,2002). A re-evaluation of FSH suppression in human contraceptive studies may
help to resolve this issue.
Genetic polymorphism of the androgen receptor has also been recently postulated as a
source of heterogeneity in population response although once again, there does not
appear to be a consensus view. Initial studies reported that CAG repeat length in the
androgen receptor (RNA) correlates inversely with sperm concentrations and that this
polymorphism may contribute to the efficiency of spermatogenesis and by
implication, the ease of its suppression in normal men (Von Eckardstein et al., 2001,
Von Eckardstein et al., 2002 ). More recent studies challenge this view citing data
from infertile men and fertile controls in which no relationship between CAG repeat
length and fertility was shown. These authors further cite retrospective analysis from
published European studies in over 600 men in support of their hypothesis (Rajpert-de
Meyts et al., 2002). As yet, there are no published data linking such polymorphism to
responder/non-responder status in contraceptive studies.
Conclusions
These studies show that experimental suppression of human spermatogenesis to
achieve effective contraception is a reality though several problems persist.
Exogenous androgen administration remains central to all effective regimes examined
thus far. Clearly, development of minimally invasive, long acting formulations is
necessary to provide an acceptable, convenient and reliable form of androgen delivery
which, ideally, should be self- administered. Understanding the heterogeneity of the
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suppression response between and within populations is pivotal to the development of
an effective contraceptive and may require changes to the orthodox views of testicular
regulation in man. Consideration of other hormonal regulatory systems is part of the
challenge to that orthodoxy.
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Prolactin receptor expression in human testis and accessory tissues:
localization and function.
Abstract
Experimental studies in animals have established prolactin as a progonadal hormone
that promotes the function of the testis and reproductive accessory glands. The present
study investigated the localization of prolactin receptor expression in the human testis
and accessory tissues. Expression of prolactin receptor was identified in human testis
and vas deferens by RT-PCR. Expression of prolactin receptor was further localized
by immunohistochemistry to the Leydig cells and differentiating cells of the testis
germ cell (developmental stages extending from pachytene spermatocytes to
elongating spermatids). Positive staining for prolactin receptor was also clearly
evident in the epithelium of vas deferens, epididymis, prostate and seminal vesicles.
Functional activation of prolactin receptor was demonstrated in fresh samples of vas
deferens collected at vasectomy by examination of the JAK/STAT (Janus
Kinase/Signal Transducer and Activator of Transcription) and MAP (Mitogen
Activated Protein) kinase ERK (Extracellular signal-Regulated Kinase) signalling
pathways. Within the vas deferens, prolactin induced rapid tyrosine phosphorylation
of JAK 2 and STAT 5 (after 10 and 20 min respectively), and tyrosine and threonine
phosphorylation of ERK 1 and 2 (after 5 min). The demonstration of function and
localization of the prolactin receptor presented here suggests multiple roles for
prolactin in the human male reproductive tract.
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Introduction
Experimental studies using animal models have established that prolactin acts in
concert with the classical gonadotrophins, luteinizing hormone (LH) and follicle
stimulating hormone (FSH), to stimulate full testicular function in the adult male rat,
mouse and hamster (Bartke, 1971, Zipf et ah, 1978, Bartke et ah, 1975, Dombrowicz
et ah, 1992). In the ram, a functional role for prolactin in the testis is indicated by the
observation that hypothalamo-pituitary disconnected rams (HPD rams), that
permanently lack gonadotrophin secretion due to blockade of gonadotrophin releasing
hormone (GnRH) secretion, continue to express cycles in testicular size in response to
photoperiod-induced changes in prolactin secretion. These gonadal changes are minor
and occur with a long latency, however, indicating that prolactin is a weak
gonadotrophin in the absence of LH and FSH (Lincoln et ah, 1996).
Prolactin receptor gene expression in the testis has been demonsreated in different
species including rat, ram and red deer (Ouhtit et ah, 1993, Hondo et al., 1995,
Jabbour et ah, 1998a, Jabbour and Lincoln, 1999). Theses studies show prolactin
receptor localized to the Leydig cells in the interstitium and the germ cells within the
seminiferous tubules (Jabbour et ah, 1999). The addition of prolactin to testicular
explants of ruminant species induces phosphorylation of JAK (Janus Kinase) and
STAT (Signal Transducer and Activator of Transcription) signalling proteins,
consistent with a functional prolactin receptor in the testis (Jabbour et al. 1999).
Prolactin is believed to stimulate testicular steroidogenesis by regulating LH receptors
(Bex and Bartke, 1977, Takase et al., 1990), or androgen/oestrogen biosynthesis
through the control of rate-limiting enzymes in the Leydig cells (Takeyama et al.,
1986; Chandrashekar and Bartke, 1988). However, the mechanism of action of
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prolactin on spermatogenesis remains to be clarified.
Expression of prolactin receptor has also been demonstrated in the rat dorsal and
lateral prostate, and seminal vesicles (Ouhtit et ah, 1993; Nevalainen et ah, 1996). In
cultured prostatic cells, androgens and oestrogens stimulate the expression of prolactin
receptor (Nevalainen et ah, 1996), and both gonadal steroids and prolactin, induce the
secretion of prostate-specific proteins (Costello and Franklin, 1994). In transgenic
mice engineered to over-express the prolactin gene, the prostate gland becomes
grossly enlarged illustrating the importance of prolactin in the control of accessory
gland physiology (Wennbo et ah, 1997). Chronic suppression of blood concentrations
of prolactin secretion in the ram produces a decrease in size and fructose content of
the seminal vesicles, with no change in testosterone secretion (Ravault et ah, 1977),
and manipulations of prolactin and androgens in the macaque monkey affect seminal
vesicular enzymes (Arunakran et ah, 1988), thus prolactin may promote the function
of various androgen-dependant male accessory structures.
Clinical observations also support a role for prolactin in the regulation of the testis and
accessory glands in man. For example, the restoration of normal prolactin levels in a
cohort of subfertile, hypoprolactinemic men caused an increase in sperm density and
quality, and restored fertility (Ufearo et ah, 1995). In another study, suppression of
gonadotrophins and prolactin secretion in eugonadal men treated for prostatic
carcinoma, caused a more marked reduction in testicular weight and spermatogenesis,
than suppression of gonadotrophin treatment alone (Fluhtaniemi, 1991). Both
observations are consistent with a progonadal role of prolactin in the testis. Early
studies using I125 labelled prolactin demonstrated the presence of a prolactin binding
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protein/receptor in human prostate (Leake et al., 1983). In addition, other studies
suggest that prolactin may play a role in the aetiology of benign prostatic hyperplasia
and cancer (Kandar et al., 1988; Nevalainen et al.,1997) and the synchronous
reduction in both prolactin and androgen improves the efficacy of the treatment of
prostatic carcinoma (Rana et al., 1995).
The purpose of the present study was to provide direct evidence for a role of prolactin
in the regulation of the testis and reproductive tract in man. To this end, the expression
of the prolactin receptor gene was investigated by RT-PCR, using RNA extracted
from human testis and vas deferens. The localization of expression of the prolactin
receptor protein was further studied using immunohistochemistry in sections prepared
from the human testis, epididymis, vas deferens, prostate and seminal vesicles. Lastly,
functional prolactin receptor was identified in the vas deferens by investigating
activation of the JAK/STAT and MAP (Mitogen Activated Protein) kinase ERK
(Extracellular signal-Regulated Kinase) specific intracellular signalling pathways.
Activation of JAK/STAT and ERK proteins, following binding of prolactin to its
receptor, mediates both proliferative and differentiating effects in target cells
(Finidiori and Kelly, 1995; Lewis et al., 1998).
Material and Methods
Subjects and Tissues
Testicular tissue (n=6), exhibiting normal morphology, was obtained by biopsy from
men exhibiting unexplained azoospermia. Vas deferens tissue (n=10) was obtained
from normal men undergoing vasectomy. Left and right vas deferens were used for
comparison between treatment and control. Ethical approval was obtained from
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Lothian Paediatric and Reproductive Medicine Research Ethics Subcommittee, and
written informed consent was obtained from each subject. Prostate and bladder tissues
were obtained from archival surgical resection specimens stored by the Department of
Pathology, Western General Hospital, Edinburgh. Epididymis and seminal vesicles
were obtained from a commercially available human cadaver tissue library.
Tissue culture
Following collection, vas deferens tissue was washed in PBS twice and subsequently
minced thoroughly with fine scissors. Four aliquots of each tissue (approximately 0.17
g each) were then incubated overnight in 2 ml serum free RPMI 1640 medium (Sigma
Chemical Co., Dorset, UK) containing 100 U/ml penicillin and 100 pg/ml
streptomycin in a 37°C incubator with 5% CO2. The following day, samples were
treated with 100 ng/ml human prolactin (hPRL-SIAFP-B2, donated by NIDDK, NIH)
for 0, 5, 10 and 20 min. The tissue was stored at -70°C prior to analysis by
immunoprecipitation and/or western blotting.
RNA extraction and RT-PCR
Total RNA was extracted from testis and vas deferens using the guanidinium
thiocyanate method as previously described (Chomczynski and Sacchi, 1987).
Polyadenylated RNA (poly A+) was purified on oligo(deoxythymidine)-cellulose
affinity columns (Pharmacia Biotech, St Albans, Herts, England); the yield and purity
of RNA was estimated by spectrophotometry. Single strand cDNA was generated
from 5 pg poly A+ RNA by reverse transcription using 1.6 ng oligo
(deoxythymidine)i2-i8 primer and Superscript reverse transcriptase, according to the
manufacturer's instructions (Gibco BRL, Paisley, Scotland). cDNA (10 ng) was then
diluted 25 times in dd^O and amplified by PCR using primers corresponding to
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nucleotide positions 182-201 (5'-CA-CCT-CCT-GAA-AAA-CCC-AAG-3'; forward
primer) and 724-743 (5'-CC-ATG-GTC-TGG-CTT-GCA-GCG-3'; reverse primer) of
the prolactin receptor open reading frame. The reaction was carried out in PCR buffer
(50 mM KC1, 2 mM MgCl2 and 20 mM Tris-HCl, pH 8.3), 200 pM deoxy-NTPs, 25
pmol forward and reverse primers and 1U Taq polymerase (Perkin-Elmer,
Warrington, Cheshire, England) in a total volume of 50 pi. Samples were subjected to
35 cycles of: 94 °C for 40 sec, 52 °C for 75 sec and 72°C for 2 min 30 sec. After a 10
min final extension at 72°C, the products were visualised on a 1% agarose gel using
ethidium bromide staining.
Histology and immunohistochemistry
Testis, vas deferens and other tissues were placed immediately in Bouins fixative for 6
h before transfer to 70% ethanol, and subsequent dehydration and embedding in wax
blocks. Sections were cut and mounted on slides coated with 2% TESPA in acetone.
Slides were then dried overnight at 50°C before dewaxing in histoclear (National
Diagnostics, Hull, UK). Tissues were rehydrated in graded ethanol and washed in
water followed by TBS (0.05 M Tris.HCl pH 7.4, 0.85% NaCl). Sections were treated
with 10% hydrogen peroxide in methanol for 30 min and blocked for 30 min with
normal swine serum (NSS) diluted 1:5 in TBS with 5% BSA. The primary antibody
for the prolactin receptor (kindly donated by Dr PM Ingleton, School of Medicine,
University of Sheffield) was raised against a 16 amino acid synthetic peptide
corresponding to residues 53-68 of the external domain of the rat prolactin receptor
(Nevalainen et al 1996). The polyclonal antibody was diluted in NSS/TBS/5% BSA
(as above) and incubated overnight at 4°C. Control sections were incubated with non¬
immune rabbit serum. All sections were washed twice in TBS (5 min each), incubated
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for 30 min with biotinylated swine anti-rabbit immunoglobulin (Dako, Bucks, UK),
diluted 1:500 in NSS/TBS. Sections were washed again twice in TBS (5 min each)
and incubated with peroxidase conjugated to avidin-biotin complex (Dako, Bucks,
UK) for 30 min at room temperature. Colour reaction was developed by incubation in
a mixture of 0.05% 3, 3'-Diaminobenzidine (DAB; Sigma) in 10 ml 0.05 M Tris.HCl
buffer (pH 7.4) and 0.033% hydrogen peroxide. Sections were subsequently
counterstained using haematoxylin.
Immunoprecipitcition and western blotting
Tissue was homogenised and lysed in 150 mM NaCl, 10 mM Tris (pH 7.4), 1 mM
EDTA, 10% glycerol, 0.6% NP40, 10 pg/ml aprotonin, 1 mM PMSF and 1 mM
Sodium orthovanadate. Cytoplasmic extracts were prepared by centrifugation for 2
min at 14000 rpm. For analysis of phosphorylation of JAK 2 and STAT 5, 50 pg of
protein was incubated with 10 pi monoclonal anti-phosphotyrosine antibody (5 pg/ml;
Affiniti, Exeter, UK) for 1 h at 4°C. Samples were then incubated overnight at 4 °C
with M-450 Dynabeads conjugated to rat anti-mouse IgG2b (Dynal, Wirral, UK). The
complexes were washed three times in PBS using a Dynal MPC magnet (Dynal,
Wirral, UK), and boiled for 5 min in sample buffer (125 mM Tris-FICl, pH 6.8, 4%
SDS, 2.5% dithiothreiotol, 20% glycerol, 0.05% bromophenol blue). For western
blotting, samples were subjected to SDS-PAGE and then transferred to PVDF
membrane (Millipore, Bedford, MA). For analysis of ERK phosphorylation, 50 pg of
protein from each sample was analysed. Membranes were incubated with antibodies
against ERK 1/2, JAK 2, STAT 5 (Santa Cruz Biotechnology, Santa Cruz CA, USA)
or phosphorylated ERK (T202/Y204, Cell Signaling, New England Biolabs, Beverly,
MA), each diluted 1000 fold in 2% dried skimmed milk/TBST (20 mM Tris-HCl pH
7.4, 500 mM NaCl, 0.1% tween 20). Membranes were washed briefly in TBST and
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incubated with secondary antibodies conjugated to HRP (Amersham pic,
Buckinghamshire, UK), in 2% milk/TBST. Membranes were again washed in TBST
and proteins detected using the ECL+ detection kit (Amersham pic, Buckinghamshire,
UK).
Results
RT-PCR ofprolactin receptor mRNA
The expression of the prolactin receptor was measured initially by RT-PCR, using
RNA extracted from testis and vas deferens. A single 312 bp transcript, corresponding
to a region in the extracellular domain of the human prolactin receptor, was amplified
in all samples of both testis and vas deferens tissue, indicative of the presence of PRL
receptor mRNA in these tissues (Fig.l).
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Figure 1. RT-PCR of prolactin receptor from RNA purified from human vas deferens
and testis. Lane 1: DNA size marker, lanes 2-5: RNA from vas deferans, lanes 6 and
7: RNA from testis, lanes 8 and 9: no reverse transcriptase added, lane 10: positive
control using PRLR cDNA as template. The predicted size of the PCR product
corresponding to the extracellular domain of the prolactin receptor mRNA is marked
as 312 bp.
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Immunohistochemistry of prolactin receptor
To determine the localisation of prolactin receptor, immunohistochemistry was
performed using sections prepared from human testis, vas deferens, epididymis,
prostate, seminal vesicle and bladder. In the testis biopsies of all 6 subjects,
immunostaining was localised to the Leydig cells in the interstitial tissue and to the
germ cells at different stages of spermatogenesis in the seminferous tubules.
Representative micrographs are shown in Fig. 2 (panels a,c). The most marked
staining was evident in the cytoplasm of the germ cells in the developmental stages
extending from pachytene spermatocytes to elongating spermatids. The
spermatogonia, early dividing spermatocytes and final differentiating spermatozoa
were devoid of staining, as were the Sertoli cells (Fig 2c). Control sections of testis
were totally devoid of staining (Fig 2b). In the vas deferens, epididymis and seminal
vesicle samples, immunostaining for the prolactin receptor was consistently evident in
the epithelium, but not in the underlying stroma and muscle tissue (Fig 2d,f,g); control
sections of vas defers were again unstained (Fig 2e). Immunostaining for the prolactin
receptor was also present in the epithelium of the prostate (data not shown as
demonstrated previously, Nevalainen et al., 1997).
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Figure 2: Immunoh istoehem istry ofPRL-R
Figure 2. Immunohistochemistry of the prolactin receptor (PRL-R) in human male
reproductive tissues. Human testis was immunostained with (a) and without (b) PRL-
R antibody and examined at X20 magnification. Panel (c) corresponds to testis
immunostained with PRL-R and examined at X40 magnifiaction. Expression of PRL-
R is evident in Leydig cells (L) in the interstitial tissue, pachytene spermatocytes (P),
and round spermatids (RS) in the seminferous tubules. There was no apparent staining
in the spermtocytes at early stages of spermatogenesis (PS) and differentiated sperm
(S). Vas deferens was immunostained with (d) and without (e) PRL-R antibody and
examined at X40 magnification. Panel (f) human epididymis and (g) human seminal
vesicle stained for PRL-R. Size bar= 100mm.
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Intracellular signalling in the vas deferens
Intracellular signalling pathways were examined by investigating tyrosine
phosphorylation of JAK 2 and STAT 5 and tyrosine and threonine phosphorylation of
ERK 1 and 2, following stimulation of fresh vas deferens tissue with human prolactin
(Fig. 3). Tyrosine phosphorylation of JAK 2 and STAT 5 was measured by an
immunoprecipitation procedure using an antibody against phosphorylated tyrosine,
followed by western blotting using antibodies against JAK 2 and STAT 5.
Phosphorylation of ERK 1 and 2 were measured by western blotting using an antibody
raised against ERK, phosphorylated on specific tyrosine and threonine residues. Rapid
phosphorylation of ERK 1 and 2 (evident from 5 min), JAK 2 (10 min), and STAT 5
(20 min) was observed following treatment with prolactin (Fig. 3). No increase in
phosphorylated proteins was observed in the absence of prolactin.
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Figure 3: Intracellular signalling in the human vas deferens
prolactin










Figure 3. Phosphorylation of JAK 2, STAT 5 and ERK1/2 in
the human vas deferens, in response to prolactin. Tissue was
serum starved and incubated with lOOng/ml of human
prolactin for 0,5,10 or 20 mins. (A) Proteins
immunoprecipitated with anti-phospholipid antibody and
analysed by Western blotting using antibodies against JAK
2(i) and STAT5 (ii). (B) Proteins analysed by Western blotting
using antibodies against phosphorylated (T202)/Y204) ERK
(i) and non-phosphorylated ERK (ii).
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Discussion
The data presented here demonstrate that prolactin receptors are expressed in the
human testis and in various male accessory glands. This is based on RT-PCR
amplification of the receptor mRNA extracted from testis and vas deferens, and the
localization of the receptor protein by immunocytochemistry in a wide range of
reproductive tissues. Furthermore, the incubation studies with fresh tissues of human
vas deferens show that the addition of prolactin activates phosphorylation of several
proteins known to mediate the intracellular effects of prolactin in target cells. These
data provide clear evidence for functional activation of the prolactin receptor in a
clinically accessible human male reproductive tissue.
Various isoforms of the prolactin receptor, differing in the intracellular domain, have
been characterised in man, and these are differentially expressed in the many prolactin
target organs (Kline et al., 1999, Hu et al., 2001). Long forms are expressed in the
testis, and long and intermediate forms in the prostate. The methodology used in the
current study was directed at the extracellular domain of the prolactin receptor (cDNA
primers for RT-PCR, and antibody for immunohistochemistry), thus it was not
possible to confirm the expression of the different isoforms of the prolactin receptor in
the human testis and other tissues. In rodent models, different isoforms of the
prolactin receptor have been identified, and both are expressed in the testis and
accessory glands (Ouhtit et al., 1993). Hence, it is plausible that similar diversity of
prolactin receptor expression exists in human testis and accessory glands.
The current immunohistochemical studies localized for the first time the prolactin
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receptor protein to the Leydig cells and germ cells of the human testis, and confirmed
the receptor expression in the secretary, adsorptive or lining epithelium in the various
accessory male structures. The pattern of immunostaining in the testis is similar to that
described in the red deer and ram (Jabbour et al 1996; Jabbour et al 1999). Expression
of the receptor in Leydig cells is consistent with a role of prolactin in the control of
testicular steroidogenesis. Evidence in rodent species suggests that prolactin
influences testosterone secretion through the stimulation and maintenance of
expression of LEI receptors in Leydig cells (Klemcke et al., 1984; Takase et al., 1990)
or by regulating specific enzymatic steps in androgen biosynthesis (Chandrashekar et
al., 1988). The effect of prolactin on steroidogenesis in the adrenal gland is also well
documented in animals and man (Glasow et al., 1996). The presence of prolactin
receptors in the differentiating germ cells in the testis is consistent with the view that
prolactin acts directly within the seminiferous tubules to affect spermatogenesis, as
well as acting indirectly through gonadal steroid secretion. In the immature
hypophysectomised rat, treatment with prolactin stimulated an increase in the number
of primary spermatocytes (Dombrowicz et al., 1992), while in hypoprolactinemic
subfertile men, exogenous prolactin, or treatment with metoclopramide to promote
prolactin secretion, increased sperm density, reduced sperm abnormalities and acted to
restore fertility (Ufearo et al., 1995). Other studies in the ram indicate that the effects
of prolactin in the testis are largely dependent on the concurrent secretion of LH and
FSH (Lincoln et al., 2001). Taken together, the data indicate that prolactin acts within
the testis to facilitate and augment the actions of LH and FSH promoting full testicular
activity.
The universal distribution of the prolactin receptor in the epithelium of the
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epididymis, vas deferens, seminal vesicles and prostate confirms that prolactin also
plays a role in the regulation of accessory gland function in man. Animal studies
clearly demonstrate that prolactin acts in association with androgens to stimulate the
activity of the accessory glands. For example, the production of secreted proteins from
cultured rat prostate cells is markedly enhanced by addition of prolactin (Nevalainen
et ah, 1996). In transgenic rodent models, over-expression of prolactin, or its receptor,
is associated with enlargement of the accessory glands, while under-expression is
associated with reduced functional activity (Wennbo et ah, 1997). The clinical
observation that prolactin enhances the effectiveness of steroid withdrawal for the
treatment of malignant disease of the prostate (Rana et ah, 1995) also supports an
action for prolactin in the human accessory glands. The presence of prolactin receptor
in the epithelial cells in the tissues of the male reproductive tract suggests that
prolactin is potentially involved in the regulation of secretion, absorption, and/or the
control of transport of fluids across the cell membrane. This is consistent with a
conserved function of prolactin in epithelial tissues across species (Nicoll, 1974).
As well as demonstrating functional prolactin receptors within the vas deferens, the
current results support the view that prolactin signals through more than one
intracellular pathway to regulate the tissue responses. In the vas deferens, prolactin
activated rapid tyrosine phosphorylation of JAK 2 and STAT 5 protein. The temporal
sequence is similar to that observed in other prolactin target-tissues including rat
mammary gland (Jahn et ah, 1997) and ovary (Ruff et ah, 1996), ram testis (Jabbour et
ah, 1999) and human endometrium (Jabbour et ah, 1998b). Upon activation, STAT
proteins dimerise, translocate to the nucleus and bind to STAT-regulatory elements in
the promoters of target genes to influence transcription (Schindler and Darnell, 1995).
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In mammary gland, activation of STAT 1 and STAT 5 proteins up-regulate
transcription of genes for (3-casein (Gouilleux et al.,1994), P-lactoglobulin (Burdon et
al.,1994) and whey acidic protein (Li and Rosen, 1995) to mediate the effects of
prolactin on milk synthesis and secretion. The target genes for prolactin in the vas
deferens epithelium are still unknown, but are likely to include genes encoding
secretory proteins.
The demonstration of rapid phosphorylation of ERK proteins in response to prolactin
in human vas deferens indicates that prolactin also acts via the ERK pathway to affect
the function of the secretory epithelium. The involvement of both the JAK/STAT and
ERK pathways acting together to influence differentiation has been documented in
other cell types (Lewis et ah, 1998). In the human endometrium prolactin induces the
JAK/STAT and ERK pathways in the epitheial cells during the secretory phase of the
menstrual cycle (Jabbour et ah, 1998b; Gubbay et ah, 2001). The activation of ERK
by prolactin in terminally differentiated secretory epithelium, as in the human vas
deferens, indicates that prolactin signals through ERK, as well as through the
JAK/STAT pathway, to provide divergent control ofmore than one cellular response.
In the current study, only fresh tissue from human vas deferens was available for
tissue culture, thus it was not possible to establish the pattern of phosphorylation of
the second messenger proteins in the different male reproductive tissues.
In conclusion, this study provides clear support for the view that prolactin is a
regulator of reproductive function in the human male. Prolactin appears to act in
Leydig cells of the testis to promote steroidogenesis, and in the germ cells of the
seminiferous tubules of the testis to promote the efficiency of spermatogenesis,
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actions that augment the more dominant progonadal effects of LH and FSH. Prolactin
also acts in the epithelia of the efferent ducts and the male accessory sex glands, in
conjunction with the gonadal steroid hormones, to regulate the secretory/adsorptive
functions of these male tissues. Our results are consistent with the pleiotrophic
character of prolactin, as a hormone with multiple target tissues signalling through
multiple pathways. A role for prolactin within the male reproductive tract, suggests
that abnormalities in circulating levels of prolactin within the body, or abnormalities
in prolactin receptor function, may have a significant impact on male fertility.
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An investigation of the effectiveness of testosterone implants in
combination with the prolactin inhibitor quinagolide in the
suppression of spermatogenesis in men
Abstract
BACKGROUND Administration of testosterone (T) inhibits gonadotrophin secretion
and spermatogenesis in men but the degree of response is highly variable. This
treatment also stimulates prolactin, itself a progonadal hormone in animals. This study
investigated whether concomitant suppression of prolactin (PRL) with the non-ergot,
dopamine receptor agonist quinagolide (Q), would enhance the efficacy of T in its
inhibition of spermatogenesis in healthy eugonadal men. METHODS Forty-six men
were randomised to three treatment groups: Group 1, T1200: 1200mg T implant plus
daily oral placebo; Group 2, T1200+Q: 1200mg T plus oral Q 75|rg/day; Group 3,
T800+Q: T 800mg plus oral Q 75 (rg/day. Treatments were for 24 weeks followed by
an 8-week recovery period. RESULTS Total number of subjects that achieved severe
oligospermia (<lmillion/ml including azoospermia) from weeks 8-16: 11/13 [85%],
11/12 [92%], 8/13 [61.5%] in the 3 groups respectively. CONCLUSIONS The results
show that inhibition of PRL does not to confer additional efficacy in spermatogenic
suppression in men. However, Q did not totally block PRL secretion in the subjects,
possibly because T replacement itself stimulated PRL by a direct action on the
lactotroph, thus the effectiveness of dual inhibition of gonadotrophin and PRL could
not be fully investigated.
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Introduction
Androgen administration aimed at producing a reversible contraceptive for men acts
by inhibition of FSH and LH secretion to suppress spermatogenesis. It does not
however suppress PRL secretion, which at least in animal models, is a weak
gonadotrophin (Bartke et ah, 1975, Ouhtit et ah, 1993, Lincoln et ah, 1996, Jabbour
and Lincoln, 1999). Initial studies showed that long-term treatments with testosterone
(T) esters, even at high doses, induce azoospermia in only a proportion (ca. 65%) of
subjects with notable differences between ethnic groups (World Health Organization
Task Force, 1990; Handelsman et ah, 1992; Sundaram et ah, 1993, Behre et ah,
1995). More recently, steroid treatments involving T combined with progestins, have
been shown to be more effective in the suppression of spermatogenesis (Merrigiolla et
ah, 1996, Handelsman et ah, 1996, Bebb et ah, 1996, Wu et ah, 1999, Martin et ah,
2000). Treatments with anti-androgenic progestins (e.g. cyproterone acetate),
however, produce undesirable changes in the haemopoeitic system (Merrigiola et ah,
1996), and progestins may produce effects on mood as is well demonstrated in women
(Pearlstein, 1995). In addition these treatments have not been shown to produce
universal azoospermia (Merrigiola et ah, 1996, Handelsman et ah, 1996, Bebb et ah,
1996, Wu et ah, 1999, Martin et ah, 2000). A number of suggestions have been
proposed to explain the heterogeneity in the contraceptive response to steroid
treatments. These include differing SHBG levels and responsiveness to gonadotropin
suppression (Behre et ah, 1995, Wang et ah, 1998), differing 5-alpha reductase
activity in the testis and its impact on intratesticular androgen levels (Anderson et ah,
1996), structural differences in testicular morphology between ethnic groups
(Zhengwei et ah, 1998), and possible differences in sex steroid metabolism and/or diet
(Santner et ah, 1998).
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An additional explanation for the failure to induce complete azoospermia is that it
may be necessary to inhibit PRL, in addition to the classical gonadotrophins, to fully
block spermatogenesis. This is because PRL potentially acts in the testis to stimulate
both androgenic and spermatogenic functions based on studies in rodents (Hondo et
1 9 S
ah, 1995). In man the progonadal role of PRL is less clear. Early studies using I -
PRL, failed to demonstrate PRL binding in the human testis, in contrast to the
situation in the rat (Wahlstrom et ah, 1983). More recently, mRNA for the PRL
receptor has been characterised in the human testis (Kline et ah, 1999), and
immunocytochemistry has revealed that PRL receptors are weakly expressed in the
Leydig cells in the interstitial tissue and more strongly expressed in germ cells
undergoing spermatogenesis in the seminferous tubules (Hair et ah, 2002). Functional
activation of these receptors and their second messenger systems Jak/STAT and ERK
by PRL has also been demonstrated in human testis and vas deferens. Furthermore,
there is clinical data indicating that PRL may promote spermatogenesis. In one study,
treatment with exogenous PRL, or a dopamine antagonist, to increase circulating PRL
concentrations was shown to restore testicular function and fertility in
hypoprolactinaemic infertile men (Ufearo and Orisakwe, 1995), and in another study,
combined suppression of gonadotrophins and PRL in eugonadal men treated for
prostatic carcinoma produced a more marked reduction in testicular weight than
gonadotrophin suppression alone (Huhtaniemi et al., 1991). Based on these
observations, and the demonstration that the administration of T and oral progestin
stimulates PRL secretion (Bellis and Wu, 1998), we infer that suppression of PRL
may enhance the effectiveness of sex steroid in inducing spermatogenic suppression
in man.
93
The purpose of the present study was to test this hypothesis. Healthy male volunteers
were treated orally with the non-ergot dopamine receptor agonist quinagolide, to
chronically suppress PRL secretion. This drug has been shown to inhibit PRL
production with minimal effects on the gastrointestinal tract and on nausea, mood and
sleep behaviours (Brownell et al., 1996). At the start of the treatment, the volunteers
also received subcutaneous implants of T to suppress gonadotrophin secretion.
Implants were used rather than intermittent injections to provide a smooth androgen
profile with less inconvenience to the subjects. A high and an intermediate dose of T
was selected to establish whether PRL inhibition would act in synergy with the degree
of gonadotrophin suppression and perhaps allow use of a lower dose of androgen to
induce azoospermia in men.




The study medication and design, information for volunteers, method of recruitment,
and the reimbursement of expenses were all approved by the Central Manchester
Ethical Committee for Medical Research and by the Medical Research Council.
Prospective volunteers were recruited from the community though local media
advertising. Written and verbal information as to the nature of the study was provided
to 480 men. Prospective candidates were then interviewed during which a full medical
history was obtained and thereafter underwent physical examination. Routine
haematology, biochemistry and semen analysis were then performed as screening
tests on two occasions 2 weeks apart, to determine if subjects met the inclusion
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criteria. The subjects were required to be within the age range 19-50, free of chronic
disease, on no long-term medication, with normal haematology and biochemical
screening tests and a normal semen profile based on World Health Organization
guidelines (WHO Manual, 1999). The subjects were also required to be willing to
continue with their existing contraceptive method. Following recruitment, 46
volunteers entered the study.
Medications
Quinagolide (Q) was used to chronically inhibit PRL secretion in the volunteers. The
drug tablets were supplied by Novartis (Norprolac, Novartis Pharmaceuticals UK Ltd,
Frimley Business Park, Frimley, Camberly, Surrey GU16 5SG). Subjects initially
received a Starter Pack containing two tablets each of 25, 50 and 75 gg of Q to allow
graded introduction of the medication. Following the introduction over 6 days, the
subjects took one 75-gg tablet per day. This dose was selected based on manufacturers
recommendations in the treatment of hyperprolactinaemia to effectively suppress PRL
secretion and minimise side effects. A small pilot study in 5 normal men was also
conducted. This demonstrated that daily administration of 75 gg Q suppressed blood
plasma PRL concentration by >80% for the 9-day treatment period with a carryover
effect for 3 days. For the main clinical trial, tablets were taken after food and before
bed. Placebo tablets supplied by our hospital pharmacy were taken by one group of
subjects as a control.
200 mg crystalline T implants were generously donated by Organon (NV Organon,
Oss, Netherlands; Product licence No. 0065/5084R). Implants were inserted using a
trocar with sterile technique in the subcutaneous fat of the anterior abdominal wall
with local anaesthesia using 1% Lignocaine. In the high dose treatment the subjects
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received 6 implants (1200 mg), and in the lower dose they received 4 implants (800
mg). These doses were selected on the basis that 1200 mg T produces severe
oligospermia in normal men, while 800 mg T less completely suppresses sperm
numbers.
Study design
Subjects were randomised to one of three treatment groups in a single blind parallel
group design: Group 1 - T 1200 mg plus daily oral placebo (T1200), Group 2 - T
1200 mg plus oral quinagolide 75 gg/ day (T1200+Q) and Group 3 - T 800 mg plus
oral quinagolide 75 gg/day (T800+Q). A more balanced design would have utilised a
T800+placebo group but this was not included due to constraints on the number of
volunteers and the power calculation requirement of no fewer than 12 subjects per
group. The protocol involved a pre-treatment phase of 4 weeks, a treatment phase of
24 weeks and a recovery phase of 8-12 weeks (see Figure 1). The treatment phase was
initiated by the insertion, on one occasion, of either 4 or 6 T implants according to
treatment-group. The subjects also commenced daily oral Q, or placebo tablets, which
were dispensed monthly at the clinical monitoring visit. Treatment of the subjects did
not occur simultaneously but was staggered according to time of recruitment. The
recovery phase was determined by the time to re-attainment of the pre-treatment
sperm concentration in the ejaculate, or to 2 consecutive sperm counts >20million/ml.
Clinical monitoring
Every 4 weeks throughout the study each subject was weighed, and pulse and blood
pressure measured. They were then interviewed to record evidence of compliance,
unused tablets were returned and any notable effects of the treatment were recorded.
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A blood sample was obtained for hormone measurements, and a semen sample was
produced for analysis. The blood samples were heparinised, centrifuged within 30
minutes of collection and stored at -20°C until analysis on completion of the full
study. Every 8 weeks, additional blood samples were obtained for monitoring of
haematological parameters, renal and liver function tests, and serum lipid
concentrations. Testis size was measured using an orchidometer. At the beginning and
end of the study a standard rectal examination of the prostate was carried out.
Semen Analysis
Semen samples were obtained by masturbation after 48hours abstinence and analysis
of semen volume, pH, sperm concentration, motility and morphology was carried out
within 60 minutes of collection according to the World Health Organization manual
(WHO Manual, 1999). Azoospermia was verified by centrifugation of the whole
semen sample and microscopic examination of the re-suspended pellet residue.
Blood analysis
Full blood counts, glucose, HbAlc, urea, electrolytes, liver enzymes and lipid profiles
were measured by a hospital autoanalyser. LDL-cholesterol was derived using the
Friedwald formula. On completion of the clinical study the blood plasma
concentrations of PRL, FSH and LH were assayed in all subjects by highly sensitive
immunofluorometric assays (Delfia, Pharmacia-Wallac, Turku, Finland) with an assay
sensitivity of 9.0 mU/L, 0.125 IU/L, 0.125 IU/L, respectively. Total T was determined
by previously described radioimmunoassay (Corker and Davidson, 1978) with
detection limit of 0.3 nmol/L.
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Statistical analysis
Results are expressed as group mean ± SEM. Data were analysed by two-way
ANOVA with repeated measures using Statistica software (version 4.0) to identify
significant time by group interactions with Tukey's post-hoc comparisons. In
addition, ANOVA with repeated measures was performed within each group to detect
significant effects of treatment. Baseline levels for each variable were defined as the
arithmetic mean of the two pre-treatment samples. Recovery levels were defined as
those obtained at 4 -12 weeks following completion of treatment according to time at
which the recovery criteria were met. Severe oligospermia was defined as a specimen
with sperm present in the ejaculate but at a concentration of <lmillion/ ml. Testis
volume was defined as the sum of volume measurements for the left and right testis.
The 8-20 week period was selected as the period ofmaximum sperm suppression.
RESULTS
Subjects
Of the 46 men who entered, 38 completed the study. Five men failed to attend regular
clinical appointments and were lost to follow-up after 4-20 weeks without
explanation. One man was withdrawn from the study due to extrusion of 2 T implants
and due to his lack of compliance with oral Q. Two subjects did not tolerate oral Q: in
one case, the treatment caused symptoms of nausea and vomiting during the first few
days of treatment and in the second case the treatment caused perceived effects on
mood and libido from week 4 and the subject subsequently withdrew at week 16.
After these losses the group sizes were 13,12,13 for T1200, T1200+Q and T800+Q
treatments respectively.
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In the 38 men who completed the study, the oral Q and T implants were generally
well tolerated and there were no serious adverse effects reported by the participants.
Transient morning nausea in the first week was reported by 2 subjects taking oral Q
and by 1 subject taking placebo. Mild acne was reported in 4 subjects and increased
libido at the start of the study was reported in 16 subjects. There was no apparent
difference in these symptoms in the three treatment groups. The men did not differ
significantly between groups in age (30.77±1.99, 33.36+1.5, 34.75±1.23 yrs, Group
T1200+placebo, Group T1200+Q, Group T800+Q, respectively), body weight
(83.54+4.54, 81.33+4.82, 76.36+3.37 kg) and testis volume (45.83+2.6, 49.64+2.43,
44.55+2.73 ml). All subjects had a pre-treatment sperm concentration >20million/ml
in the ejaculate.
PRL/T manipulations
Q treatment. Blood plasma concentrations of PRL are shown in Figure 1 (upper left
panel). The treatment with Q suppressed PRL concentrations but with notable inter-
subject variability. The statistical analysis of the PRL profiles revealed a significant
(P<0.05) time by treatment interaction. PRL concentrations were significantly
(P<0.05) decreased at weeks 4-24 (throughout the treatment period) in the T1200+Q
and T800+Q groups, compared with the T1200+placebo group. The mean PRL
concentrations for the treatment period were as follows: 43.5+18.6, 52.6+21.4 and
162.3+14.9 mU/L for the T1200+Q, T800+Q and T1200+placebo groups,
respectively. There was no significant difference in the PRL concentrations between
the two groups that received Q. PRL was suppressed by at least 80% (compared to
pre-treatment values) in 9/12 (75%) subjects in the T1200+Q group, and in 9/13
(69%) subjects in the T800+Q group. The remaining subjects suppressed to a mean
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47.73±8.26% (range 11.2-72.2%). There was no disclosed non-compliance to explain
this variability in PRL suppression.
There was also evidence that T alone increased PRL secretion. In the T 1200+placebo
group, plasma PRL concentrations increased significantly (p<0.05) relative to pre-
treatment values at week 4 following insertion of the T implants. In the T 1200+Q and
T800+Q groups, PRL concentrations also increased significantly (p<0.05) above the
placebo group at week 28, as a rebound response to cessation of Q.
T Implantation. After insertion of the T implants, total T concentration increased
above baseline for 4-8 weeks in all groups (Figure 1, upper right panel). The analysis
of the total T concentration in blood plasma showed a significant (p<0.001) effect of
time but no statistical differences between groups, although plasma concentrations of
T were lower in the T800 group.
Gonadotrophin suppression
Plasma LH and FSH concentrations were markedly suppressed by the T treatment in
all groups (Figure 1, lower panels). Concentrations were lowest at week 4 and
remained suppressed until week 12 before increasing to pre-treatment values by week
24. The analysis revealed a significant (p<0.001) time by treatment interaction; the
plasma LH and FSH concentrations were significantly (p<0.05) lower in both T1200
groups compared with the T800+Q group from weeks 4-16. There was no significant
difference in gonadotrophin concentrations between the T1200+ placebo and the T
1200+Q groups during the phases of suppression and recovery.
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Figure 1: Plasma Hormone concentrations (group means)
WEEKS WEEKS
Figure 1. Long term changes in the blood plasma concentrations of prolactin (PRL),
testosterone (T), FSH and LH in groups of male volunteers treated with T implants
with either quinagolide (Q) or placebo as follows: i) T1200mg+daily oral placebo
(open square symbol), ii) T1200mg + 75qg daily oral Q (closed square symbol), iii)
T800mg+75ng daily oral Q (open round symbol). The T implants were inserted once
only at week 0 and the Q treatment was continued for 24 weeks (horizontal bar -
treatment period). Values are mean ± SEM. n=13, 12, 13 for the 3 groups respectively.
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Sperm suppression and recovery
Pre-treatment sperm concentrations in the ejaculate were similar in the 3 treatment
groups (group means: 55.19±8.09, 40.62±6.97, 51.08±9.36 millions/ml for
T1200+placebo, T1200+Q and T800+Q respectively) (Figure 2). Sperm concentration
fell sharply in all groups by week 4 of treatment and continued to decline until weeks
12-16 before increasing by week 24. Sperm concentrations returned to pre-treatment
values by weeks 28-32. The analysis demonstrated a significant (p<0.001) time by
treatment interaction, with sperm concentrations significantly (p<0.05) reduced in
both T1200 groups, compared with the T800+Q group from weeks 12-20. There was
no significant difference in sperm concentrations between the T1200+placebo and the
T 1200+Q groups during the phases of suppression and recovery.
The proportion of subjects in each group who achieved severe
oligospermia/azoospermia (sperm concentration <1million/ml) for at least 4 weeks
was 11/13 (85%), 11/12(92%), 8/13 (61.5%) in T1200+placebo, T1200+Q and
T800+Q groups respectively. The corresponding numbers achieving azoospermia
were 5/13 (38%), 6/12 (50%), 5/13 (38%). The group profiles for the incidence of
oligospermia and azoospermia are summarised in Figure 3. Inhibition was maximal at
weeks 8-16 with a similar pattern in the 3 treatment groups; the incidence of sustained
oligo/azoospermia was least in the T 800+Q group. In this group, the subjects in
which PRL secretion was maximally inhibited (suppression >80% of pre-treatment,
n=9), the degree of spermatogenic suppression was notably greater than in those
subjects in whom PRL was inadequately suppressed (n=4). Severe
oligospermia/azoospermia was achieved in 78% of the PRL inhibited group but only
102







Figure 2. Long term changes in sperm density in the ejaculate of groups of male
volunteers treated with T implants with either quinagolide (Q) or placebo as follows:
i) T1200mg+daily oral placebo (open square symbol), ii) T1200mg + 75|iig daily oral
Q (closed square symbol), iii) T800mg+75gg daily oral Q (open round symbol). The
T implants were inserted once only at week 0 and the Q treatment was continued for
24 weeks (horizontal bar - treatment period). Values are mean ± SEM. n=13, 12, 13
for the 3 groups, respectively
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Figure 3. Percentage of subjects achieving severe oligospermia (sperm concentration
in the ejaculate <1million/ml - hatched histogram) and azoospermia (absence of
sperm in ejaculate - filled histogram), in groups of male volunteers treated with T
implants with either quinagolide (Q) or placebo as follows: (a) T1200mg+daily oral
placebo, (b) T1200mg + 75gg daily oral Q and (c) T800mg+75gg daily oral Q. The T
implants were inserted once only at week 0 and the Q treatment was continued for 24
weeks (horizontal bar - treatment period).
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25% in the poorly inhibited group; this apparent association between PRL and sperm
production was not evident in the T 1200+Q group.
Progressive motility (WHO categories, a+b) was unaffected by treatment in the 3
groups. Ejaculate volume was marginally decreased in the 3 treatment groups from
weeks 12-20 (range 8-29%) with no difference between groups. Semen pH was
unaffected by treatment.
Metabolic, haematological and general effects of treatment
Blood plasma concentration of HDL-cholesterol was decreased at week 12-20 during
treatment with no significant differences between the 3 groups. Concentrations had
not returned to pre-treatment values by the end of the recovery period. Total
cholesterol, triglycerides and LDL-cholesterol concentrations were not affected by the
treatments. Body weight, blood pressure, pulse, liver function tests (albumin, AST,
ALT, Alkaline phophatase and albumin), glucose metabolism (fasted blood glucose,
HbAlc) and renal function (electrolytes, urea, creatinine) were also unaffected by the
treatments. Haemoglobin concentrations were significantly (p<0.01) increased at
week 12 in all groups, in parallel with experimentally induced changes in T. but were
otherwise unaffected. Other haematology indices (white blood cell count, platelets)
were unaffected. Prostate examination revealed no changes related to any treatment.
DISCUSSION
The aim of this study was to establish whether suppression of PRL enhances the
effectiveness of exogenous T in inhibiting sperm production in normal men. This was
based on the potential progonadal effects of PRL, and the presumption that the
105
simultaneous suppression of both PRL, and the classical gonadotrophins LH and FSH,
would induce more complete spermatogenic arrest. The overall results do not support
the hypothesis. The degree of spermatogenic arrest and the period of induced
azoo/oligospermia was similar in the T1200 and T1200+Q groups, and the effects in
the T800+Q group were comparable to those previously reported for men receiving
this dose of T alone (Handelsman et ah, 1992). There was therefore, no significant
effect on the spermatogenic profiles associated with the chronic treatment with our
selected dose of quinagolide.
The current experiment was designed to compare treatments with and without
quinagolide in the presence of a standardised high dose of T (T1200mg). This was
based on the expectation that this level of T would produce sub-maximal sperm
suppression and allow us to detect an additional effect due to Q. However, the
T1200mg treatment alone in this study produced a very high degree of sperm
suppression, leaving little scope to observe an additional effect of Q during the
treatment phase. We therefore looked for an effect of the PRL manipulation on the
pattern of recovery at the time when the T implants were becoming exhausted (weeks
12-24) and daily quinagolide treatment continued. Again, there was no significant
difference between the T1200+placebo and T1200+Q groups in this pattern of
recovery, although the T1200+Q subjects were the last to return to pre-treatment
values, and there was a period at weeks 24-28 where there was no overlap in sperm
concentrations between the two groups that is suggestive of a marginal effect. The
only evidence that the Q treatment may have had some androgen dose-sparing effect
was obtained from the T800+Q group. In this group, there was marked individual
variation in the degree of inhibition of PRL and degree of spermatogenic suppression.
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In the subjects in which PRL secretion was maximally inhibited (suppression >80%
of pre-treatment, n=9), the degree of spermatogenic suppression was greater than in
those subjects in whom PRL was inadequately suppressed (n=4). Severe oligospermia
was achieved in 78% of the PRL inhibited group, which was comparable with 85%
for the T1200+placebo group. This provides minimal support for the view that only in
partial hypogonadotrophic states when gonadotrophin concentrations are sub-
maximally reduced (as in the T800 group), is it possible to observe any concomitant
effect of PRL withdrawal. A subtle interactive effect of PRL and gonadotrophin status
has previously been described in animal models where the effects LH and FSH on
testicular physiology always predominate (Bartke, 1999; Lincoln et al., 2001).
The unexpected finding in our trial was that the oral quinagolide was not fully
effective at blocking PRL and there was marked variability in the degree of PRL
suppression between subjects in both the T800+Q and T1200+Q groups. This was
despite the findings of the short pilot study clearly showing that oral quinagolide at
75|ug/d markedly suppressed blood PRL concentrations towards the minimum assay
detection limit. There are several possible explanations to account for this anomaly.
The first is that the subjects failed to comply with the experimental protocol of taking
daily quinagolide. However, monthly tablet returns and rigorous questioning at the
monthly clinical monitoring did not suggest a significant level of non-compliance.
Given that the elimination half-life of quinagolide is 17.5 hours (Brownell et al.,
1995), the omission of occasional tablets is unlikely to have had a significant long-
term effect on PRL control. Moreover, at the end of the treatment period, there was a
notable increase in PRL concentrations in all subjects that received Q. This is a
rebound response to chronic dopamine receptor agonist withdrawal and further
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supports our contention that subject compliance was good. The second explanation is
that chronic quinagolide treatment resulted in the development of refractoriness to
PRL inhibition. Quinagolide is routinely used clinically in the treatment of
hyperprolactinaemia in both men and women without clear evidence of long-term loss
of responsiveness (Homburg et al., 1990; Schultz et ah, 2000). Such refractoriness,
however, may obtain in the suppression of PRL in men with normal physiological
concentrations ofPRL (Rana et al., 1995).
The third, and perhaps most important factor, is that the T treatments themselves
activated PRL secretion, thus rendering the quinagolide less effective. Previous work
has shown that plasma PRL concentrations are significantly increased in men treated
with T enanthate injections (Bellis et al., 1998). In the current study, blood PRL
concentrations were significantly increased in the placebo treated subjects 4 weeks
after the administration of the 1200mg T implants. Furthermore, it is well known from
pituitary cell culture studies using animal tissues that both testosterone and oestradiol
potently stimulate PRL synthesis and release due to a direct genomic effect on the
lactotroph (Shull et al., 1985; Lambert and McLeod, 1990). This can occur
independently of the inhibitory effect of dopamine receptor activation. Clinical
studies also support the view that sex steroid status affects PRL secretion. For
example, the efficacy of bromocriptine in the suppression of PRL secretion is reduced
in hyperprolactinaemic women during pregnancy when oestradiol concentrations are
increased and PRL secretion decreases in the menopause and after pregnancy when
sex steroid concentrations decline (Karunakaran et al., 2001). Such steroid effects on
PRL secretion in our trial subjects would render quinagolide inhibition of PRL less
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effective. These effects of chronic treatment in normal men were not anticipated, but
clearly compromised the objective of this study.
A final point is that quinagolide was well tolerated with no serious adverse effects
reported. Prolactin acts in multiple target tissues including brain, liver, skin, prostate
and accessory glands. Despite this, chronic PRL suppression using quinagolide had no
demonstrable effects on semen volume, sexual behaviour and a wide range of
haematological and biochemical indices demonstrating desirable specificity of action
on the reproductive axis. Treatment with T produced the expected effects on HDL-C
(Wallace and Wu, 1990), but this was not blocked or enhanced by the manipulation of
PRL. There were a number of casual observations on the effect of chronic PRL
suppression. The incidence of acne was lower than expected and two subjects noted
an improvement in the condition of their skin and hair.
Conclusions
The current study investigated for the first time whether manipulation of PRL would
enhance the efficacy of T in the suppression of spermatogenesis in men. The results
did not support this idea. Unexpectedly it proved difficult to achieve consistent long-
term inhibition of PRL secretion in the men. Future studies will need to establish a
means of totally blocking PRL release, or to utilise a cross-over design in which all
subjects receive both PRL inhibitor and placebo, to test whether concomitant T and
PRL blockade will induce complete spermatogenic arrest. The idea of employing
lower levels of T, and reducing PRL due to its trophic effects on the prostate, make a
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A novel male contraceptive pill-patch combination: oral desogestrel
and transdermal testosterone in the suppression of spermatogenesis
in normal men.
Abstract
This study investigated the effect of transdermal testosterone and oral desogestrel on
the reproductive axis and extra-gonadal metabolism of healthy men. 23 men were
randomised to one of three treatment groups and received a daily transdermal
testosterone patch plus oral desogestrel at a dose of 75pg, 150pg or 300pg/day for 24
weeks. Baseline blood and semen samples were obtained and then 4 weekly thereafter
for 32 weeks. The outcome measures were sperm density, plasma levels of FSH, LH,
total and free T and lipids. The results show dose dependent suppression of
spermatogenesis and gonadotrophins. Seven of the seventeen subjects became
azoospermic. Desogestrel 300pg daily, in combination with 5mg daily transdermal T,
was the most effective (57% azoospermic) while 75pg was ineffective (0%
azoospermic). Total and free plasma T were reduced by approximately 50%. HDL-
cholesterol was significantly reduced. No serious side effects were encountered. We
conclude that daily self - administered desogestrel with transdermal T is capable of
suppressing the male reproductive axis although the efficacy was less marked and less
consistent than injectable regimes. The lower efficacy is likely to be due to failure of




The principle that exogenous sex steroid-induced oligo- and azoospermia can confer
effective, reversible contraceptive protection in men was established in two multi-centre
trials employing an androgen-only prototype regime of intramuscular (i.m.) injections of
testosterone (T) enanthate (WHO Task Force 1990, 1995). The pharmacokinetics of T
enanthate are such that a relatively high dose (200mg), administered at weekly intervals,
is required to ensure maximum suppression of gonadotrophins and spermatogenesis
(Schearer et ah, 1978). This regimen produced repeated supraphysiological peaks and
markedly fluctuating levels of T (Anderson et al., 1995). which induced significant extra-
gonadal androgenic effects on lipid metabolism, skin, muscle, liver and haemopoeisis
(Wu et al., 1996). These unwanted effects, coupled with the impracticality of
uncomfortable weekly i.m. injections, underline the need to use lower doses of
testosterone with more stable delivery in hormonal male contraception.
Spermatogenesis can be effectively suppressed by combining a reduced dose of
testosterone with a second anti - gonadotrophic agent such as a progestagen
(Handelsman et al., 1996) or GnRH antagonist (Tom et al., 1992). It has been
previously reported that i.m. T enanthate at the relatively low doses of only lOOmg or
50 mg weekly, if combined with a 19-nortestosterone derived oral synthetic progestin,
desogestrel (DSG), can suppress spermatogenesis very effectively in men; the best
dose combination, 300pg DSG daily with 50 mg of testosterone enanthate weekly,
induced consistent azoospermia in all subjects (Wu et al., 1999). This study also
showed that DSG and testosterone both contributed additively and interchangeably to
the reproductive as well as the non-reproductive metabolic effects e.g. reduction of
HDL-cholesterol and SHBG levels. T enanthate 50 mg i.m. weekly, delivering 5mg of
free T daily, is regarded as the minimal effective dose and also the minimal dose
required to maintain androgen sufficiency. Although it can be surmised that lower
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doses of DSG or alternate formulations of T, which can reproduce stable
physiological (rather than sharply - fluctuating) levels, may reduce these unwanted
actions, the minimally effective dose combination is currently unknown.
Transdermal T delivery systems have been recently developed for use as a non¬
invasive method of androgen replacement therapy in hypogonadal men (Miekle 1998,
Miekle et ah, 1992). Daily self - application of these systems offer the potential of
maintaining stable levels of testosterone within the normal range with a small diurnal
fluctuation which closely mimics the physiological pattern. Transdermal T systems
has not been studied in male contraception.
To date, few male contraceptive studies have employed an entirely subject-
administered regime. Since this is likely to be preferred by the majority of potential
users, it is important to determine if daily self-administration, independent of provider
or research personnel, can still be effective. This will give important clues about the
tolerance or margin of safety in hormonal male contraceptive regimes against a
backdrop of the varying levels of compliance which will inevitably be encountered
with preventative medications across any population.
We have conducted a study which employs a novel, non-invasive, daily, self-
administered treatment regimen to effect reversible suppression of spermatogenesis in
healthy male volunteers. The specific aims of the study were:
1. To evaluate the effects of oral desogestrel combined with a non-scrotal
transdermal testosterone delivery on gonadotrophin secretion and
spermatogenesis.
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2. To compare the effects of reducing doses of desogestrel combined with a fixed
dose of T designed for physiological androgen replacement.
3. To determine the minimally effective contraceptive combination and the tolerance
for breakthrough of suppression in this self-administered regimen
4. To assess the non-reproductive effects of these combinations in men.
Materials and Methods
Subjects
Of 101 respondents to our advertisements, 33 were suitable for screening. After the
initial interview and screening tests, 10 were excluded because of low sperm counts (n
= 5) or high cholesterol (n=5) leaving 23 Caucasian men, mean age 34.2 ± 7.0 year
(range 20 - 43) to take part in the study.
Study Design
Subjects who met the admission criteria similar to our previous study were
randomised into one of three treatment groups to receive: 1) oral DSG 300pg daily
and transdermal T 5mg daily (n=7), 2) oral DSG 150jug daily and transdermal T 5mg
daily (n=6), or 3) oral DSG 75jug daily and transdermal T 5mg daily (n=4) for 24
weeks in a single blind parallel group design.
Subjects were studied in three phases: 1) Control phase: medical screening
examination, two baseline semen analyses and hormonal and biochemical assessments
were carried out over 4 weeks; 2) Treatment phase: each subject was randomly
allocated to one of the three treatment groups described above. Both transdermal T
and DSG were administered for twenty-four weeks. Medical review including
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physical examination, blood sampling and semen analyses were performed every four
weeks. 3) Recovery phase: all subjects were monitored every 4 weeks by medical
review, semen analysis and blood sampling until recovery criteria were satisfied
namely; geometric mean pre-treatment sperm density was reached or two consecutive
specimens showed sperm density greater than 20 million/ml.
All subjects provided informed written consent and were advised to continue with
their existing forms of contraception during the study. The study was approved by the
Central Manchester Healthcare Trust ethical committee for medical research.
Medications
Desogestrel (75pg and 150pg tablets) were supplied by NV Organon, Oss,
Netherlands. Each subject received one tablet per day in the case of the 75pg and
150pg or two 150pg tablets in the case of the 300p.g/day group. Tablets were taken in
the evening before bed. Testosterone was administered by the volunteers as two
transdermal delivery systems (Andropatch, SKB, Welwyn Garden City, England)
applied to skin of the upper back, legs or flanks, changed daily at bedtime, employing
a different site at each application.
Clinical Monitoring
Subjects were interviewed monthly with particular emphasis on eliciting any side
effects and monitoring sexual function. Body weight, pulse and blood pressure were
measured monthly and testicular size (by orchidometer) measured 3-monthly. A
digital prostate examination was carried out pre-treatment and on recovery.
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Semen analysis
Semen collection and analysis of semen volume, sperm density and motility were
carried out according to the WHO Laboratory Manual for the Examination of Human
Semen and sperm-cervical mucus interaction 3rd edition 1993. The suppression targets
are defined as:- azoospermia - complete absence of spermatozoa in the ejaculate
verified by centrifugation of a whole semen sample; severe oligospermia - sperm
concentration of less than 1 million/mL; oligospermia - sperm concentration of less
than 3 million/mL in one sample.
Blood Tests
Blood samples were obtained twice pre-treatment and at four-weekly intervals
thereafter for hormone measurements (testosterone, LH, FSH, sex hormone binding
globulin) and haematological (haemoglobin, haematocrit, and white cell count),
biochemical (urea, electrolytes, liver enzymes, glucose, and haemoglobin Ale) and
lipid profiles (total cholesterol, low density lipoprotein cholesterol (LDL-C), high
density lipoprotein cholesterol (HDL-C), triglyceride and Apolipoprotein Al).
Hormone Assays
All plasma samples were stored at -20 C until assay. Plasma gonadotropins were
assayed by previously reported highly sensitive immunofluorimetric assays (Delfia,
Pharmacia-wallac, Turku, Finland (Miekle et al., 1992) with an assay sensitivity of
0.05 IU/ml for both LH and FSH. Testosterone was determined by previously
described RIA with an assay sensitivity of 0.3nmol/L (Wu et al., 1991). SHBG was
determined by an immunoradiometric assay (Farmos Diagnostica, Oulun Salo,
Finland). Free Testosterone was kindly measured in an external laboratory by Dr
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Christina Wang, using an established equilibrium dialysis technique (Wang et al.,
1998). All serial samples from one individual were assayed in a single batch to reduce
variability.
Biochemical analyses
Full blood count, glucose, haemoglobin Ale, lipids (total cholesterol, HDL-C, and
triglyceride) and renal and liver function was measured by routine autoanalyser
methods. LDL-C was derived from the other lipid indices using Friedwalds formula.
Statistical analyses
The data were analysed by repeated measures ANOVA, paired t tests, one-way
ANOVA with Tukeys's post-hoc test for continuous variables with statistical
significance set at p<0.05. Values were expressed as the arithmetical mean ± SEM.
LFI and FSH below the sensitivity of the assay were allocated a value of 0.05 U/L, the
lower limit of detection.
Results
Spermatogenesis
Seventeen subjects completed the suppression phase and six subjects were
discontinued (See below). The mean sperm densities before, during and after DSG
and transdermal T administration in each of the three treatment groups are shown in
Fig. la. The rates of suppression to 3 target sperm densities i.e. azoospermia (no
sperm), severe oligospermia (<lmillion/mL) and oligospermia (<3million/mL) are
shown in fig. lb. Sperm density was significantly (P<0.05) reduced in all treatment
groups with respect to baseline showing a clear dose - dependent although the
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differences between treatment groups failed to achieve significance. Seven (41%) of
the seventeen subjects who completed the suppression phase achieved azoospermia. 9
(53%) of the seventeen achieved suppression to less than 1 million/mL with no
additional subjects achieving suppression to less than 3 million/mL. The most
effective drug regimen was DSG 300pg and 5mg transdermal T daily in which four
(57%) of the seven subjects achieved azoospermia, the earliest by week 8 and the
remainder by week 16. One further subject suppressed to less than 1 million/mL by
week 12 giving a total of 71% for this group. In the DSG 150pg group, 3 (50%) of the
6 subjects achieved azoospermia, the earliest by week 8, the others by week 12 whilst
the remainder failed to suppress to oligospermia. In the DSG 75pg group none of the
four subjects achieved azoospermia although one became severely oligospermic
(<1million/mL) by week 12 while the others (75 %) remained outside the
oligospermic range with sperm densities above 10 M/mL throughout treatment.
Pre - treatment sperm densities were not significantly different between the
azoospermic or oligozoospermic responders and the non - suppressors.
Examination of the individual sperm density profiles in each group demonstrates
marked heterogeneity of response within treatment groups (Fig. la). In 4 of the seven
subjects who achieved azoospermia there was escape from suppression before the end
of the treatment period - the others remaining fully suppressed until treatment ended.
This phenomenon was also observed in one of the two subjects who became severely
oligospermic. Sperm density values began to recover within four weeks of cessation
of therapy. All but one of the subjects achieved the recovery criteria by week 48 (i.e.
24 weeks after end of treatment). One subject, despite normal gonadotrophins did not
recover until week 64. His testosterone levels were also subnormal over a similar time
course although his gonadotrophins were normal.
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Figure 1: Suppression of spermatogenesis
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Figure 1. Suppression of spermatogenesis. Column A shows individual sperm density
profiles for subjects in each of the three treatment groups at 4 week intervals during
24 weeks of treatment.
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Figure 1. continued. Column B shows rates of suppression of spermatogenesis
indicated by the percentage of subjects attaining azoospermia, (closed bar)
oligospermia <3million/mL (open bar) and <1 million/mL (hatched bar) over the
same time course. Subjects received transdermal T 5mg/day plus daily oral DSG at a
dose of either 300pg or 150pg or 75pg.
126
LH
LH levels were significantly (P<0.05) suppressed during the treatment phase in all
treatment groups from Week 4 onwards. Suppression was dose - dependent, the most
effective being in the DSG 300pg group although the difference between treatment
groups did not achieve statistical significance (fig. 2). In the DSG 300pg group, LH
was significantly (P<0.05) suppressed from a baseline mean of 4.5 ± 0.7 U/L to nadir
of 0.2 ± 0.1 U/L (Week 8), whilst in the DSG 150pg group mean levels fell from
4.5±1.0 U/L to nadir 0.8+0.3 U/L (Week 4). In the DSG 75pg group LH levels were
suppressed from baseline mean of 4.6±1.5 U/L to 0.9±0.7 U/L (Week 12).
Suppression of LH was not fully maintained during continued treatment. In the 300
pg DSG group, LH decreased to below the assay detection limit initially in four and
to <0.3 U/L by week 8 in the other three subjects. Between week 8 and end of
treatment, all subjects in this group showed some degree of escape, mostly transient
and below 0.8 U/L, except for one which broke through to 1.6 U/L at week 16 having
had undetectable LH four weeks earlier. In the 150pg DSG group, LH suppressed to
below assay detection in four of the six subjects two of whom escaped while the other
two maintained undetectable LH until end of treatment. In the 75 pg DSG group,
suppression was variable and none reached the detection limit. Pre - treatment LH
was significantly higher in subjects who did not respond compared to those that
suppressed to azoospermia and oligozoospermia (<3 M/mL). This was largely
attributable to one unresponsive subject with a baseline LH of 9.1U/L. In all subjects
LH recovered to baseline within 4 weeks after cessation of treatment. There was no
significant difference in the rate of recovery in the three treatment groups
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FSH
FSH levels were significantly (P<0.05) suppressed during the treatment phase in all
treatment groups. Suppression was dose - dependent, the most effective being in the
DSG 300pg group although the difference between treatment groups did not achieve
statistical significance (Figure 2). In the 300pg DSG group, FSH was significantly
suppressed from a baseline mean of 2.7±0.3 U/L to a nadir of 0.4±0.2 U/L (Week 8)
whilst in the DSG 150pg group, mean levels fell from a baseline of 4.2±0.5 U/L to a
nadir of 0.5±0.3 U/L (Week 4). In the 75pg group mean FSH levels fell from a
baseline of 3.4±0.4 to nadir of 0.9±0.4 (week 8). There was a consistent pattern of
gradual escape from suppression after week 8 in all three groups.
In both the DSG 300pg and 150pg groups, FSH suppressed to below assay detection
limits in three subjects but only one in each group could maintained the suppression
until the end of treatment. In the 75pg DSG group, FSH suppressed to under 1.0 U/L
in two subjects but only transiently.
There was no difference in pre - treatment FSH levels in subjects who suppressed to
azoospermia and oligozoospermia (<3 M/mL) compared to those that did not. Mean
FSH during treatment was significantly lower in azoopermic and oligozoospermic
responders compared to non - responders. FSH recovered rapidly on cessation of
treatment reaching normal levels by week 28 i.e. the first post-treatment assessment.
There was no significant difference in the rate of recovery in the three treatment
groups.
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Figure 2. Hormone data: group means. Figure shows the levels of plasma FSH, LH,
total and free T at 4 week intervals during the 24 week treatment period and
subsequent recovery. Groups received transdermal T 5mg/day plus daily oral
desogestrel at a dose of 300pg or 150pg or 75pg. Values are mean±SEM. Subjects
received transdermal T 5mg daily plus oral desogestrel at a dose of either 300pg
(solid rhomboids), 150pg (solid squares), or 75pg (solid triangles).
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Testosterone
Total testosterone levels were significantly (p<0.05) decreased during the treatment
phase compared to baseline in all three groups though they remained within the
normal physiological range throughout the study. There was no significant difference
in total T between the three groups. In the 300pg DSG group, T levels fell from a
baseline of 22.0±2.7 nmol/L to treatment mean of 14.2±2.5 (64.5% of basal) and nadir
of 12.5±2.2 nmol/L (week 20), whilst in the 150pg DSG group, levels fell from a
baseline of 25.2±3.1 nmol/L to a mean of 17.8±2.7 (70.6% of basal) and a nadir of
15.5±3.1 nmol/L (week 24). In the 75pg DSG group T levels decreased from a
baseline of 21.3±1.8 nmol/L to a mean of 16.4±2.4 (76.8% of basal) and a nadir of
11.4±2.8 nmol/L (week 8).
Free T levels also decreased significantly (p<0.05) during the treatment phase. In the
300jag DSG group levels fell from baseline mean of 8.0±0.8 ng/dL to treatment period
mean of 4.9±0.4 ng/dL (61.6% of basal). In the 150pg DSG group free T levels fell
from 8.8±0.9 to 6.9±1.2 ng/dL (78.4%) and in the DSG 75pg group, from 8.6±0.4 to
5.7±1.0 ng/dL (66.3% of basal). There was no difference in pre - treatment total T
levels in subjects who suppressed to azoospermia and oligozoospermia (<3 M/mL)
compared to those that did not. Mean T during treatment was not significantly
different in azoopermic and oligozoospermic responders compared to non -
responders. Total and free T levels returned to pre-treatment levels by the end of the
recovery period in all groups.
SHBG
SHBG levels were significantly reduced (P<0.05) in all treatment groups during the
treatment phase although there was no significant difference between treatment group
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in this regard. In the DSG 300pg group, mean levels fell from a baseline of 31.3±4.8
nmol/L to a nadir of 20.7±3.9 (week 12), whilst in the DSG 150pg group levels fell
from baseline mean of 30.2±6.7 nmol/L to a nadir of 22.5±5.5 nmol/L (week 24). In
the DSG 75pg group, levels fell from a baseline mean of 35±8.92nmol/L to a nadir of
27.8±6.3 nmol/L (week 12). SHBG levels returned to pre-treatment levels by the end
of the recovery period in all groups.
Biochemical and haematological parameters
There were no significant changes in plasma urea, creatinine, sodium, potassium,
calcium, alkaline phosphatase, AST, ALT, GGT, bilirubin, glucose, HbAlc,
haemoglobin, haematocrit, white cell count and platelets during treatment. (Data not
shown).
Lipids
HDL-cholesterol was significantly decreased (P<0.05) with respect to baseline during
treatment in all groups. In the DSG 300pg group, HDL-C fell from a baseline of
1.34± 0.10 mmol/L to a nadir of 1.11 ±0.06 mmol/L (week 24), a fall of 17%. In the
DSG 150pg group, HDL-C fell from a baseline of 1.29±0.15mmol/L to a nadir of
0.86±0.06 mmol/L (week 16) representing a fall of 33%. In the DSG 75pg group,
HDL-C fell from a baseline of 1.18±0.17 mmol/L to a nadir of 0.90±0.02 mmol/L
(week 12), a fall of 24%. The differences in HDL-C suppression between treatment
groups did not achieve statistical significance. Overall, the mean decrease in HDL-C
levels at the end of the treatment period was 12 ±3.2%.
There were no significant changes in total cholesterol, LDL-C, triglycerides or
Apoprotein Al. Total cholesterol was found to be significantly increased in the
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recovery period compared to baseline - this significance disappeared on removing
one outlier from the analysis. All lipid parameters returned to pre-treatment levels by
the end of the recovery phase in all treatment groups.
Physical changes
There was a small but significant (PO.OOl) increase of 1.94±0.56 kg (range -4 to
+7kg) in body weight by the end of the treatment phase. This gain persisted, the
average weight gain at the end of the recovery period being 2.53±0.67kg (range -3 to
+9.5kg). There was no significant difference between treatment groups in this regard.
Testicular volume decreased by an average of 3.3±l.lml (range 0-7.25ml) during
treatment and returned to pre-treatment values by the end of the recovery phase. There
were no significant changes in systolic or diastolic blood pressure throughout the
study.
Discontinuations and side effects.
There were six discontinuations - two due to marked and persistent skin reaction to
the T patches. The remaining subjects were either lost to follow-up before completion
of the study (n=2) or withdrew for non-treatment related reasons i.e. job relocation or
marital discord (n=2). During the treatment phase 11 subjects reported side effects,
namely increased sex drive (n=4), decreased sex drive (n=7), emotional lability (n=2),
irritability (n=5) and tiredness (n=2) though these were transient in nature. In addition
15 (65%) of the subjects reported skin reactions of varying degree to the T patches. In
three subjects the reaction was classified as mild (transient erythema), whilst in a
further 8 subjects the reaction was classified as moderate (marked erythema and itch
requiring treatment with topical hydrocortisone). The remaining four subjects were
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classified as having severe reactions, manifest as marked skin erythema and
blistering.
Discussion
Previous studies in hormonal male contraception have overwhelmingly employed i.m.
injections of T (enanthate in particular) in doses (200mg weekly) which generated
supraphysiological levels in the circulation (Hair et ah, 1999). The thrust of these
earlier endeavours has been to ensure maximal suppression of spermatogenesis.
Consequently, not only have side effects been observed, but also the minimal
effective dose for spermatogenesis suppression has remained undefined. In the
development of new therapies, especially novel contraceptives, once primary efficacy
has been ascertained, it is important to demonstrate the extent of the safety margin for
breakthrough and the tolerance to variable/suboptimal compliance. This can only be
revealed by systematically investigating the effects of reducing doses and establishing
the minimally effective dose level. In a previous study (Wu et ah, 1999), it was shown
that spermatogenesis suppression could be effectively achieved even when i.m. T
enanthate was reduced to the lowest physiological maintenance dose of 50mg weekly
(equivalent to 5mg of unesterified T daily) when combined with the synthetic oral
progestin, desogestrel. However, despite substantially reducing the total dose, the
suboptimal pharmacokinetics of T enanthate inevitably produced sharp fluctuations
with supraphysiological post - injection peak T levels (Snyder et ah, 1980). This
contributed to demonstrable non - reproductive effects and rendered interpretation of
minimal effective doses of drug combinations difficult. At the equivalent dose of 5
mg of T daily, transdermal systems can maintain stable physiological levels of T and
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offer the opportunity to investigate the minimal dose combination of progestin
required to suppress spermatogenesis effectively.
In the present study a downward dose - ranging design was employed to determine the
threshold dose of desogestrel, combined with a fixed daily amount of 5mg of
transdermally - delivered T, for suppression of spermatogenesis. We have
demonstrated a trend of progressively declining efficacy in achieving the three target
levels of sperm density with reducing doses of DSG. 300 and 150pg of DSG daily
induced azoospermia in 57 and 50% of subjects respectively. This is approaching the
range of azoospermic suppression observed with levonorgestrel 500 pg with T
enanthate lOOmg weekly (67%) (Anawalt et al., 1999), T enanthate 200mg weekly
(WHO Task Force 1990) (65%) and T implants 1200mg (56%) (Handelsman et al.,
1992) in Caucasian men. Suppression to oligozoospermia (either <1 or <3 M/mL) in
the present study (71 and 50% with 300 and 150pg of DSG respectively) however
was clearly inferior to the other regimens (Wu et al., 1999, Meriggiola et al., 1998,
Pavlou et al., 1991) which can achieve the <3M/mL target in 94-100% of subjects.
Below 150pg/day of desogestrel, there was a marked drop in effectiveness with none
of the subjects achieving azoospermia. Nevertheless, even at this suboptimal dose,
one of the four subjects suppressed to <1 million/mL consistently while the other
three failed to reach sperm densities less than 10 M/mL. This divergence between
responders and non - responders was also observed in the 150pg but not the 300pg
DSG group. Thus, in contrast to previous studies that emphasised the resistance to
achieving azoospermia in a minority of men receiving maximal doses (Anderson et
al., 1996), we have demonstrated a marked between - subject variation in sensitivity
to hormonal suppression by exploring threshold (150pg DSG daily) to sub - threshold
(75 pg DSG daily) doses of treatment. This heterogeneous response pattern suggests
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that a substantial proportion, may be up to 50%, of healthy men are able to respond to
much lower doses of exogenous sex steroids than customarily used before in attaining
effective contraception. These susceptible individuals however cannot be easily
identified by any baseline characteristics such as sperm density, LH, FSH or T levels
but they tend to show a more precipitous decline in sperm density in within the first 8
weeks after starting treatment.
Suppression of spermatogenesis with daily oral DSG and transdermal T was also less
effective than similar doses of DSG combined with weekly i.m. injections of T
Enanthate (Table 1) although the speed of decline in sperm density was not different
(Wu et ah, 1999, Anawalt et ah, 1999). This was particularly true for the oligospermic
targets. In the two previous studies using DSG, the least effective combination
employing 150pg of DSG daily with 50 mg of T Enanthate weekly, produced
suppression rates similar to the best results obtained in the group receiving 300mg
DSG with 5mg of transdermal T. Furthermore, the breakthrough of suppression in 3
of the 7 men who reached azoospermia and the partial recovery or 'escape' before the
end of the treatment period in most subjects was not observed previously with DSG
and T Enanthate or Enanthate alone. It appears that substituting transdermal T for i.m.
T enanthate has resulted in a loss of efficacy in spermatogenesis suppression.
Similarly, inhibition of gonadotrophins by DSG and transdermal T was less effective
and less consistent than previous regimes employing i.m. T enanthate (Handelsman et
al 1995, Anawalt et ah, 2000). Suppression of gonadotrophins showed the same dose
- related trend as spermatogenesis suppression with LH and FSH reaching assay
sensitivity in 57 and 43% of subjects respectively in the 300pg DSG group and none
in the 75pg group. In line with sperm density, very few subjects maintained consistent








































































































































































































before the end of treatment. Unsurprisingly, azoospermic and oligozospermic
responders achieved significantly lower levels of gonadotrophins than non -
responders during treatment. It is therefore highly probable that the inadequate
suppression of spermatogenesis engendered by reducing doses of DSG and
transdermal T is due to incomplete inhibition of gonadotrophins.
The torso transdermal testosterone delivery system has been shown to produce
physiological circulating T levels in the mid - normal range for long - term
maintenance of sexual ands other androgen - dependent functions in hypogonadal
men (Miekle 1998, Miekle et al., 1998, Dobs et al., 1999). In eugonadal men rendered
hypogonadal by exogenous sex steroid in the present study however, total T decreased
from baseline by about 30% during treatment but mean levels at 16.1±2.4 nmol/L (all
3 groups combined) (normal 10-35 nmol/L) remained within the physiological
range. None of the subjects reported symptoms of androgen deficiency and
haemoglobin and haematocrit did not fall during the treatment phase. Equilibrium
dialysis - measured free T levels also decreased significantly by similar extents as
total T. Lower SHBG concentration, associated with DSG and other oral synthetic
progestin treatment, therefore did not correct for the low total T and an absolute
decline in circulating bioavailable T levels was extant during treatment. Insufficient T
may therefore be one explanation for the lower efficacy in gonadotrophin and
spermatogenesis suppression compared with other studies using same doses of oral
DSG (Table 1). Nevertheless, this study showed that improved suppression of
spermatogenesis can be obtained with DSG and transdermal T compared to LNG
combined with a similar dose but a different transdermal T preparation (Buchter et al.,
1999) and also compared to CPA and oral T Undecanoate (Merrigiola et al., 1997)































































































































































































different progestins and/or preparations of non-injection T. Our results suggest that
self - administration of male hormonal contraceptive steroids is potentially viable
particularly in more responsive individuals. However, the transdermal systems are
clearly less reliable than injectable T regimens (see later). The loss of efficacy when
weekly i.m. injections of T enanthate is substituted by daily self - administered non -
injection preparations of T is a consistent finding across all three paired comparisons
(Table 2). This highlighted the critical role of T action and some important practical
issues in the development ofmale hormonal contraception.
When the supraphysiological dose of lOOmg T enanthate (Snyder et ah, 1980) was co¬
administered with LNG or CPA, the much higher dose and the higher peak levels of T
compared with the transdermal dose of 5mg daily and the T Undecanoate dose of
80mg bid may account for the discrepancy in efficacy. In our two studies on DSG and
T (Table 2), we deliberately targeted our comparisons with a lower yet effective dose
of 50mg weekly of T Enanthate i.m. which delivers 5mg of unesterified T daily, an
amount equivalent to the daily delivery rates of transdermal system studied. T
enanthate 50mg i.m. weekly produced pre - injection trough levels of T at 11 nmol/L
(Wu et ah, 1999), peaks of around 22 nmol/L and mean levels of 16 - 17 nmol/L
(extrapolated from Snyder et ah, 1980). This is not significantly different from mean
T level of 16.1±2.4 nmol/L encountered during DSG and transdermal T treatment in
the present study. The decline in efficacy in non - injection delivery of T is therefore
unlikely to be due to lower mean levels of T and other explanations have to be
considered. The fluctuating T levels giving high post - injection peaks with T
Enanthate are probably not required for maximal gonadotrophin suppression since
relatively stable T levels generated by 800mg of T implants when combined with
DMPA was highly effective (Handelsman et ah, 1996). Scrutiny of individual profiles
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showed that many subjects in our study had transient, decreases in total and free T
levels to the hypogonadal range with concomitant or subsequent escape in
gonadotrophins and sperm density (Table 3. Subject 1). The relatively low nadir T
levels during treatment in all three groups is a reflection of this. In contrast, the few
individuals whose T levels were maintained in the normal range throughout the
treatment phase were able to sustain suppression of gonadotrophins and
spermatogenesis throughout treatment (Table 3. Subject 2). Analogously, the short
half - life of oral T Undecanoate and its unpredictable absorption (Behre et al., 1998)
make it unlikely that twice-daily administration can maintain stable T levels within
the physiological range (Skakkebaek et ah, 1981). These observations suggest that the
common thread that links the low efficacy in the three studies using non - injectable T
preparations is likely to be non - maintenance of adequate T levels in the mid -
normal range which may have resulted from delivery problems or subject non¬
compliance. All these daily regimens of T are liable to the vagaries of
inconsistent/unreliable delivery and non-compliance with daily self- administration
in healthy volunteers. The consequence of these intermittent plunges in circulating T
may not be important or clinically detectable in hypogonadal replacement but is likely
to be of critical importance in maintenance of spermatogenesis suppression for
contraception. The cumulative effects of repeated troughs in T (probably under -
estimated by monthly monitoring) provide the most likely explanation not only for the
lower initial efficacy but also the subsequent breakthrough and progressive escape
seen across all three studies using non - injectable T preparations (Table 2).
This study also shows that as we descend to lower threshold doses of DSG, the 'safety
margin' is gradually eroded and the tolerance of the combination regimen to




































































































































suppression of spermatogenesis to maintain contraceptive efficacy is relatively
narrow. Doses of T adequate for physiological replacement (5-6 mg daily) represent
the minimum requirement but only if drug delivery is strictly reliable. This raises the
important issue of compliance in potential contraceptive users who are healthy young
men unaccustomed to daily self - medication. Although most of our subjects claimed
full compliance with the drug regimen, closer questioning revealed problems with the
transdermal patches other than the significant skin reaction. These included patch
removal to go swimming, playing sport or lovemaking, patch detachment with excess
perspiration or showering and poor patch adhesion to hirsute skin and in hot weather.
Daily oral DSG administration is more likely to be complied with and not subject to
the same problems as transdermal systems. The full efficacy when oral DSG was
combined with i.m. T enanthate 50mg weekly, the well maintained plasma levels of
etonogestrel after 6 month's treatment (the active metabolite of DSG) and the
persistent lowering of SHBG attest to a high degree of compliance (Wu et ah, 1999).
We have previously shown that DSG alone decreased levels of HDL-C as well as
apolipoprotein Al, an effect augmented by co-administration of T Enanthate. In the
present study with transdermal T, HDL-C was reduced significantly in all treatment
groups. This confirms that, in absence of high peak T levels, reduction of HDL-C is
due to the action of oral DSG on hepatic lipid metabolism.
Side effects were relatively common with skin irritation the most widely reported.
Our findings that 65% of subjects experienced skin irritation of varying degrees is in
agreement with recent experience with the same preparation in hypogonadal men
(Parker et al., 1999). These local problems with currently available transdermal
systems for T further undermine the appeal for this mode of delivery in male
contraception.
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In conclusion, we have shown that oral DSG combined with a non-scrotal transdermal
T delivery system produces suppression of gonadotrophins and spermatogenesis but is
less effective than regimens incorporating injectable T. The minimally effective dose
of desogestrel is 150pg. Escape from suppression is apparent in those subjects in
whom T replacement is inconsistent or inadequate at all dose levels of DSG. These
findings serve to further emphasise the critical role of T delivery and highlight some
important practical issues concerning daily self - administered regimens for hormonal
male contraception. In the current state of patch technology, the transdermal route of
delivery may not be optimal for male contraception.
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The literature review ofmale contraceptive studies describes increasing research
activity over several decades and it is clear that a number of challenges remain:
• Need for effective, minimally -invasive, long acting androgen delivery
• Between-subject variation in sensitivity to spermatogenic suppression
• A lack of consistent reliable suppression to azoospermia in large numbers of
subjects
The requirement for effective, self-administered, long-term androgen delivery forms
the basis for the transdermal patch study which for the first time tested the
effectiveness of transdermal testosterone in combination with oral desogestrel as a
male contraceptive. This study employed a wholly subject administered drug regimen
and was set against the backdrop of previously reported studies which employed T
implants or i.m injections of T enanthate, alone or in combination with various
progestins often administered by researchers themselves. The rates of azoopsermia
achieved were comparable with some previously reported androgen/progestin
regimes. It is clear however, that suppression of spermatogenesis with daily oral DSG
and transdermal T was less effective than similar doses of DSG combined with
weekly i.m. injections of T enanthate at doses which deliver the same amount of daily
unesterified T. It seems likely that the transdermal system failed to produce smooth,
sustained delivery of T sufficient to consistently suppress gonadotrophins and leading
to intermittent escape and restoration of spermatogenesis. The consequence of these
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intermittent falls in circulating T may not be important or clinically detectable in
hypogonadal replacement but may be pivotal in maintenance of spermatogenesis
suppression for contraception. Nevertheless, the study demonstrated that, on the
whole, men, are dependable users of this type of contraception and have sufficient
motivation to self medicate in a reliable way.
Understanding the heterogeneity of the suppression response between and within
populations remains central to the development of an effective contraceptive and
challenges conventional views of testicular regulation in man. Consideration of other
hormonal regulatory systems is part of that challenge and forms the basis for the two
studies which examine the role of prolactin as a putative progonadal hormone in man.
The laboratory studies described have unequivocally shown that prolactin receptors
are expressed in the human testis and in male accessory glands based on RT-PCR
amplification of the receptor mRNA, the localization of the receptor protein by
immunocytochemistry and the functional activation of the receptor demonstrated by
the second messenger experiments. The methodology used in the current study (using
primers or antibodies directed at the extracellular domain of the prolactin receptor)
precluded the demonstration different isoforms of the prolactin receptor in the human
testis and other tissues. Various isoforms of the prolactin receptor, differing in the
intracellular domain, have been characterised in man, and these are differentially
expressed in the many prolactin target organs. Hence, it is plausible that similar
diversity of prolactin receptor expression exists in human testis and accessory glands.
The current immunohistochemical studies localized for the first time the prolactin
receptor protein to the Leydig cells and germ cells of the human testis, and confirmed
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receptor expression in the epithelium in various accessory male structures. The pattern
of immunostaining in the human testis is similar to that described in other mammals
and points to a putative role for prolactin in the control of testicular steroidogenesis.
Such a role in humans has not yet been demonstrated but is an attractive prospect for
future studies. For example the immunostaining images for Leydig cells might be
further strengthened through the use of in-situ hybridisation techniques although the
technical challenges may prove considerable.
As well as demonstrating functional prolactin receptors within the vas deferens, the
current results suggest that prolactin signals through more than one intracellular
pathway to regulate the tissue responses. In the vas deferens, prolactin activated rapid
phosphorylation of JAK 2, STAT 5 and ERK proteins. The temporal sequence is
similar to that observed in other prolactin target-tissues in both animals and man. The
involvement of both the JAK/STAT and ERK pathways acting together to influence
differentiation has been documented in other cell types and suggests that PRL acts to
provide divergent control ofmore than one cellular response. The target genes for
prolactin in the vas deferens epithelium are still unknown, but on the basis of these
and earlier studies are likely to include genes encoding secretory proteins. In the
current study, only fresh tissue from human vas deferens was available for tissue
culture, thus it was not possible to establish the pattern of phosphorylation of the
second messenger proteins in the different male reproductive tissues, but this, subject
to adequate sourcing of fresh tissue, may be considered for future work.
A role for prolactin within the human male reproductive tract suggests that
manipulation of circulating levels of prolactin within the body may have a significant
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impact on male fertility and forms the basis for the subsequent clinical trial. This
study set out to establish whether suppression of PRL enhances the effectiveness of
exogenous T in inhibiting sperm production in normal men. This was based on the
potential progonadal effects of PRL, and the presumption that the simultaneous
suppression of both PRL, and the classical gonadotrophins LH and FSH, would more
complete effectively suppress spermatogenesis. The overall results did not support the
hypothesis: the degree of spermatogenic suppression arrest was similar in the T1200
and T1200+Q groups, and the effects in the T800+Q group were comparable to those
previously reported for men receiving this dose of T alone. The experiment was
designed to compare treatments with and without quinagolide in the presence of a
standardised high dose of T (T1200mg) based on the expectation that this level of T
would produce sub-maximal sperm suppression and allow us to detect an additional
effect due to Q. However, the T1200mg treatment alone in this study produced an
unexpectedly high degree of sperm suppression, leaving little scope to observe an
additional effect of Q during the treatment phase.
The only evidence that the Q treatment may have had some androgen dose-sparing
effect was obtained from the T800+Q group. At the time of the study design, this
group was introduced to ascertain whether addition of Q allowed for dose sparing of
androgen in the regimen without compromising efficacy. No control group (i.e.T800
alone) was therefore felt to be necessary and in retrospect it is disappointing that such
a group was not included. In the T800+Q group, there was marked individual
variation in the degree of inhibition of PRL and degree of spermatogenic suppression.
Steroid effects on PRL secretion in the trial subjects appeared to render quinagolide
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inhibition ofPRL less effective. These effects of chronic treatment in normal men
were not anticipated, but clearly compromised the objective of this study.
Interestingly, in the subjects in which PRL secretion was maximally inhibited, the
degree of spermatogenic suppression was greater than in those subjects in whom PRL
was inadequately suppressed. Although subject numbers were too small to allow
robust comparisons, this provides support, albeit rather tentative, for the view that
only in partial hypogonadotrophic states when gonadotrophin concentrations are sub-
maximally reduced is it possible to observe any concomitant effect of PRL
withdrawal. Such a subtle interactive effect ofPRL and gonadotrophin status has
previously been described in animal models where, like man, the effects LH and FSH
on testicular physiology appear always to predominate. Future studies will need to
establish a means of totally blocking PRL release and be carefully design to test
whether concomitant T and PRL blockade will induce complete spermatogenic arrest.
The idea of employing lower levels of T, and reducing PRL due to its trophic effects
on the prostate, make a combined preparation of this kind an attractive prospect in the
regulation of male fertility.
The studies described here have shown that men are enthusiastic and willing
participants in contraception. Despite troublesome skin effects, the subjects in the
patch study persisted with treatment over 36 weeks and were highly supportive of the
idea of hormonal contraception for men. To address the continuing issue of inter-
subject variability and a lack of a comprehensive azoospermic drug regimen, other
hormonal regulatory systems have been considered. It was postulated and
subsequently demonstrated that functional prolactin receptors are distributed in the
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human male reproductive tract. To further test the concept of prolactin as a
progonadal hormone in men, the clinical study set out to test the idea that combined
suppression of prolactin and gonadotrophins would produce more effective
suppression of spermatogenesis. Difficulties with prolactin suppression in normal
healthy subjects did not allow this question to be unequivocally answered by the study
with the data providing only rather tentative support for the concept of prolactin as a
progonadal hormone in men. It is the ambition of researchers in this field to develop
an effective safe, reversible hormonal contraceptive which men can administer
themselves. It is hoped that these studies contribute to the realisation of that ambition.
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Appendix: Published papers from these studies
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Initial studies undertaken by the World Health Organisation
demonstrated the efficacy of testosterone enanthate administered
weekly by intramuscular injection as a potential hormonal male
contraceptive. In the decade following these multicenter trials,
alternative methods of testosterone delivery have been developed
with improved pharmacokinetics and patient acceptability.
Combination therapies are also under evaluation with the promise
of improved contraceptive efficacy whilst curtailing unwanted
extratesticular effects. This review systematically discusses and
evaluates these drug regimens with respect to contraceptive
efficacy, unwanted effects and future developments.
Introduction
Overcrowding is a key global health issue contributing to
many major worldwide problems such as poverty, resource
depletion and pollution. The world's population currently
stands at around 6 billion and, unless global fertility rates are
curtailed, will more than triple to 19 billion by 2100 [1]. This
realization is a key factor underpinning research efforts
directed towards the regulation of human fertility, which
began in the second half of the twentieth century. In the last
two decades, this field has enjoyed a broader perspective,
moving from research principally directed at the control of
processes in the female to include regulation of male fertility in
general, and male hormonal contraception in particular. Three
broad approaches are currently being pursued: (i) suppression
of sperm production; (ii) disruption of sperm maturation
and/or function; and, (iii) interruption of sperm transport.
Physiological principles underlying the
approach to male contraception
Normal spermatogenesis is absolutely dependent on
sufficient concentrations of testosterone within the testis,
normally 50- to 100-fold higher than in peripheral blood, in
concert with the action of follicle-stimulating hormone
(FSH). Testosterone production is maintained by luteinizing
hormone (LH) stimulation of Leydig cells within the testis.
Hormonal suppression of spermatogenesis therefore
requires that intratesticular testosterone be profoundly
inhibited. This is achieved indirectly through suppression of
both LH and FSH, which then results in inhibition of
testicular steroidogenesis and spermatogenesis. The
implication of this is that exogenous testosterone
supplementation will be an invariant feature of any effective
male hormonal contraceptive regime in order to maintain
extratesticular functions such as libido, bone and muscle
metabolism and hemopoiesis. Gonadotrophin withdrawal
and the resultant depletion of intratesticular testosterone
arrests spermatogenesis without affecting the stem cell
population. This explains why hormonal suppression of
spermatogenesis is invariably reversible.
The epididymis would appear to be an ideal target for a
contraceptive agent, by preventing the acquisition of
motility and fertilizing potential through disruption of
epididymal function. Loss of sperm motility through
interference with energy metabolism, or disruption of sperm
surface protein chemistry causing impaired sperm-ovum
binding, acrosome reaction and fertilizing capacity are all
possible modes of action for such drugs.
Interruption of sperm transport by physical barriers, such as
vasectomy and condoms or by coitus interruptus have been
the mainstay of male contraceptive methods thus far.
Improvement of these techniques may be brought about
through developments such as non-latex condoms with
virucidal spermicides and immunization against specific
sperm surface antigens to interfere with the sperm-ovum
interactions required for fertilization.
Hormonal methods
Pituitary gonadotrophin secretion can be inhibited by a
number of agents, some of which have been investigated as
potential male hormonal contraceptives.
Androgen-only regimes
Testosterone enanthate
From studies in the 1970s it was found that
supraphysiological doses of testosterone alone can
consistently and reliably suppress spermatogenesis to
azoospermia in 40 to 70% of Caucasian males [2], The most
effective regimen was intramuscular testosterone enanthate
(TE), 200 mg weekly (Figure 1). This was chosen as the
prototype candidate for subsequent male hormonal
contraceptive trials because of its well-documented safety
over many years in the treatment of hypogonadal men,
despite its suboptimal pharmacokinetics.
Between 1986 and 1990, the first ever study to examine the
contraceptive efficacy of testosterone-induced azoospermia
was conducted by the World Health Organization (WHO) in
271 healthy volunteers in seven countries using TE, at a dose
of 200 mg weekly [3«].
A total of 157 men achieved azoospermia, and these men
entered the 12-month efficacy phase, in which the weekly
testosterone injections were the only form of contraception
used. Only one pregnancy occurred during the 1486 months of
exposure, giving a Pearl rate of 0.8 (95% CI 0.02 to 4.5) (Pearl
rate = [(number of pregnancies)/(number of woman months of
pregnancy risk)] x 1200). This established that hormonal
suppression to azoospermia yielded an efficacy rate
comparable to female injectables, slightly better than female
oral contraception, and substantially better than the condom.
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Figure 1. Molecular structures of testosterone and other androgen preparations used in male contraception.
While azoospermia has been confirmed as the logical target for
inducing infertility, a substantial minority of men remain
oligospermic despite maximal sex steroid suppression. It is
interesting to note that even when men are severely
oligospermic, the remaining sperm are functionally normal [4],
A second WHO trial was conducted to investigate the
contraceptive efficacy of TE-induced oligospermia [5«], In this
study, 349 of 358 (98%) healthy men in nine countries were
suppressed to azoospermia or oligospermia (< 5 x 106/ml)
using TE at 200 mg im weekly. They accumulated 283.5 years
of exposure during which there were nine pregnancies. It
became clear that pregnancy was related to sperm
concentrations below 5 x 106/ml, which enabled a threshold
sperm density of below 3 x 10'/ml to be identified, above
which the failure rate was deemed unacceptably high
compared to existing reversible contraceptive methods. Thus a
total of 4 pregnancies during 49.5 years of exposure
contributed by men with sperm densities between 0.1 and 3 x
106/ml yielded a Pearl rate of 8.1 (2.2 to 20.7 per 100 person-
years). This study yielded a Pearl rate for the method as a
whole of 1.4 per 100 person-years for those men with sperm
densities below 3 x 106/ml (ie, azoospermia to 3 x 106/ml),
which is comparable with the failure rate of current female
reversible contraceptives (combined pill, injectables and
medicated intrauterine devices) and is superior to the condom
(12 per 100 person-years). These trials have become the
benchmark against which future contraceptive studies may be
compared.
Intramuscular TE produced markedly fluctuating levels of
testosterone with repeated high peaks which predisposed
subjects to androgen-related effects on lipid metabolism
(lowering of high-density lipoprotein-cholesterol (HDL-C)),
skin (increased sebum production leading, in some cases, to
acne), liver (raised transaminases) [6*] and hemopoeisis
(raised hemoglobin, red cell count, and hematocrit) [7].
Clearly, the availability of improved methods for the
delivery of testosterone is crucial for the continued
development of safe hormonal contraceptives that are
acceptable to healthy young men.
Testosterone implants
Testosterone implants are small cylindrical pellets of
crystalline testosterone which are implanted surgically, usually
under local anesthesia, into the subcutaneous fat of the anterior
abdominal wall. Kinetics approximate to first-order release,
yielding 0.65 mg/day for 100 mg pellets and 1.5 mg/day for
200 mg pellets, with near complete bioavailability [8]. A 600
mg dose of implants will give physiological replacement over
a period of four to six months [9,10], However, a
supraphysiological dose of 1200 mg is required to produce
azoospermia in 65% of men. Fewer androgenic side-effects
than weekly injections of TE were reported [11]. Implants are
relatively inexpensive to produce and despite the fact that a
minor surgical procedure is required, this is a popular method
of androgen replacement in Europe and Australia, although
this is not the case for the rest of the world [9].
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Testosterone buciclate
Testosterone-l 7p-trans-4-n-butyl-cyclohexylcarboxylate
(testosterone buciclate, Figure 1) is a long-acting ester of
testosterone developed jointly by the WHO and the National
Institute for Child Health and Human Development, USA,
for specific use as a male contraceptive. The ester is
formulated as finely-milled crystals (10 to 15 pm particle
size) and is administered as an aqueous suspension by im
injection. Single-dose injections of 600 mg and 1000 mg
raised plasma testosterone in hypogonadal men into the
low/normal range and maintained a stable concentration for
16 and 20 weeks, respectively [12]. A single dose of 1200 mg
testosterone buciclate produced azoospermia in 3 of 8
volunteers whose plasma testosterone levels remained
within the normal range [13]. At the time of writing it is
unavailable due to persistent formulation difficulties.
Further studies of this promising long-acting ester are
planned.
Testosterone undecanoate
Testosterone undecanoate (TU, Figure 1) has a long aliphatic
side chain, which increases its lipid solubility. It was initially
formulated as a capsule in arachis oil which facilitates oral
absorption (vide infra). In a castor oil or tea oil base, itmay be
administered im, and has a significantly longer half-life (t1/2)
than TE [14]. These initial studies in orchidectomized
monkeys have more recently been extended to androgen
replacement in hypogonadal men [15]. TU kinetics show
both a long duration of effectiveness (up to 8 weeks from a
single im injection of 1000 mg), plus the absence of the initial
supraphysiological peak seen with TE, thereby reducing the
likelihood of androgenic side-effects. A multicenter
contraceptive study in China is ongoing.
Methyl-nortestosterone
7a-Methyl-19-nortestosterone (MENT) is a highly potent
synthetic androgen which, like testosterone, is a free steroid
rather than an ester, and consequently is usually formulated
as a subdermal implant. MENT is not 5a-reduced to
dihydrotestosterone (DHT), and in the rat has been found to
be 12-fold more potent than testosterone in suppression of
gonadotrophins, whilst it is 4-fold more potent in the
maintenance of prostate and seminal vesicle weight and 10-
fold more potent in maintaining muscle weights [16]. As a
result of its increased potency and tissue selectivity, this
compound has, theoretically, the potential advantage of
being able to suppress gonadotrophin production and
maintain adult sexual function and muscle mass at relatively
low doses that would not stimulate the prostate [17].
Recent studies in non-human primates have been
encouraging in this respect; MENT was 10-fold more potent
than testosterone in the suppression of gonadotrophins but
only twice as potent in stimulating prostate growth [18].
However, it was also found to be 10-fold more potent than
testosterone in its effects on lipids, causing decreases in both
HDL-C and total cholesterol.
Phase I pharmacokinetic studies in healthy men using
micronized MENT (2 to 8 mg), given as a single im injection
have recently been completed showing effective suppression
of gonadotrophins without reported side-effects [19].
Further clinical studies in hypogonadal men are planned.
19-Nortestosterone
19-Nortestosterone (19-NT, nandrolone; Figure 1) is one of a
group of anabolic steroids which have been in clinical use
for over 30 years. Given that 19-NT possesses a higher
affinity for the androgen receptor and is 10-fold more
progestagenic than testosterone, it is a potentially attractive
antifertility drug, either as a single agent or in combination
with another progestagen.
19-NT alone [20] or in combination with a depot of the
progestagen, medroxy-progesterone acetate [21] induced
suppression of gonadotrophins and testosterone for 12
weeks and achieved azoospermia in 6 and 8 out of 12
volunteers, respectively. 19-NT may, therefore, have a role
as a single-agent contraceptive, providing it is able to
maintain essential androgen-dependent functions without
producing undesirable metabolic, prostatic and behavioral
effects which have not been studied to date.
Transdermal testosterone
Delivery of testosterone via the transdermal route is a more
recent development. Compared to transdermal estrogen
delivery in female hormone replacement therapy which
requires 50 to 100 pg of steroid daily, much higher amounts
- around 3 to 10 mg of testosterone - are required to
maintain androgen-dependent physical functions. The rich
vascular network of the scrotal skin is particularly suited to
rapid drug absorption and is able to facilitate the increased
delivery of steroid required [22],
Scrotal systems
This method was initially employed in the treatment of
hypogonadal men using Testoderm - testosterone
transdermal system (TTS, ALZA Corporation) [23]. This
system contains testosterone incorporated in a layer of self-
adhering ethylene vinyl acetate co-polymer with a soft
flexible bonded polyester backing which is applied to
shaved scrotal skin and proximal penile shaft and worn for
22 h before it is replaced. Two sizes are available delivering
2.4 mg and 3.6 mg testosterone per day, which allows
testosterone levels to be maintained in the adult
physiological range over a 24-h period without fluctuations
outside this normal range, representing an improvement
over injectable testosterone. DHT levels in these patients are
elevated - up to three times the normal range - yielding a
DHT/testosterone ratio of 0.5 (normal range 0.1 to 0.2)
which is a reflection of the rich 5a-reductase activity within
scrotal skin. The consequences regarding unwanted effects
on DHT-dependent tissues are not yet known.
Non-scrotal systems
More recently, non-scrotal transdermal delivery systems
have been developed for use in androgen replacement
therapy in hypogonadal men [24]. Androderm Testosterone
Transdermal Systems (TheraTech) is one such system
containing testosterone in a permeation-enhancing vehicle
composed of water, ethyl alcohol, glycerine, glycerol mono-
oleate, methyl laurate and pharmaceutical gelling agents
[25]. Two types of system are available, delivering 2.5 mg or
5 mg of testosterone. For adult hypogonadal men, two of the
lower strength patches or one of the higher strength
provides adequate androgen replacement without alteration
of the DHT /testosterone ratio. This system, marketed as
Andropatch in Europe, is currently under evaluation in a
male contraceptive study.
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However, the alcoholic excipients employed have caused
considerable problems. A recent study reported adverse
effects in 84% of hypogonadal men receiving androgen
replacement by this method (most commonly
dermatological problems) and of these, 72% elected to return
to injected depot preparations [26®]. Other systems
producing a more physiological, pulsatile release of
testosterone are under development [27].
A hydroalcoholic gel containing a 2.5% solution of 5a-DHT
(Andractim, Unimed Pharmaceuticals Inc) is currently in use
in Europe. If applied over a sufficiently large surface area,
eg, chest and abdomen, adequate androgen substitution is
achieved [22]. More recent studies describe an improved
formulation employing a 0.7% DHT hydroalcoholic gel
(Besco Icovesco, France) delivering 16 mg DHT as a metered
dose [28], The study reports no skin irritation or adverse
hematological or biochemical events. Studies are currently
in progress to determine its efficacy as a method of
androgen replacement.
Testosterone microspheres
Testosterone encapsulated into biodegradable polylactide-
glycolide co-polymer microspheres can be administered as a
depot injection, yielding a biphasic pattern of testosterone
release over 11 weeks [29]. By varying the particle size, a
second-generation microsphere system containing 315 mg
testosterone has recently been shown to provide
approximately zero-order testosterone release at
physiological levels for 70 days [30]. Recent animal studies
have confirmed that the microspheres are completely
degraded in this particular study after a period of 10 weeks
[31]. There have been no recent developments employing
this approach in human subjects.
Orally-active testosterone
Orally-administered free testosterone is efficiently absorbed
from the intestine but undergoes virtually complete hepatic
first-pass metabolism. Avoiding first-pass metabolism,
orally-administered TU (see above) is absorbed into lymph
and enters the thoracic duct and thence to the systemic
circulation via the subclavian vein. TU (40 mg) dissolved in
arachis oil (Restandol, Organon NV) is available in capsule
form. However, its variable reabsorption coupled with a
short t1/2 and duration of action requires that patients take
two to four capsules per day to achieve adequate androgen
substitution [32®].
Testosterone complexed with hydroxy-jTcyclodetrins, an
oligosaccharide ring digested by bacteria, can, when
administered sublingually, give rise to short-lived (2 h)
peaks in testosterone. However, once again, multiple (three
times daily) administrations are required for adequate
androgen replacement [33].
Inhaled preparations
Using a new type of aerosol characterized by particles of
small mass and large size, it has been shown [34] that
inhalation of such particles complexed with testosterone
yielded high systemic bioavailability of the hormone and
avoids first-pass metabolism. This system offers a potential
non-invasive means of androgen replacement as part of a
hormonal contraceptive regime though, as yet, no such
studies have been reported.
Combined hormonal regimes
Experience with androgen-only regimes indicates that
supraphysiological levels of testosterone are required for
maximal suppression of gonadotrophins. Due to the direct
stimulatory action of testosterone on spermatogenesis,
especially at high doses, the ability of these regimes to
suppress spermatogenesis remains suboptimal. Dose-
dependent, androgen-related side-effects already described,
provide further impetus to lower the testosterone content of
future male contraceptives. In addition, until unequivocal
long-term safety data are available with regard to the effect
of testosterone on conditions such as benign and malignant
disease of the prostate, cardiovascular disease and
behavioral disturbance, it seems prudent to pursue
alternative regimens which minimize the amount of
exogenous testosterone that is employed.
Progestogen and androgen combinations
Progestogens are potent inhibitors of gonadotrophin
secretion in men [35] and may also directly suppress
spermatogenesis [36]. By acting synergistically or additively
with androgens, they permit lower doses of each steroid to
be used. Synthetic steroids such as levonorgestrel (LNG),
desogestrel, gestodene and norgestimate and
medroxyprogesterone acetate (DMPA) are highly potent
progestational compounds that are effective in microgram
quantities with only moderate androgenic properties.
Structural modification of the parent molecules from which
they are derived, namely 19-nortestosterone and 17-
hydroxyprogesterone, has allowed the development of these
orally-active hormones. The comparatively low mass of
drug required has also allowed the successful development
of long-acting subdermal implants such as Norplant
(levonorgestrel, Wyeth Ayerst) and Implanon (3-
ketodesogestrel, Organon NV).
DMPA and testosterone
A single depot injection of the progestin DMPA, in
combination with testosterone (800 mg) implants [37] showed
that the addition of DMPA markedly increased the rate of
azoospermia compared to testosterone alone, although did not
reduce the time course over which this was achieved.
LNG and testosterone
Initial studies using LNG [38] in combination with
subreplacement doses of testosterone produced results that
did not improve on those expected for androgen alone.
Similar results were obtained using DMPA [2], danazol [39]
and Norethisterone [40].
Recent studies have been more encouraging; Bebb reports a
study [41] in which volunteers received 500 pg LNG in
combination with higher doses of TE (100 mg/week). With
this regime, significantly greater and faster suppression of
spermatogenesis than with the same dose of testosterone alone
was observed. However, HDL-C levels were significantly
reduced in those patients receiving LNG plus testosterone
though not in the control group receiving androgen alone.
Reduced HDL-C levels have been associated with increased
risk of atherosclerotic heart disease [42],
Desogestrel and testosterone
Studies have recently been completed showing oral
desogestrel (300 pg/day) in combination with low-dose
testosterone (50 mg/weekly im injection) provides effective
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suppression of gonadotropins and rates of
spermatogenesis superior to androgen only regimes and
earlier studies using progestin/androgen combinations
[43»]. The rate of azoospermia for this regime (100% in the
above treatment group) also compares very favorably with
more recent studies using progestin/androgen
combinations, described above: LNG (67% azoospermia)
[41]; and, DMPA (90%) [37]. As with LNG, there was a
significant reduction in HDL-C levels in those patients
receiving desogestrel. It remains to be seen whether
employing lower doses of desogestrel or newer
progestagens can minimize these lipid effects without
compromising contraceptive efficacy.
A novel feature of this study was the phased treatment
regimen in which testosterone treatment was initiated after 3
weeks of pre-treatment using desogestrel alone. By virtue of
the phased introduction of androgen the authors were able
to demonstrate the relative contributions made by each drug
to suppression of spermatogenesis and gonadotrophins.
Interestingly, it was found that desogestrel alone, even at
maximal dose, suppressed the hypothalamo-pituitary-
testicular axis only partially and that the addition of
testosterone was crucial in achieving maximal suppression.
This demonstrates that testosterone is not only essential for
maintenance of androgen-dependent physiological functions
but also to achieve optimal suppression of gonadotrophins.
Anti-androgen/androgen combination
Cyproterone acetate (CPA) is a synthetic steroid which
blocks testosterone effects on the testis, through competitive
binding at the androgen receptor, as well as suppressing
gonadotrophin production by the pituitary. It has been used
in Europe for the treatment of hirsuitism in females
(Dianette; Schering) and prostatic malignancy in males
(Cyprostat; Schering).
When CPA alone is administered orally to men at doses of 5
mg to 20 mg daily, disruption of sperm motility and
morphology occurs, but with associated symptoms of
androgen deficiency [44-47]. More recent studies have
combined low-dose CPA with androgen supplementation to
good effect [48]. Initial studies employed a regime of CPA
(50 or 100 mg/day) and weekly injections of TE (100
mg/week), which caused complete azoospermia in the small
number of volunteers treated with either dose of CPA. In a
more recent study by the same group, an oral regime was
employed for the first time [49»]. Using a lower dose of oral
CPA (25 mg/day) in combination with oral capsules of TU
(160 mg/day), however, produced much lower rates of
azoospermia (only 12.5% of subjects).
Also of note is the significant decrease in hemoglobin and
hematocrit seen in subjects treated with CPA in all studies
so far reported, which in the long-term may produce
anemia. It remains to be seen whether lower doses of CPA
may elicit the desired effect on spermatogenesis without
manifesting these important effects on hemopoeisis.
Estrogen/androgen combination
Combined estradiol and testosterone implants have been
shown in the rat [50] and the monkey [51] to effectively
suppress spermatogenesis without affecting mating
behavior.
In man, the counterbalancing effects of small amounts of
estrogens on lipid and bone metabolism complemented by
the anti-estrogenic properties of testosterone may,
theoretically, produce an ideal formulation for the
suppression of spermatogenesis.
Studies have recently begun evaluating the combination of
implants of estradiol and testosterone.
5a-Reductase inhibitor/androgen combination
The enzyme 5a-reductase converts testosterone to DHT, a
steroid, which, in some tissues exhibits a greater potency than
testosterone, eg, prostate, seminal vesicles and hair follicles.
Studies to evaluate the effects of the 5a-reductase inhibitor
finasteride (Merck & Co) in conjunction with testosterone
are currently in progress. It is hoped that the attenuation of
DHT production will diminish unwanted extra-testicular




Abolition of gonadotrophin secretion and therefore of
spermatogenesis can be produced by gonadotrophin-releasing
hormone (GnRH) agonists, which downregulate pituitary
GnRH receptors and have the advantage that this is a highly
specific action, thereby eliminating unwanted actions on
metabolism, hemostasis, and the cardiovascular system.
A number of studies have explored the potential of GnRH
agonists in suppressing sperm production [52]. In total, only
23% of subjects achieved azoospermia. These results are
clearly disappointing, although it may be argued that the
dose of agonist employed was not adequate or that there
may have been persistence (or escape) of FSH activity
during GnRH agonist suppression [53,54].
The GnRH agonist leuprolide (Takeda Chemical Industries)
has recently been found to produce effective reversible
azoospermia in dogs [55] though as yet, no human studies
have been reported. Further studies are required to more
fully evaluate the true potential of GnRH agonists.
GnRH antagonists
These are capable of the complete and rapid reversible
suppression of gonadotrophins [56]. They have higher
affinity and slower dissociation rates than either GnRH itself
or any of the GnRH agonists [57,58]. The principal drawback
of GnRH antagonists is low potency, necessitating milligram
amounts to be administered systemically via complex
delivery systems and low oral bioavailability [59]. Given
that most are produced by substitution of the natural
decapeptide with unnatural, synthetic amino acids [60], they
are also extremely expensive to produce, have low solubility
and are difficult to formulate, which currently limits their
potential for large-scale clinical trials.
Despite these constraints, the effects of daily, subcutaneous
injections of Nal-Glu GnRH antagonist given in combination
with weekly injections of low-dose TE (50 mg im/week)
were examined in men and showed greater suppression of
gonadotrophins than with testosterone alone [61,62].
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More recent studies using the same antagonist showed that
azoospermia was achieved more rapidly and at higher
incidence than TE alone [63*]. In addition, having
suppressed spermatogenesis during the combination
induction phase, it remained suppressed when maintenance
treatment of TE alone (100 mg/week) was continued. This
reduction of lag time between treatment and response
addresses criticisms of earlier regimes in which maximal
suppression of spermatogenesis took up to three months to
achieve. Future developments in pharmaceutical technology
may allow more economical production of these compounds
as well as orally-active, non-peptide GnRH antagonists,
making them more attractive prospects for use in male
fertility regulation.
Selective FSH suppression
FSH is currently not considered to be essential for
maintenance of spermatogenesis in the presence of LH. This
is suggested by monkey studies in which inhibition of FSH
alone (achieved by raising antibodies against it) causes
reduction in sperm concentration but not azoospermia [64].
Further evidence may be found in studies of men with
mutations of FSH receptors. Tapanainen et al report that
although sperm production was quantitatively impaired,
absence of FSH activity in these men did not abolish
spermatogenesis [65*]. Accordingly, peptides such as
inhibin and follistatin, which selectively suppress FSH
production, are not considered promising candidates as
male contraceptives.
Heterogeneity of response to hormonal
suppression of spermatogenesis
Variation between population groups
A striking finding from the studies described thus far is the
marked difference both between and within population
groups in the degree of steroid-induced suppression of
spermatogenesis. It is known that supraphysiological doses
of testosterone induce rates of azoospermia ranging from
40% to 70% in Caucasian men, with the remainder becoming
oligospermic [3«]. The reasons for this variation in
spermatogenic suppression are not entirely understood
although there are a number of studies which address this
question.
Men who become oligospermic during testosterone
treatment exhibit a higher 5a-reductase activity than those
who develop azoospermia which may cause altered
intratesticular androgen levels [66»]. This higher residual
androgenic action on the seminiferous tubules may cause
resistance to complete suppression of spermatogenesis.
More recent studies report the histological evaluation of the
effects of testosterone treatment on spermatogenesis using
open testicular biopsy material from healthy males awaiting
vasectomy pre-treated with weekly doses of im TE [67]. This
study demonstrates that the most consistent lesion induced
by TE treatment was in the reduction in formation of type B
spermatogonia - the germ cells that enter meiosis. Studies in
the rat support the view that the development of A to B
spermatogonia is androgen-dependent and can be impaired
by a 5a-reductase inhibitor [68*].
One of the surprising findings from the WHO trials was that
Asian (Chinese, Indonesian and Thai) men showed a
consistently higher rate of spermatogenic suppression (89.9%)
when compared with European or American (74.3%) men (p <
0.001) [30], Given the much greater efficacy of testosterone-
alone regimes in these countries, the national authorities of
China, Indonesia and India have initiated large-scale phase HI
trials evaluating testosterone as a single-agent contraceptive.
The source of this heterogeneity has been extensively
investigated, though the underlying reasons remain unclear.
Characteristics such as body size, mass, serum biochemistry, as
well as baseline endocrine and semen parameters do not
explain the observed differences [69].
A recent study examining the comparative rates of androgen
production and metabolism in Caucasian and Chinese
subjects showed increased levels of 5a-reduced metabolites
in Caucasians [70]. However, this was not found to be due to
a difference in 5a-reductase activity or testosterone to
dihydrotestosterone conversion ratios in the two groups.
The study did show, however, raised levels of androgenic
steroid precursors, which serve as substrates for these
metabolites in the Caucasian group, and interestingly, in
Chinese men resident in the USA. The authors postulate that
this is indicative of an environmental or dietary origin to
these population differences rather than differences in 5a-
reductase activity. Differences in the gonadotiophin
negative feedback response to exogenous testosterone in
Asian and Caucasian men have also been reported [71].
More recently, differences in testicular structure between
Asian men and Caucasians have been observed [72].
Histological examination of testes taken from post-mortem
examination of previously healthy Asian males dying from
sudden traumatic injury has demonstrated that Asian males
have fewer spermatogonia, smaller diameter seminiferous
tubules and fewer Sertoli cells per man than do Caucasians.
This variation in testicular structure results in differences in
spermatogenic potential between the two groups, and is
tendered by the authors as a potential explanation as to why
Asian men exhibit more complete suppression of testicular
function in response to exogenous testosterone administration.
Further studies are currently directed towards a more
complete understanding of these population differences.
Non-hormonal drugs
Serendipity has played its role in uncovering the fertility-
suppressing side-effects of compounds developed for other
uses. The majority of these have not showed promise, and
indeed, many have unacceptable levels of toxicity [73-75]. The
most important of these compounds will briefly be reviewed.
Anti-spermatogenic agents
Plant-based compounds
In the 1970s, more than 8000 Chinese men were given
gossypol, a polyphenolic plant pigment derived from
cottonseed oil, with a view to determining its contraceptive
activity. Side-effects, such as hypokalemia coupled with its
high incidence of irreversibility, saw gossypol abandoned as
a potential male contraceptive in 1986.
56 Current Opinion in Oncologic, Endocrine & Metabolic Investigational Drugs 1999 Vol 1 No 1
Triptolide and tripdiolide are oxygenated diterpine
compounds derived from the plant Tryptergium wilfordii
whose prime use is as a traditional Chinese medicine in the
treatment of inflammatory and dermatological diseases.
They are among several compounds which have now been
extracted in sufficient amounts to allow more detailed
evaluation of their chemical structure, actions and side-
effects [76]. Initial animal studies have shown effective
suppression of spermatogenesis but a narrow therapeutic
index: immunosuppression was seen at doses of 5- to 12-fold
greater than those required to produce azoospermia [76].
Recent studies in the rat have demonstrated that triptolide was
moderately effective in the suppression of spermatogenesis
and also completely inhibited motility in the epididymis
without effects on gonadotrophins, giving a so-called post-
testicular contraceptive [77]. Careful toxicology studies are
required before these compounds are more fully evaluated in
men, although the low therapeutic index coupled with a recent
report of infantile meningoencephalocele in a pregnantwoman
taking triptolide for rheumatoid arthritis [78] is less than
encouraging.
Antifolate drugs
Dihydrofolate (DHF) reductase inhibitors such as the early
sulpha-containing antibiotics are know to have modest
antifertility effects. Similarly, the antimalarial drug
pyrimethamine (also a DHF reductase inhibitor),
reversibly abolishes fertility in male rats [79], resulting in
a search for analogous, but more potent, compounds
through, eg, substitution of the basic diaminopyrimidine
structure which will, it is hoped, improve the selectivity of
these compounds [72].
Epididymal agents
A few compounds which inhibit the oxidative metabolism of
spermatozoa, and hence inhibit motility, have been
evaluated. a-Chlorohydrin and 6-chloro-6-deoxyglucose are
metabolized to 3-chlorolactaldehyde, a compound with the
same stereochemistry as R-glyceraldehyde - a key substrate
in the glycolytic pathway. Administration of these
compounds results in competitive inhibition of the key
enzyme, glyceraldehyde-3-phosphate dehydrogenase, and
glycolysis, thereby inhibiting sperm motility. Perhaps not
surprisingly, given the effects on a core biochemical process,
these compounds have serious systemic side-effects,
particularly on the nervous system and bone marrow
precluding further exploration of their contraceptive
potential [80].
The antifungal agent ketoconazole is known to accumulate
in seminal plasma and inhibit sperm motility post-
ejaculation. This property has been ascribed to the imidazole
ring structure in ketoconazole and consequently, a variety of
substituted imidazole compounds were evaluated as orally-
administered, rather than topical, inhibitors of sperm
motility [81]. There have been no studies using these
compounds reported in the last decade.
Nitioimidazole derivatives, often used as antibiotics and
anti-protozoan treatments suppress fertility by inhibiting
sperm maturation in the epididymis though once again, the
broad side-effect profile makes long-term use in
contraception impractical [82].
Conclusions
In the decade since the publication of the initial WHO study
reporting the contraceptive efficacy of testosterone-induced
azoospermia, substantial progress has been made towards a
fuller understanding of the control of male fertility.
Improved androgen delivery systems and combination
therapies promise greater efficacy, whilst efforts are ongoing
to reduce the impact of these therapies on lipids and other
extra-testicular metabolic processes. Drug industry interest,
although slow to develop, is now becoming established. The
development of diverse and improved methods of male
fertility control increases choice for both men and women
and provides potentially rich benefits for all.
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Experimental studies in animals have established prolactin (PRL) as a progonadal hormone that promotes the function of the
estis and reproductive accessory glands. The present study investigated the localization of PRL receptor (PRL-R) expression
—n the human testis and accessory tissues. Expression of PRL-R was identified in human testis and vas deferens by RT-PCR,
ind further localized by immunohistochemistry to the Leydig cells and differentiating germ cells of the testis (developmental
—tages extending from pachytene spermatocytes to elongating spermatids). Positive staining for PRL-R was also clearly evident
n the epithelium of vas deferens, epididymis, prostate and seminal vesicles. Functional activation of PRL-R was demonstrated
n fresh samples of vas deferens collected at vasectomy by examination of the JAK/STAT (Janus kinase/signal transducer and
ictivator of transcription) and MAP (mitogen-activated protein) kinase ERK (extracellular signal-regulated kinase) signalling
jathways. Within the vas deferens, PRL induced rapid tyrosine phosphorylation of JAK 2 and STAT 5 (after 10 and 20 min
espectively), and tyrosine and threonine phosphorylation of ERK 1 and 2 (after 5 min). The demonstration of function and
ocalization of PRL-R presented here suggests multiple roles for PRL in the human male reproductive tract.
=JCey words: male reproductive tract/prolactin/prolactin receptor/testis
■Introduction
-Experimental studies in animals have established that prolactin acts
in concert with the classical gonadotrophins, LH and FSH, to stimulate
full testicular function in the adult male rat, mouse and hamster
(Bartke, 1971; Bartke et al., 1975; Zipf et al., 1978; Dombrowicz
et al., 1992). In the ram, a functional role for prolactin (PRL) in the
testis is indicated by the observation that hypothalamo-pituitary
disconnected rams, that permanently lack gonadotrophin due to a
blockade of GnRH secretion, continue to express cycles in testicular
size in response to photoperiod-induced changes in PRL secretion.
These gonadal changes are minor and occur with a long latency, but
they indicate that PRL is a weak gonadotrophin in the absence of
LH and FSH (Lincoln et al., 1996).
Prolactin receptor (PRL-R) gene expression in the testis has been
demonstrated in different species including rat, ram and red deer
(Ouhtit et al., 1993; Hondo et al., 1995; Jabbour et al., 1998a;
Jabbour and Lincoln, 1999). These studies show PRL-R to be localized
to the Leydig cells in the interstitium and germ cells within the
seminiferous tubules (Jabbour and Lincoln, 1999). The addition of
PRL to testicular explants of ruminant species induces phosphorylation
of JAK (Janus kinase) and STAT (signal transducer and activator
of transcription) signalling proteins, consistent with a functional
PRL-R in the testis (Jabbour et al., 1998b). PRL is believed to
stimulate testicular steroidogenesis by regulating LH receptors (Bex
and Bartke, 1977; Takase et al., 1990), or androgen/estrogen biosyn¬
thesis through the control of rate-limiting enzymes in the Leydig
cells (Takeyama et al., 1986; Chandrashekar and Bartke, 1988).
However, the mechanism of action of PRL on spermatogenesis
remains to be clarified.
Expression of PRL-R has also been demonstrated in the rat dorsal
and lateral prostate, and seminal vesicles (Ouhtit et al., 1993;
Nevalainen et al., 1996). In cultured prostatic cells, androgens and
estrogens stimulate the expression of PRL-R (Nevalainen et al.,
1996), and both gonadal steroids and PRL, induce the secretion of
prostate-specific proteins (Costello and Franklin, 1994). In transgenic
mice engineered to over-express the PRL gene, the prostate gland
becomes grossly enlarged illustrating the importance of PRL in the
control of accessory gland function (Wennbo et al., 1997). Chronic
suppression of blood concentrations of PRL secretion in the ram
produces a decrease in size and fructose content of the seminal
vesicles, with no change in testosterone secretion (Ravault et al.,
1977), and manipulations of PRL and androgens in the macaque
monkey affect seminal vesicular enzymes (Arunakaran et al., 1988);
thus, PRL may promote the function of various androgen-dependant
male accessory structures.
Clinical observations also support a role for PRL in the regulation
of the testis and accessory glands in man. For example, the restoration
of normal PRL levels in a cohort of subfertile, hypoprolactinaemic
men caused an increase in sperm density and quality, and restored
fertility (Ufearo et al., 1995). In another study, suppression of
gonadotrophins and PRL secretion in eugonadal men treated for
prostatic carcinoma caused a more marked reduction in testicular
weight and spermatogenesis than suppression of gonadotrophin secre¬
tion alone (Huhtaniemi et al., 1991). Both observations are consistent
with a progonadal role of PRL in the testis, although early studies
using I125-iodo PRL failed to demonstrate the presence of PRL
binding in the human testis, in contrast to the situation in the rat
(Wahlstrom et al., 1983). PRL binding has been demonstrated in the
human prostate (Leake et al., 1983), and other studies suggest that
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PRL may play a role in the aetiology of benign prostatic hyperplasia
and cancer (Kadar et al., 1988; Nevalainen et al., 1997). The
synchronous reduction in both PRL and androgen improves the
efficacy of the treatment of prostatic carcinoma (Rana et al., 1995).
The purpose of the present study was to provide direct evidence
for a role of PRL in the regulation of the testis and reproductive tract
in man. To this end. the expression of the PRL-R gene was investigated
by RT-PCR using RNA extracted from human testis and vas deferens.
The localization of expression of the PRL-R protein was further
studied using immunohistochemistry in sections prepared from the
human testis, epididymis, vas deferens, prostate and seminal vesicles.
Lastly, a functional PRL-R was identified in the vas deferens by
investigating activation of the JAK/STAT and MAP (mitogen activated
protein) kinase ERK (extracellular signal-regulated kinase) specific
intracellular signalling pathways. Activation of JAK/STAT and ERK
proteins, following binding of PRL to its receptor, mediates both
proliferative and differentiating effects in target cells (Findiori and
Kelly, 1995; Lewis et al., 1998).
Materials and methods
Subjects and tissues
Testicular tissue (n = 6), exhibiting normal morphology, was obtained by
biopsy from men exhibiting unexplained infertility. Vas deferens tissue
(n = 10) was obtained from normal men undergoing vasectomy. Left and
right vas deferens were used for comparison between treatment and control.
Ethical approval was obtained from Lothian Paediatric and Reproductive
Medicine Research Ethics Subcommittee, and written informed consent was
obtained from each subject. Prostate and bladder tissues were obtained from
archival surgical re-section specimens stored by the Department of Pathology,
Western General Hospital, Edinburgh. Epididymis and seminal vesicles were
obtained from a commercially available human cadaver tissue library.
Tissue culture
Following collection, vas deferens tissue was washed in phosphate-buffered
saline (PBS) twice and subsequently minced thoroughly with fine scissors.
Four aliquots of each tissue (-0.17 g each) were then incubated overnight in
2 ml serum-free RPMI 1640 medium (Sigma Chemical Co., Dorset, UK)
containing 100 IU/ml penicillin and 100 mg/ml streptomycin in a 37°C
incubator with 5% CC>2:95% air. The following day, samples were treated
with 100 ng/ml human PRL (hPRL-S!AFP-B2; donated by NIDDK, N1H) for
0, 5, 10 and 20 min. The tissue was stored at -70°C prior to analysis by
immunoprecipitation and/or Western blotting.
RNA extraction and RT-PCR
Total RNA was extracted from testis and vas deferens using the guanidinium
thiocyanate method as previously described (Chomczynski and Sacchi, 1987).
Polyadenylated RNA (poly A+) was purified on oligo(deoxythymidine)-
cellulose affinity columns (Pharmacia Biotech, St Albans, Herts, UK); the
yield and purity of RNA was estimated by spectrophotometry. Single strand
cDNA was generated from 5 pg poly A+ RNA by reverse transcription
using 1.6 ng oligo (deoxythymidine)]2_i8 primer and Superscript reverse
transcriptase, according to the manufacturer's instructions (Gibco BRL, Paisley,
UK). cDNA (10 ng) was then diluted 25 times in double-distilled H2O and
amplified by PCR using primers corresponding to nucleotide positions 182-
201 (5 '-CACCTCCTGAAAAACCCAAG-3'; forward primer) and 724-743
(5'-CCATGGTCTGGCTTGCAGCG-3'; reverse primer) of the PRL-R open
reading frame. The reaction was carried out in PCR buffer (50 mmol/1 KC1,
2 mmol/1 MgCl2 and 20 mmol/1 Tris-HCl, pH 8.3), 200 pmol/1 deoxy-NTPs,
25 pmol forward and reverse primers and 1 IU Taq polymerase (Perkin-Elmer,
Warrington, Cheshire, UK) in a total volume of 50 pi. Samples were subjected
to 35 cycles of 94°C for 40 s, 52°C for 75 s and 72°C for 150 s. After a
10 min final extension at 72°C, the products were visualized on a 1% agarose
gel using ethidium bromide staining.
Histology and immunohistochemistry
Testis, vas deferens and other tissues were placed immediately in Bouin's
fixative for 6 h before transfer to 70% ethanol, and subsequent dehydration
and embedding in wax blocks. Sections were cut and mounted on slides
coated with 2% 3-aminoproyltriethoxysilane (TESPA) in acetone. Slides
were then dried overnight at 50°C before dewaxing in histoclear (National
Diagnostics, Hull, UK). Tissues were rehydrated in graded ethanol and washed
in water followed by Tris-buffered saline (TBS; 0.05 mol/1 Tris-HCl, pH 7.4,
0.85% NaCl). Sections were treated with 10% hydrogen peroxide in methanol
for 30 min and blocked for 30 min with normal swine serum (NSS) diluted
1:5 in TBS with 5% bovine serum albumin (BSA).
The primary antibody for PRL-R (kindly donated by Dr P.M.Ingleton,
School of Medicine, University of Sheffield) was raised against a 16 amino
acid synthetic peptide corresponding to residues 53-68 of the external domain
of the rat PRL-R (Nevalainen et al., 1996). The polyclonal antibody was
validated for use in human tissue based on the manner that pre-absorption of
the antibody with the corresponding synthetic peptide totally blocked the
immunostaining (Nevalainen et al., 1999). The polyclonal antibody was
diluted in NSS/TBS/5% BSA (as above) and incubated overnight at 4°C.
Control sections were incubated with non-immune rabbit serum. All sections
were washed twice in TBS (5 min each), incubated for 30 min with biotinylated
swine anti-rabbit Ig (Dako, Bucks, UK), diluted 1:500 in NSS/TBS. Sections
were washed again twice in TBS (5 min each) and incubated with peroxidase
conjugated to avidin-biotin complex (Dako) for 30 min at room temperature.
Colour reaction was developed by incubation in a mixture of 0.05%
3,3'-diaminobenzidine (DAB; Sigma) in 10 ml 0.05 mol/1 Tris-HCl buffer
(pH 7.4) and 0.033% hydrogen peroxide. Sections were subsequently coun-
terstained using haematoxylin.
Immunoprecipitation and Western blotting
Tissue was homogenized and lysed in 150 mmol/1 NaCl, 10 mmol/l Tris
(pH 7.4), 1 mmol/1 EDTA, 10% glycerol, 0.6% NP40, 10 pg/ml aprotonin,
1 mmol/1 phenylmethylsulphonyl fluoride and 1 mmol/1 sodium orthovanadate.
Cytoplasmic extracts were prepared by centrifugation for 2 min at 10 000 g.
For analysis of phosphorylation of JAK 2 and STAT 5, 50 pg of protein was
incubated with 10 pi monoclonal anti-phosphotyrosine antibody (5 mg/ml;
Affiniti, Exeter, UK) for 1 h at 4°C. Samples were then incubated overnight
at 4°C with M-450 Dynabeads conjugated to rat anti-mouse lgG2b (Dynal,
Wirral, UK). The complexes were washed three times in PBS using a Dynal
MPC magnet (Dynal), and boiled for 5 min in sample buffer [125 mmol/1
Tris-HCl, pH 6.8, 4% sodium dodecyl sulphate (SDS), 2.5% dithiothreiotol,
20% glycerol, 0.05% Bromophenol Blue].
For Western blotting, samples were subjected to SDS-PAGE and then
transferred to polyvinylidene difluoride membrane (Millipore, Bedford, MA,
USA). For analysis of ERK phosphorylation, 50 pg of protein from each
sample was analysed. Membranes were incubated with antibodies against
ERK 2, JAK 2, STAT 5 (Santa Cruz Biotechnology, Santa Cruz CA, USA) or
phosphorylated ERK (T202/Y204, Cell Signaling, New England Biolabs,
Beverly, MA, USA), each diluted 1000-fold in 2% dried skimmed milk/TBST
(20 mmol/1 Tris-HCl pH 7.4, 500 mmol/1 NaCl, 0.1% Tween 20). Membranes
were washed briefly in TBST and incubated with secondary antibodies
conjugated to horse radish peroxidase (Amersham, Buckinghamshire, UK), in
2% milk/TBST. Membranes were again washed in TBST and proteins detected
using the ECL+ detection kit (Amersham).
Statistical analysis
The degree of phosphorylation of proteins in response to PRL was measured
at four time points by densitometry, and the significance of the changes was
analysed by analysis of variance (ANOVA) with repeated measures.
Results
RT-PCR of PRL-R mRNA
The expression of PRL-R was analysed initially by RT-PCR. using
RNA extracted from testis and vas deferens. A single 312 bp transcript,
corresponding to a region in the extracellular domain of the human






Figure 1. RT-PCR analysis of prolactin receptor (PRL-R) from RNA
purified from human vas deferens and testis. Lane 1: DNA size marker,
lanes 2-5: RNA from vas deferens, lanes 6 and 7: RNA from testis, lanes 8
and 9: no reverse transcriptase added, lane 10: positive control using PRL-R
cDNA as template. The predicted size of the PCR product corresponding to
the extracellular domain of the PRL-R mRNA is marked as 312 bp.
deferens tissue, indicative of the presence of PRL-R mRNA in these
tissues (Figure 1).
Immunohistochemistry of PRL-R
To determine the localization of PRL-R, immunohistochemistry was
performed using sections prepared from human testis, vas deferens,
epididymis, prostate, seminal vesicle and bladder. In the testis biopsies
of all six subjects, weak but consistent immunostaining was localized
to the Leydig cells in the interstitial tissue and stronger staining
localized to the germ cells at different stages of spermatogenesis in
the seminiferous tubules. Representative micrographs are shown in
Figure 2a.c. The most marked staining was evident in the cytoplasm
of the germ cells in the developmental stages extending from
pachytene spermatocytes to elongating spermatids. The spermato¬
gonia, early dividing spermatocytes and final differentiating sperm
were devoid of staining, as were the Sertoli cells (Figure 2c). Control
sections of testis were totally devoid of staining (Figure 2b). In vas
deferens collected from 10 different subjects, and in epididymis
and seminal vesicle samples collected from three other subjects,
immunostaining for PRL-R was consistently evident in the epithelium,
with minimal staining in the underlying stroma and muscle tissue
(Figure 2d,f,g); control sections of vas deferens were again unstained
(Figure 2e). Immunostaining for PRL-R was also consistently present
in the epithelium of the prostate in three subjects (data not shown;
demonstrated previously) (Nevalainen et al., 1997).
Intracellular signalling in the vas deferens
Intracellular signalling pathways were examined by investigating
tyrosine phosphorylation of JAK 2 and STAT 5 and tyrosine and
threonine phosphorylation of ERK 1 and 2, following stimulation of
fresh vas deferens tissue with human PRL (Figure 3). This was
repeated using fresh tissue from three different subjects attending for
vasectomy. Tyrosine phosphorylation of JAK 2 and STAT 5 was
measured by an immunoprecipitation procedure using an antibody
against phosphorylated tyrosine, followed by Western blotting using
antibodies against JAK 2 and STAT 5. Phosphorylation of ERK 1
and 2 were measured by Western blotting using an antibody raised
against ERK, phosphorylated on specific tyrosine and threonine
residues, and the density of the signal was measured by densitometry.
Rapid phosphorylation, with a significant increase in signal intensity
{P < 0.05, ANOVA), was observed following treatment with PRL
for ERK 1 and 2 (evident from 5 min), JAK 2 (10 min) and STAT
5 (20 min) (Figure 3). No increase in phosphorylated proteins was
observed in the absence of PRL.
Discussion
The data presented here demonstrate that PRL-R is expressed in the
human testis and in various male accessory glands. This is based on
RT-PCR amplification of the receptor mRNA extracted from testis
and vas deferens, and the localization of the receptor protein by
immunocytochemistry in a range of reproductive tissues. Furthermore,
incubation studies with fresh tissues of human vas deferens show
that the addition of PRL activates phosphorylation of several proteins
known to mediate the intracellular effects of PRL in target cells.
These data provide clear evidence for functional activation of
PRL-R in a clinically accessible human male reproductive tissue.
Various isoforms of PRL-R, differing in the intracellular domain,
have been characterized in man, and these are differentially expressed
in the many PRL target organs (Kline et al., 1999; Hu et al., 2001).
Long forms are expressed in the testis, and long and intermediate
forms in the prostate. In the human testis, the abundance of PRL-R
mRNA is low compared with many tissues (Kline et al., 1999), and
there is evidence that a consistent portion of PRL-R present in the
testis is in a truncated form which may block, or alter, the function
of the long form of the receptor (Hu et al., 2001). The methodology
used in the current study was directed at the extracellular domain of
PRL-R (cDNA primers for RT-PCR, and antibody for immunocyto¬
chemistry). Thus, it was not possible to confirm the expression of
the different isoforms of PRL-R in the human testis and other tissues.
In the rat, different isoforms of PRL-R have been identified, and both
are expressed in the testis and accessory glands (Ouhtit et al., 1993).
Hence, it is likely that a similar diversity of PRL-R expression exists
in human testis and accessory glands; this may permit tissue-specific
responses to PRL within the male reproductive tract.
The current immunohistochemical studies localized for the first
time the PRL-R protein to the Leydig cells and germ cells of the
human testis. This is contrary to the results of an earlier study which
failed to detect PRL-R in human testicular tissue using a radioreceptor
method, although the receptor was readily demonstrated in the rat
(Wahlstrom et al., 1983). This was despite the use of fresh human
testicular tissue, and a comprehensive study of the binding charac¬
teristics of human PRL in testis homogenates. The most likely
explanation for the discordance is that PRL-R is expressed at
low abundance in the human testis, and it requires a sensitive
immunohistochemical or molecular amplification method to resolve
the localization or gene expression in the tissue. The current study
also confirmed PRL-R expression in the secretory, adsorptive or
lining epithelium in the various accessory male structures. The pattern
of immunostaining in the testis is similar to that described in the red
deer and ram (Jabbour et al., 1998a; Jabbour and Lincoln, 1999).
Expression of the receptor in Leydig cells is consistent with a role
of PRL in the control of testicular steroidogenesis. Evidence in rodent
species suggests that PRL influences testosterone secretion through
the stimulation and maintenance of expression of LH receptors in
Leydig cells (Klemcke et al., 1984; Takase et al., 1990) or by
regulating specific enzymatic steps in androgen biosynthesis
(Chandrashekar and Bartke, 1988). The effect of PRL on steroidogen¬
esis in the adrenal gland is also well documented in animals and man
(Glasow et al., 1996).
The presence of PRL-R in the differentiating germ cells in the
testis is consistent with the view that PRL acts directly within the
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Figure 2. Immunohistochemistry of the prolactin receptor (PRL-R) in human male reproductive tissues. Human testis was immunostained with (a) and
without (b) PRL-R antibody and examined at X20 magnification. Panel (c) corresponds to testis immunostained with PRL-R and examined at X40
magnification. Expression of PRL-R is evident in Leydig cells (L) in the interstitial tissue, pachytene spermatocytes (P), and around spermatids (RS) in the
seminiferous tubules. There was no apparent staining in the spermatocytes at early stages of spermatogenesis (PS) and differentiated sperm (S). Vas deferens
was immunostained with (d) and without (e) PRL-R antibody and examined at X40 magnification. Panel (f) human epididymis and panel (g) human seminal
vesicle stained for PRL-R. Size bar = 100 mm.
seminiferous tubules to affect spermatogenesis, as well as acting
indirectly through gonadal steroid secretion. In the immature hypophy-
sectomized rat, treatment with PRL stimulated an increase in the
number of primary spermatocytes (Dombrowicz et al., 1992), while
in hypoprolactinaemic subfertile men, exogenous PRL, or treatment
with metoclopramide to promote PRL secretion, increased sperm
density, reduced sperm abnormalities and acted to restore fertility










Figure 3. Phosphorylation of JAK 2, STAT 5 and ERK1/2 in the human vas
deferens, in response to prolactin. Tissue was serum starved and incubated
with 100 ng/ml of human prolactin for 0, 5, 10 or 20 min. (A) Proteins
immunoprecipitated with anti-phosphotyrosine antibody and analysed by
Western blotting using antibodies against JAK 2 (i) and STAT5 (ii). (B)
Proteins analysed by Western blotting using antibodies against
phosphorylated (T202/Y204) ERK (i) and (non-phosphorylated) ERK (ii).
of PRL in the testis are largely dependent on the concurrent secretion
of LH and FSH (Lincoln et al., 2001). Taken together, the data
indicate that PRL acts within the testis to facilitate and augment the
actions of LH and FSH in promoting full testicular activity.
The universal distribution of PRL-R in the epithelium of the
epididymis, vas deferens, seminal vesicles and prostate confirms that
PRL also plays a role in the regulation of accessory gland function
in man. Animal studies clearly demonstrate that PRL acts in associ¬
ation with androgens to stimulate the activity of the accessory glands.
For example, the production of secreted proteins from cultured rat
prostate cells is markedly enhanced by addition of PRL (Nevalainen
et al., 1996). In transgenic rodent models, over-expression of PRL,
or its receptor, is associated with enlargement of the accessory glands,
while under-expression is associated with reduced functional activity
(Wennbo et al., 1997). The clinical observation that suppression of
PRL enhances the effectiveness of steroid withdrawal for the treatment
of malignant disease of the prostate (Rana et al., 1995) also supports
an action for PRL in the human accessory glands. The presence of
PRL-R in the epithelial cells in the tissues of the male reproductive
tract suggests that PRL is potentially involved in the regulation of
secretion, absorption, and/or the control of transport of fluids across
the cell membrane. This is consistent with a conserved function of
PRL in epithelial tissues across species (Nicoll, 1974).
As well as demonstrating functional PRL-R within the vas deferens,
the current results support the view that PRL signals through more
than one intracellular pathway to regulate the tissue responses. In the
vas deferens, PRL activated rapid tyrosine phosphorylation of JAK
2 and STAT 5 protein. The temporal sequence is similar to that
observed in other PRL target-tissues including rat mammary gland
(Jahn et al., 1997) and ovary (Ruff et al., 1996), ram testis (Jabbour
and Lincoln, 1999) and human endometrium (Jabbour et al., 1998b).
Upon activation, STAT proteins dimerize. translocate to the nucleus
and bind to STAT-regulatory elements in the promoters of target
genes to influence transcription (Schindler and Darnell, 1995). In the
mammary gland, activation of STAT 1 and STAT 5 proteins up-
regulate transcription of genes for (3-casein (Gouilleux et al., 1994),
P-lactoglobulin (Burdon et al., 1994) and whey acidic protein (Li
and Rosen, 1995) to mediate the effects of PRL on milk synthesis
and secretion. The target genes for PRL in the vas deferens epithelium
are still unknown, but are likely to include genes encoding secret¬
ory proteins.
The demonstration of rapid phosphorylation of ERK proteins in
response to PRL in human vas deferens indicates that PRL also acts
via the ERK pathway to affect the function of the secretory epithelium.
The involvement of both the JAK/STAT and ERK pathways acting
together to influence differentiation has been documented in other
cell types (Lewis et al., 1998). In the human endometrium, PRL
induces the JAK/STAT and ERK pathways in the epithelial cells
during the secretory phase of the menstrual cycle (Jabbour et al.,
1998b; Gubbay et al., 2001). The activation of ERK by PRL in
terminally differentiated secretory epithelium, as in the human vas
deferens, indicates that PRL signals through ERK, as well as through
the JAK/STAT pathway, to provide divergent control of more than
one cellular response. In the current study, only fresh tissue from
human vas deferens was available for tissue culture, thus it was not
possible to establish the pattern of phosphorylation of the second
messenger proteins in the different male reproductive tissues.
In conclusion, this study provides clear support for the view that
PRL is a regulator of reproductive function in the human male.
PRL appears to act in the Leydig cells of the testis to promote
steroidogenesis, and in the germ cells of the seminiferous tubules of
the testis to promote the efficiency of spermatogenesis, actions that
augment the more dominant progonadal effects of LH and FSH. PRL
also acts in the epithelia of the efferent ducts and the male accessory
sex glands, in conjunction with the gonadal steroid hormones, to
regulate the secretory/adsorptive functions of these male tissues. Our
results are consistent with the pleiotrophic character of PRL, as a
hormone with multiple target tissues signalling through multiple
pathways. A role for PRL within the male reproductive tract, suggests
that abnormalities in circulating levels of PRL within the body, or
abnormalities in PRL-R function, may have a significant impact on
male fertility.
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BACKGROUND: Administration of testosterone inhibits gonadotrophin secretion and spermatogenesis in men but
the degree of response is highly variable. This treatment also stimulates prolactin, itself a progonadal hormone in
animals. This study investigated whether concomitant suppression of prolactin (PRL) with the non-ergot, dopamine
receptor agonist quinagolide (Q), would enhance the efficacy of testosterone in its inhibition of spermatogenesis in
healthy eugonadal men. METHODS: A total of 46 men were randomized to three treatment groups: Group 1,
T1200: 1200 mg testosterone implant plus daily oral placebo; Group 2, T1200 + Q: 1200 mg testosterone plus oral Q
75 pig/day; Group 3, T800 + Q: testosterone 800 mg plus oral Q 75 pg/day. After an initial pre-treatment period of 4
weeks, subjects were treated for 24 weeks followed by an 8-week recovery period. RESULTS: The total numbers of
subjects that achieved severe oligospermia (=sl06/ml including azoospermia) from weeks 8-16 were 11/13 (85%), 11/
12 (92%), 8/13 (61.5%) in the three groups respectively. CONCLUSIONS: The results show that inhibition of PRL
does not to confer additional efficacy in spermatogenic suppression in men. However, Q did not totally block PRL
secretion in the subjects, possibly because testosterone replacement itself stimulated PRL by a direct action on the
lactotroph, thus the effectiveness of dual inhibition of gonadotrophin and PRL could not be fully investigated.
Key words: prolactin inhibition/quinagolide/spermatogenesis/testosterone
Introduction
Androgen administration aimed at producing a reversible
contraceptive for men acts by inhibition of FSH and LH
secretion to suppress spermatogenesis. It does not however
suppress PRL secretion, which, at least in animal models, is a
weak gonadotrophin (Bartke et al., 1975; Ouhtit et al., 1993;
Lincoln et al., 1996; Jabbour and Lincoln, 1999). Initial studies
showed that long-term treatments with testosterone esters, even
at high doses, induce azoospermia in only a proportion (-65%)
of subjects with notable differences between ethnic groups
(World Health Organization Task Force, 1990; Handelsman
et al., 1992; Sundaram et al., 1993; Behre et al., 1995). More
recently, steroid treatments involving testosterone combined
with progestins, have been shown to be more effective in the
suppression of spermatogenesis (Bebb et al., 1996;
Handelsman et al., 1996; Meriggiola et al., 1996; Wu et al.,
1999; Martin et al., 2000). Treatments with anti-androgenic
progestins (e.g. cyproterone acetate) however, produce
undesirable changes in the haemopoeitic system (Meriggiola
et al., 1996), and progestins may produce effects on mood, as is
well demonstrated in women (Pearlstein, 1995). In addition
these treatments have not been shown to produce universal
© European Society of Human Reproduction and Embryology
azoospermia (Bebb et al., 1996; Handelsman et al., 1996;
Meriggiola et al., 1996; Wu et al., 1999; Martin et al., 2000). A
number of suggestions have been proposed to explain the
heterogeneity in the contraceptive response to steroid treat¬
ments. These include differing sex hormone-binding globulin
(SHBG) levels and responsiveness to gonadotrophin suppres¬
sion (Behre et al., 1995; Wang et al., 1998), differing 5-alpha
reductase activity in the testis and its impact on intra-testicular
androgen levels (Anderson et al., 1996), structural differences
in testicular morphology between ethnic groups (Zhengwei
et al., 1998) and possible differences in sex steroid metabolism
and/or diet (Santner et al., 1998).
An additional explanation for the failure to induce complete
azoospermia is that it may be necessary to inhibit PRL, in
addition to the classical gonadotrophins, to fully block
spermatogenesis. This is because PRL potentially acts in the
testis to stimulate both androgenic and spermatogenic func¬
tions, based on studies in rodents (Hondo et al., 1995). In man
the progonadal role of PRL is less clear. Early studies using
II25-PRL failed to demonstrate PRL binding in the human
testis, in contrast to the situation in the rat (Wahlstrom et al.,
1983). More recently, nnRNA for the PRL receptor has been
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characterized in the human testis (Kline et al., 1999), and
immunocytochemistry has revealed that PRL receptors are
weakly expressed in the Leydig cells in the interstitial tissue
and more strongly expressed in germ cells undergoing
spermatogenesis in the seminiferous tubules (Hair et al.,
2002). Functional activation of these receptors and their
secondary messenger systems JAK-STAT and the extracellular
signal-regulated kinase (ERK) by PRL has also been demon¬
strated in human testis and vas deferens. Furthermore, there is
clinical data indicating that PRL may promote spermato¬
genesis. In one study, treatment with exogenous PRL, or a
dopamine antagonist to increase circulating PRL concentra¬
tions was shown to restore testicular function and fertility in
hypoprolactinaemic infertile men (Ufearo and Orisakwe,
1995), and in another study, combined suppression of
gonadotrophins and PRL in eugonadal men treated for prostatic
carcinoma produced a more marked reduction in testicular
weight than gonadotrophin suppression alone (Huhtaniemi
et al., 1991). Based on these observations, and the demonstra¬
tion that the administration of testosterone and oral progestin
stimulates PRL secretion (Bellis and Wu, 1998), we infer that
suppression of PRL may enhance the effectiveness of sex
steroid in inducing spermatogenic suppression in man.
The purpose of the present study was to test this hypothesis.
Healthy male volunteers were treated orally with the non-ergot
dopamine receptor agonist quinagolide (Q), to chronically
suppress PRL secretion. This drug has been shown to inhibit
PRL production with minimal effects on the gastrointestinal
tract and on nausea, mood and sleep behaviours (Brownell
et al., 1996). At the start of the treatment, the volunteers also
received s.c. implants of testosterone to suppress gonadotro¬
phin secretion. Implants were used rather than intermittent
injections to provide a smooth androgen profile with less
inconvenience to the subjects. A high and an intermediate dose
of testosterone was selected to establish whether PRL inhib¬
ition would act in synergy with the degree of gonadotrophin
suppression and perhaps allow use of a lower dose of androgen
to induce azoospermia in men.
A preliminary report on this study has been published as an
abstract (Hair et al., 2000).
Materials and methods
Subjects
The study medication and design, information for volunteers, method
of recruitment and the reimbursement of expenses were all approved
by the Central Manchester Ethical Committee for Medical Research
and by the Medical Research Council. Prospective volunteers were
recruited from the community though local media advertising. Written
and verbal information as to the nature of the study was provided to
480 men. Prospective candidates were then interviewed during which
a full medical history was obtained and thereafter underwent physical
examination. Routine haematology, biochemistry and semen analysis
were then performed as screening tests on two occasions 2 weeks
apart, to determine if subjects met the inclusion criteria. The subjects
were required to be within the age range 19-50 years, free of chronic
disease, on no long-term medication, with normal haematology and
biochemical screening tests and a normal semen profile based on
World Health Organization (WHO) guidelines (World Health
Organization, 1999). The subjects were also required to be willing
to continue with their existing contraceptive method. Following
recruitment, 46 volunteers entered the study.
Medications
Quinagolide (Q) was used to chronically inhibit PRL secretion in the
volunteers. The drug tablets were supplied by Novartis (Norprolac;
Novartis Pharmaceuticals UK Ltd. Frimley, Surrey, UK). Subjects
initially received a Starter Pack containing two tablets each of 25, 50
and 75 pg of Q to allow graded introduction of the medication.
Following the introduction over 6 days, the subjects took one 75 pg
tablet per day. This dose was selected based on manufacturer's
recommendations in the treatment of hyperprolactinaemia to effect¬
ively suppress PRL secretion and minimize side effects. A small pilot
study in five normal men was also conducted. This demonstrated that
daily administration of 75 pg Q suppressed blood plasma PRL
concentration by >80% for the 9 day treatment period with a carryover
effect for 3 days. For the main clinical trial, tablets were taken after
food and before bed. Placebo tablets supplied by our hospital
pharmacy were taken by one group of subjects as a control.
Crystalline testosterone implants (200 mg) were generously
donated by Organon (Product licence No. 0065/5084R; NV
Organon, Oss, Netherlands). Implants were inserted using a trocar
with sterile technique in the s.c. fat of the anterior abdominal wall with
local anaesthesia using 1% lignocaine. In the high dose treatment the
subjects received six implants (1200 mg), and in the lower dose they
received four implants (800 mg). These doses were selected on the
basis that 1200 mg testosterone produces severe oligospermia in
normal men, while 800 mg testosterone less completely suppresses
sperm numbers.
Study design
Subjects were randomized to one of three treatment groups in a single
blind parallel group design: Group 1; testosterone 1200 mg plus daily
oral placebo (T1200); Group 2: testosterone 1200 mg plus oral Q
75 |ig/day (T1200 + Q); and Group 3: testosterone 800 mg plus oral Q
75 |Xg/day (T800 + Q). A more balanced design would have utilized a
T800 + placebo group but this was not included due to constraints on
the number of volunteers and the power calculation requirement of no
fewer than 12 subjects per group. The protocol involved a pre-
treatment phase of 4 weeks, a treatment phase of 24 weeks and a
recovery phase of 8-12 weeks (see Figure 1). The treatment phase was
initiated by the insertion, on one occasion, of either four or six
testosterone implants according to treatment-group. The subjects also
commenced daily oral Q, or placebo tablets, which were dispensed
monthly at the clinical monitoring visit. Treatment of the subjects did
not occur simultaneously but was staggered according to time of
recruitment. The recovery phase was determined by the time to re-
attainment of the pre-treatment sperm concentration in the ejaculate,
or to two consecutive sperm counts >20x 106/ml.
Clinical monitoring
Every 4 weeks throughout the study each subject was weighed and
pulse and blood pressure measured. They were then interviewed to
record evidence of compliance, unused tablets were returned and any
notable effects of the treatment were recorded. A blood sample was
obtained for hormone measurements, and a semen sample was
produced for analysis. The blood samples were heparinized,
centrifuged within 30 min of collection and stored at -20°C until
analysis on completion of the full study. Every 8 weeks, additional
blood samples were obtained for monitoring of haematological
parameters, renal and liver function tests and serum lipid concentra¬
tions. Testis size was measured using an orchidometer. At the
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Figure 1. Long term changes in the blood plasma concentrations of prolactin (PRL), testosterone (T), FSH and LH in groups of male
volunteers treated with testosterone implants with either quinagolide (Q) or placebo as follows: (i) T1200 mg + daily oral placebo (open
square symbol), (ii) T1200 mg + 75 |lg daily oral Q (closed square symbol), (iii) T800 mg + 75 pg daily oral Q (open round symbol). The
testosterone implants were inserted once only at week 0 and the Q treatment was continued for 24 weeks (horizontal bar = treatment period).
Values are mean ± SEM. n = 13, 12 and 13 for the three groups respectively.
beginning and end of the study a standard rectal examination of the
prostate was carried out.
Semen analysis
Semen samples were obtained by masturbation after 48 h abstinence
and analysis of semen volume, pH, sperm concentration, motility and
morphology was carried out within 60 min of collection according to
WHO guidelines (World Health Organization, 1999). Azoospermia
was verified by centrifugation of the whole semen sample and
microscopic examination of the re-suspended pellet residue.
Blood analysis
Full blood counts, glucose, HbAlc, urea, electrolytes, liver enzymes
and lipid profiles were measured by a hospital auto-analyser. Low-
density lipoprotein (LDL) cholesterol was derived using the Friedwald
formula. On completion of the clinical study the blood plasma
concentrations of prolactin (PRL), FSH and LH were assayed in all
subjects by highly sensitive immunofluorometric assays (Delfia,
Pharmacia-Wallac, Turku, Finland) with an assay sensitivity of 9.0,
0.125 and 0.125 IU/1, respectively. Total testosterone was determined
by previously described radioimmunoassay (Corker and Davidson,
1978) with a detection limit of 0.3 nmol/1.
Statistical analysis
Results are expressed as group mean ± SEM. Data were analysed by
two-way ANOVA with repeated measures using Statistica software
(version 4.0) to identify significant time-by-group interactions with
Tukey's post-hoc comparisons. In addition, ANOVA with repeated
measures was performed within each group to detect significant
effects of treatment. Baseline levels for each variable were defined as
the arithmetic mean of the two pre-treatment samples. Recovery levels
were defined as those obtained at 4-12 weeks following completion of
treatment according to time at which the recovery criteria were met.
Severe oligospermia was defined as a specimen with sperm present in
the ejaculate but at a concentration of <1X 106/ml. Testis volume was
defined as the sum of volume measurements for the left and right




Of the 46 men who entered, 38 completed the study. Five men
failed to attend regular clinical appointments and were lost to
follow-up after 4-20 weeks without explanation. One man was
withdrawn from the study due to extrusion of two testosterone
implants and due to his lack of compliance with oral Q. Two
subjects did not tolerate oral Q: in one case, the treatment
caused symptoms of nausea and vomiting during the first few
days of treatment and in the second case the treatment caused
perceived effects on mood and libido from week 4 and the
subject subsequently withdrew at week 16. After these losses
the group sizes were 13, 12 and 13 for T1200, T1200 + Q and
T800 + Q treatments respectively.
In the 38 men who completed the study, the oral Q and
testosterone implants were generally well tolerated and there
were no serious adverse effects reported by the participants.
Transient morning nausea in the first week was reported by two
subjects taking oral Q and by one subject taking the placebo.
Mild acne was reported in four subjects and increased libido at
the start of the study was reported in 16 subjects. There was no
apparent difference in these symptoms in the three treatment
groups. The men did not differ significantly between groups in
age (Group T1200 + placebo, 30.77 ± 1.99 years; Group
T1200 + Q, 33.36 ± 1.5 years and Group T800 + Q, 34.75 ±
751
W.M.Hair, F.C.W.Wu and G.A.Lincoln
I.23 years), body weight (83.54 ± 4.54, 81.33 ± 4.82, 76.36 ±
3.37 kg respectively) and testis volume (45.83 ± 2.6, 49.64 ±
2.43, 44.55 ± 2.73 ml). All subjects had a pre-treatment sperm
concentration >20X106/ml in the ejaculate.
PRL/testosterone manipulations
Q treatment
Blood plasma concentrations of PRL are shown in Figure 1
(upper left panel). The treatment with Q suppressed PRL
concentrations but with notable inter-subject variability. The
statistical analysis of the PRL profiles revealed a significant
{P < 0.05) time-by-treatment interaction. PRL concentrations
were significantly (P < 0.05) decreased at weeks 4-24
(throughout the treatment period) in the T1200 + Q and
T800 + Q groups, compared with the T1200 + placebo group.
The mean PRL concentrations for the treatment period were as
follows: 43.5 ± 18.6, 52.6 ± 21.4 and 162.3 ± 14.9 mIU/1 for
the T1200 + Q, T800 + Q and T1200 + placebo groups
respectively. There was no significant difference in the PRL
concentrations between the two groups that received Q. PRL
was suppressed by at least 80% (compared to pre-treatment
values) in 9/12 (75%) subjects in the T1200 + Q group, and in
9/13 (69%) subjects in the T800 + Q group. The remaining
subjects suppressed to a mean 47.73 ± 8.26% (range
II.2-72.2%). There was no disclosed non-compliance to
explain this variability in PRL suppression.
There was also evidence that testosterone alone increased
PRL secretion. In the testosterone 1200 + placebo group,
plasma PRL concentrations increased significantly (P < 0.05)
relative to pre-treatment values at week 4 following insertion
of the testosterone implants. In the testosterone 1200 + Q and
T800 + Q groups, PRL concentrations also increased signifi¬
cantly (P < 0.05) above the placebo group at week 28, as a
rebound response to cessation of Q.
Testosterone implantation
After insertion of the testosterone implants, total testosterone
concentration increased above baseline for 4-8 weeks in all
groups (Figure 1, upper right panel). The analysis of the
total testosterone concentration in blood plasma showed a
significant (P < 0.001) effect of time but no statistical
differences between groups, although plasma concentrations
of testosterone were lower in the T800 + Q group.
Gonadotrophin suppression
Plasma LH and FSH concentrations were markedly suppressed
by the testosterone treatment in all groups (Figure 1, lower
panels). Concentrations were lowest at week 4 and remained
suppressed until week 12 before increasing to pre-treatment
values by week 24. The analysis revealed a significant (P <
0.001) time-by-treatment interaction; the plasma LH and FSH
concentrations were significantly (P < 0.05) lower in both
T1200 groups compared with the T800 + Q group from weeks
4-16. There was no significant difference in gonadotrophin
concentrations between the T1200 + placebo and the testos¬
terone 1200 + Q groups during the phases of suppression and
recovery.
Figure 2. Long term changes in sperm density in the ejaculate of
groups of male volunteers treated with testosterone (T) implants
with either quinagolide (Q) or placebo as follows: (i) T1200 mg +
daily oral placebo (open square symbol), (ii) T1200 mg + 75 pg
daily oral Q (closed square symbol), (iii) T800 mg + 75 pg daily
oral Q (open round symbol). The testosterone implants were
inserted once only at week 0 and the Q treatment was continued for
24 weeks (horizontal bar = treatment period). Values are mean ±
SEM. n = 13, 12 and 13 for the three groups respectively.
Sperm suppression and recovery
Pre-treatment sperm concentrations in the ejaculate were
similar in the three treatment groups (group means: 55.19 ±
8.09, 40.62 ± 6.97, 51.08 ± 9.36 millions/ml for T1200 +
placebo, T1200 + Q and T800 + Q respectively) (Figure 2).
Sperm concentration fell sharply in all groups by week 4 of
treatment and continued to decline until weeks 12-16 before
increasing by week 24. Sperm concentrations returned to pre-
treatment values by weeks 28-32. The analysis demonstrated a
significant {P < 0.001) time-by-treatment interaction, with
sperm concentrations significantly (P < 0.05) reduced in both
T1200 groups, compared with the T800 + Q group from weeks
12-20. There was no significant difference in sperm concen¬
trations between the T1200 + placebo and the testosterone
1200 + Q groups during the phases of suppression and
recovery.
The proportion of subjects in each group who achieved
severe oligospermia/azoospermia (sperm concentration
<lxl06/ml) for at least 4 weeks was 11/13 (85%), 11/12
(92%), 8/13 (61.5%) in T1200 + placebo, T1200 + Q and
T800 + Q groups respectively. The corresponding numbers
achieving azoospermia were 5/13 (38%), 6/12 (50%) and 5/13
(38%). The group profiles for the incidence of oligospermia
and azoospermia are summarized in Figure 3. Inhibition was
maximal at weeks 8-16 with a similar pattern in the three
treatment groups; the incidence of sustained oligo/azoospermia
was least in the testosterone 800 + Q group. In this group, the
subjects in which PRL secretion was maximally inhibited
(suppression >80% of pre-treatment, n = 9), the degree of
spermatogenic suppression was notably greater than in those
subjects in whom PRL was inadequately suppressed (n = 4).
Severe oligospermia/azoospermia was achieved in 78% of the
PRL inhibited group but only 25% in the poorly inhibited
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Figure 3. Percentage of subjects achieving severe oligospermia
(OLIGO) (sperm concentration in the ejaculate <lX106/ml, hatched
histogram) and azoospermia (AZO) (absence of sperm in ejaculate,
filled histogram), in groups of male volunteers treated with
testosterone implants with either quinagolide (Q) or placebo as
follows: (i) T1200 mg + daily oral placebo, (ii) T1200 mg + 75 |lg
daily oral Q and (iii) T800 mg + 75 (Ig daily oral Q. The
testosterone implants were inserted once only at week 0 and the Q
treatment was continued for 24 weeks (horizontal bar = treatment
period).
group; this apparent association between PRL and sperm
production was not evident in the testosterone 1200 + Q group.
Progressive motility (WHO categories, a + b) was unaffected
by treatment in the three groups. Ejaculate volume was
marginally decreased in the three treatment groups from weeks
12-20 (range 8-29%) with no difference between groups.
Semen pH was unaffected by treatment.
Metabolic, haematological and general effects of treatment
Blood plasma concentration of high-density lipoprotein (HDL)
cholesterol was decreased at week 12-20 during treatment with
no significant differences between the three groups.
Concentrations had not returned to pre-treatment values by
the end of the recovery period. Total cholesterol, triglycerides
and LDL cholesterol concentrations were not affected by the
treatments. Body weight, blood pressure, pulse, liver function
tests (albumin, aspartate amino transferase, alanine amino
transferase, alkaline phosphatase and albumin), glucose
metabolism (fasted blood glucose, HbAlc) and renal function
(electrolytes, urea, creatinine) were also unaffected by the
treatments. Haemoglobin concentrations were significantly
(P < 0.01) increased at week 12 in all groups, in parallel with
experimentally induced changes in testosterone, but were
otherwise unaffected. Other haematology indices (white blood
cell count and platelets) were unaffected. Prostate examination
revealed no changes related to any treatment.
Discussion
The aim of this study was to establish whether suppression of
PRL enhances the effectiveness of exogenous testosterone in
inhibiting sperm production in normal men. This was based on
the potential progonadal effects of PRL, and the presumption
that the simultaneous suppression of both PRL, and the
classical gonadotrophins LH and FSH, would induce more
complete spermatogenic arrest. The overall results do not
support the hypothesis. The degree of spermatogenic arrest and
the period of induced azoo/oligospermia was similar in the
T1200 and T1200 + Q groups, and the effects in the T800 + Q
group were comparable to those previously reported for men
receiving this dose of testosterone alone (Handelsman et al.,
1992). There was, therefore, no significant effect on the
spermatogenic profiles associated with the chronic treatment
with our selected dose of Q.
The current experiment was designed to compare treatments
with and without Q in the presence of a standardized high dose
of testosterone (T1200 mg). This was based on the expectation
that this level of testosterone would produce sub-maximal
sperm suppression and allow us to detect an additional effect
due to Q. However, the T1200 mg treatments in this study
produced a very high degree of sperm suppression, leaving
little scope to observe an additional effect of Q during the
treatment phase. We therefore looked for an effect of the PRL
manipulation on the pattern of recovery at the time when the
testosterone implants were becoming exhausted (weeks 12-24)
and daily Q treatment continued. Again, there was no
significant difference between the T1200 + placebo and
T1200 + Q groups in this pattern of recovery, although the
T1200 + Q subjects were the last to return to pre-treatment
values, and there was a period at weeks 24-28 where there was
no overlap in sperm concentrations between the two groups,
that is suggestive of a marginal effect. The only evidence that
the Q treatment may have had some androgen dose-sparing
effect was obtained from the T800 + Q group. In this group,
there was marked individual variation in the degree of
inhibition of PRL and degree of spermatogenic suppression.
In the subjects in which PRL secretion was maximally
inhibited (suppression >80% of pre-treatment, n = 9), the
degree of spermatogenic suppression was greater than in those
subjects in whom PRL was inadequately suppressed (n = 4).
Severe oligospermia was achieved in 78% of the PRL inhibited
group, which was comparable with 85% for the T1200 +
placebo group. This provides minimal support for the view that
only in partial hypogonadotrophic states when gonadotrophin
concentrations are sub-maximally reduced (as in the T800
group), is it possible to observe any concomitant effect of PRL
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withdrawal. A subtle interactive effect of PRL and gonado¬
tropin status has previously been described in animal models
where the effects of LH and FSH on testicular physiology
always predominate (Bartke, 1999; Lincoln et al., 2001).
The unexpected finding in our trial was that the oral Q was
not fully effective at blocking PRL and there was marked
variability in the degree of PRL suppression between subjects
in both the T800 + Q and T1200 + Q groups. This was despite
the findings of the short pilot study clearly showing that oral Q
at 75 (ig/day markedly suppressed blood PRL concentrations
towards the minimum assay detection limit. There are several
possible explanations to account for this anomaly. The first is
that the subjects failed to comply with the experimental
protocol of taking daily Q. However, monthly tablet returns
and rigorous questioning at the monthly clinical monitoring did
not suggest a significant level of non-compliance. Given that
the elimination half-life of quinagolide is 17.5 h (Brownell
et al., 1996), the omission of occasional tablets is unlikely to
have had a significant long-term effect on PRL control.
Moreover, at the end of the treatment period, there was a
notable increase in PRL concentrations in all subjects that
received Q. This is a rebound response to chronic dopamine
receptor agonist withdrawal and further supports our conten¬
tion that subject compliance was good. The second explanation
is that chronic Q treatment resulted in the development of
refractoriness to PRL inhibition. Q is routinely used clinically
in the treatment of hyperprolactinaemia in both men and
women without clear evidence of long-term loss of respon¬
siveness (Homburg et al., 1990; Schultz et al., 2000). Such
refractoriness, however, may obtain in the suppression of PRL
in men with normal physiological concentrations ofPRL (Rana
et al., 1995).
The third, and perhaps most important factor, is that the
testosterone treatments themselves activated PRL secretion,
thus rendering the Q less effective. Previous work has shown
that plasma PRL concentrations are significantly increased in
men treated with testosterone enanthate injections (Bellis et al.,
1998). In the current study, blood PRL concentrations were
significantly increased in the placebo treated subjects 4 weeks
after the administration of the 1200 mg testosterone implants.
Furthermore, it is well known from pituitary cell culture studies
using animal tissues that both testosterone and estradiol
potently stimulate PRL synthesis and release due to a direct
genomic effect on the lactotroph (Shull et al., 1985; Lambert
and McLeod, 1990). This can occur independently of the
inhibitory effect of dopamine receptor activation. Clinical
studies also support the view that sex steroid status affects PRL
secretion. For example, the efficacy of bromocriptine in the
suppression of PRL secretion is reduced in hyperprolactin-
aemic women during pregnancy when estradiol concentrations
are increased and PRL secretion decreases in the menopause
and after pregnancy when sex steroid concentrations decline
(Karunakaran et al., 2001). Such steroid effects on PRL
secretion in our trial subjects would render Q inhibition of PRL
less effective. These effects of chronic treatment in normal men
were not anticipated, but clearly compromised the objective of
this study.
A final point is that Q was well tolerated with no serious
adverse effects reported. Prolactin acts in multiple target
tissues including brain, liver, skin, prostate and accessory
glands. Despite this, chronic PRL suppression using Q had no
demonstrable effects on semen volume, sexual behaviour and a
wide range of haematological and biochemical indices demon¬
strating desirable specificity of action on the reproductive axis.
Treatment with testosterone produced the expected effects on
HDL cholesterol (Wallace and Wu, 1990), but this was not
blocked or enhanced by the manipulation of PRL. There were a
number of casual observations on the effect of chronic PRL
suppression. The incidence of acne was lower than expected
and two subjects noted an improvement in the condition of
their skin and hair.
Conclusions
The current study investigated for the first time whether
manipulation of PRL would enhance the efficacy of testoster¬
one in the suppression of spermatogenesis in men. The results
did not support this idea. Unexpectedly it proved difficult to
achieve consistent long-term inhibition of PRL secretion in the
men. Future studies will need to establish a means of totally
blocking PRL release, or to utilise a cross-over design in which
all subjects receive both PRL inhibitor and placebo, to test
whether concomitant testosterone and PRL blockade will
induce complete spermatogenic arrest. The idea of employing
lower levels of testosterone, and reducing PRL due to its
trophic effects on the prostate, make a combined preparation of
this kind an attractive prospect in the regulation of male
fertility.
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This study investigated the effect of transdermal T and oral
desogestrel on the reproductive axis ofhealthy men. Twenty-
three men were randomized to 1 of 3 treatment groups and
received a daily transdermal T patch plus oral desogestrel at
a dose of 75, 150, or 300 /xg/d for 24 wk. Baseline blood and
semen samples were obtained and then every 4 wk thereafter
for 32 wk. The outcome measures were sperm density and
plasma levels of FSH, LH, total and free T. The results show a
dose-dependent suppression of spermatogenesis and gonad¬
otropins. Seven of the 17 subjects became azoospermic. Deso¬
gestrel (300 pg daily) in combination with 5 mg daily trans¬
dermal T was the most effective (57% azoospermic), whereas
a dose of 75 pg was ineffective (0% azoospermic). Total and
free plasma T were reduced by approximately 30%. High den¬
sity lipoprotein cholesterol was significantly reduced. No se¬
rious side-effects were encountered. We conclude that daily
self-administered desogestrel with transdermal T is capable
of suppressing the male reproductive axis, although the effi¬
cacy was less marked and less consistent than injectable reg¬
imens. The lower efficacy is likely to be due to failure of the
transdermal T system to maintain circulating T levels consis¬
tently in the required range. (J Clin Endocrinol Metab 86:
5201-5209, 2001)
THE PRINCIPLE THAT exogenous sex steroid-inducedoligo- and azoospermia can confer effective, reversible
contraceptive protection in men was established in two mul-
ticenter trials employing an androgen-only prototype regi¬
men of im injections of T enanthate (1, 2). The pharmacoki¬
netics of T enanthate are such that a relatively high dose (200
mg), administered at weekly intervals, is required to ensure
maximum suppression of gonadotropins and spermatogen¬
esis (3). This regimen produced repeated supraphysiological
peaks and markedly fluctuating levels of T (4) which induced
significant extra-gonadal androgenic effects on lipid metab¬
olism, skin, muscle, liver and hemopoiesis (5). These un¬
wanted effects coupled with the impracticality of uncom¬
fortable weekly im injections underline the need to use lower
doses of T with more stable delivery in hormonal male
contraception.
Spermatogenesis can be effectively suppressed by com¬
bining a reduced dose of T with a second antigonadotropic
agent such as a progestagen (6) or GnRH antagonist (7). We
previously reported that im T enanthate at the relatively low
doses of only 100 or 50 mg weekly, if combined with a
19-nortestosterone-derived oral synthetic progestin, deso¬
gestrel (DSG), can suppress spermatogenesis very effectively
in men; the best dose combination, 300 jug DSG daily with 50
mg T enanthate weekly, induced consistent azoospermia in
all subjects (8). This study also showed that DSG and T both
contributed additively and interchangeably to the reproduc¬
tive as well as the nonreproductive metabolic effects, e.g.
reduction of high density lipoprotein cholesterol (HDL-C)
and SHBG levels. T enanthate (50mg, im, weekly), delivering
Abbreviations: DSG, Desogestrel; HDL-C, high density lipoprotein
cholesterol; LDL-C, low density lipoprotein cholesterol.
5 mg free T daily, is regarded as the minimal effective dose
and also the minimal dose required to maintain androgen
sufficiency. Although it can be surmised that lower doses of
DSG or alternate formulations of T, which can reproduce
stable physiological (rather than sharply fluctuating) levels,
may reduce these unwanted actions, the minimally effective
dose combination is currently unknown.
Transdermal T delivery systems have been recently de¬
veloped for use as a noninvasive method of androgen re¬
placement therapy in hypogonadal men (9, 10). Daily self-
application of these systems offers the potential of
maintaining stable levels of T within the normal range with
a small diurnal fluctuation that closely mimics the physio¬
logical pattern.
To date, few male contraceptive studies have employed an
entirely subject-administered regimen. As this is likely to be
preferred by the majority of potential users, it is important
to determine whether daily self-administration, independent
of provider or research personnel, can still be effective. This
will give important clues about the tolerance or margin of
safety in hormonal male contraceptive regimens against a
backdrop of the varying levels of compliance that will in¬
evitably be encountered with preventative medications
across any population.
We have conducted a study that employs a novel, non¬
invasive, daily, self-administered treatment regimen to effect
reversible suppression of spermatogenesis in healthy male
volunteers. The specific aims of the study were 1) to evaluate
the effects of oral DSG combined with a nonscrotal trans¬
dermal T delivery on gonadotropin secretion and spermat¬
ogenesis; 2) to compare the effects of reducing doses of DSG
combined with a fixed dose of T designed for physiological
androgen replacement; 3) to determine the minimally effec-
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tive contraceptive combination and the tolerance for break¬
through of suppression in this self-administered regimen;




Of 101 respondents to our advertisements, 33 were suitable for screen¬
ing. After the initial interview and screening tests, 10 were excluded
because of low sperm counts (n = 5) or high cholesterol (n = 5), leaving
23 Caucasian men (mean age, 34.2 ± 7.0 yr; range, 20-43 yr) to take part
in the study.
Study design
Subjects who met the admission criteria similar to our previous study
(8) were randomized into one of three treatment groups to receive 1) oral
DSC (300 pg daily) and transdermal T (5 mg daily; n = 7), 2) oral DSG
(150 p.g daily) and transdermal T (5 mg daily; n = 6), or 3) oral DSG (75
fig daily) and transdermal T (5 mg daily; n = 4) for 24 wk in a single
blind, parallel group design.
Subjects were studied in three phases. 1) In the control phase medical
screening examination, two baseline semen analyses, and hormonal and
biochemical assessments were carried out over 4 wk. 2) In the treatment
phase each subject was randomly allocated to one of the three treatment
groups described above. Both transdermal T and DSG were adminis¬
tered for 24 wk. Medical review, including physical examination, blood
sampling, and semen analyses, were performed every 4 wk. 3) In the
recovery phase all subjects were monitored every 4 wk by medical
review, semen analysis, and blood sampling until recovery criteria were
satisfied; namely, geometric mean pretreatment sperm density was
reached or two consecutive specimens showed sperm density greater
than 20 million/ml.
All subjects provided informed written consent and were advised to
continue with their existing forms of contraception during the study. The
study was approved by the Central Manchester Healthcare Trust ethical
committee for medical research.
Medications
Desogestrel (75- and 150-fig tablets) were supplied by NY Organon
(Oss, The Netherlands). Each subject received one tablet per d in the case
of the 75- and 150-frg tablets or two 150-fig tablets in the case of the 300
fxg/d group. Tablets were taken in the evening before bed. T was
administered by the volunteers as two transdermal delivery systems
(Andropatch, SKB, Welwyn Garden City, UK) applied to skin of the
upper back, legs, or flanks and changed daily at bedtime, employing a
different site at each application.
Clinical monitoring
Subjects were interviewed monthly, with particular emphasis on
eliciting any side-effects,monitoring sexual function, and checking med¬
ication compliance. The latter consisted of direct questioning and count¬
ing tablets and patches remaining in returned containers. Each subject
was also asked to record the occasions they missed their medications in
writing. Body weight, pulse, and blood pressure were measured
monthly, and testicular size (by orchidometer) was measured every 3
months. A digital prostate examination was carried out before treatment
and on recovery.
Semen analysis
Semen collection and analysis of semen volume, sperm density, and
motility were carried out according to the WHO Laboratory Manual for
the Examination of Human Semen and Sperm-Cervical Mucus Interac¬
tion. The suppression targets are defined as: azoospermia, complete
absence of spermatozoa in the ejaculate verified by centrifugation of a
whole semen sample; severe oligospermia, sperm concentration of less
than 1 million/ml; and oligospermia, sperm concentration of less than
3 million/ml in one sample.
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Blood tests
Blood samples were obtained twice before treatment and at 4-wk
intervals thereafter for hormone measurements (T, LH, FSH, and SHBG)
and hematological (hemoglobin, hematocrit, and white cell count), bio¬
chemical (urea, electrolytes, liver enzymes, glucose, and hemoglobin
Alc), and lipid profiles [total cholesterol, low density lipoprotein cho¬
lesterol (LDL-C), HDL-C, triglycerides, and apolipoprotein Al].
Hormone assays
All plasma samples were stored at -20 C until assay. Plasma go¬
nadotropins were assayed by previously reported highly sensitive im-
munofluorometric assays (Delfia, Pharmacia-Wallac, Inc., Turku, Fin¬
land) (10) with an assay sensitivity of 0.05 IU/ml for both LH and FSH.
Twas determined by previously describedRIAwith an assay sensitivity
of 0.3 nmol/liter (11). SHBG was determined by an immunoradiometric
assay (Farmos Diagnostica, Oulun Salo, Finland). Free Twas determined
using an established equilibrium dialysis technique (12). All serial sam¬
ples from one individual were assayed in a single batch to reduce
variability.
Biochemical analyses
Full blood count, glucose, hemoglobin A,c, lipids (total cholesterol,
HDL-C, and triglyceride), and renal and liver function was measured by
routine autoanalyzer methods. LDL-C was derived from the other lipid
indices using Friedwald's formula.
Statistical analyses
The data were analyzed by repeated measuresANOVA, paired t tests,
and one-way ANOVA with Tukey's post-hoc test for continuous vari¬
ables with statistical significance set at P < 0.05. Values were expressed
as the arithmeticalmean ± sem. LH and FSH levels below the sensitivity




Seventeen subjects completed the suppression phase, and
6 subjects were discontinued (see below). The mean sperm
densities before, during, and after DSG and transdermal T
administration in each of the 3 treatment groups are shown
in Fig. 1A. The rates of suppression to three target sperm
densities, i.e. azoospermia (no sperm), severe oligospermia
(<1 million/ml), and oligospermia (<3 million/ml), are
shown in Fig. IB. Sperm density was significantly (P < 0.05)
reduced in all treatment groups with respect to baseline
showing a clear dose dependence, although the differences
between treatment groups failed to achieve significance.
Seven (41%) of the 17 subjects who completed the suppres¬
sion phase achieved azoospermia. Nine (53%) of the 17
achieved suppression to less than 1 million/ml, with no
additional subjects achieving suppression to less than 3 mil¬
lion/ml. The most effective drug regimen was 300 pg DSG
and 5 mg transdermal T daily in which 4 (57%) of the 7
subjects achieved azoospermia, the earliest by wk 8 and the
remainder by wk 16. One additional subject suppressed to
less than 1 million/ml by wk 12, giving a total of 71% for this
group. In the 150 pg DSG group, 3 (50%) of the 6 subjects
achieved azoospermia, the earliest by wk 8, and the others by
wk 12, while the remainder failed to suppress to oligosper¬
mia. In the 75 pg DSG group none of the 4 subjects achieved
azoospermia, although 1 became severely oligospermic (<1
million/ml) by wk 12, whereas the others (75%) remained
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Fig. 1. Suppression ofspermatogenesis. A, Individual sperm density profiles for subjects in each ofthe three treatment groups at 4-wk intervals
during 24 wk of treatment. B, Rates of suppression of spermatogenesis indicated by the percentage of subjects attaining azoospermia (■) or
oligozoospermia below 1 million/ml (H) and below 3 million/ml (□) over the same time course. Subjects received transdermal T (5 mg/d) plus
daily oral DSG at a dose of 300, 150, or 75 p,g.
outside the oligospermic range, with sperm densities above
10 m/ml throughout treatment. Pretreatment sperm densi¬
ties were not significantly different between the azoospermic
or oligozoospermic responders and the nonsuppressors.
Examination of the individual sperm density profiles in
each group demonstrates marked heterogeneity of response
within treatment groups (Fig. 1A). In 4 of the 7 subjects who
achieved azoospermia there was escape from suppression
before the end of the treatment period; the others remained
fully suppressed until treatment ended. This phenomenon
was also observed in 1 of the 2 subjects who became severely
oligospermic. Sperm density values began to recover within
4wk of cessation of therapy. All but 1 of the subjects achieved
the recovery criteria by wk 48 (i.e. 24 wk after the end of
treatment). One subject, despite normal gonadotropin levels,
did not recover until wk 64. His T levelswere also subnormal
over a similar time course, although his gonadotropin levels
were normal.
LH
LH levels were significantly (P < 0.05) suppressed during
the treatment phase in all treatment groups from wk 4 on¬
ward. Suppression was dose dependent, the most effective
being in the 300 p,g DSG group, although the difference
between treatment groups did not achieve statistical signif¬
icance (Fig. 2). In the 300 /xg DSG group, LH was significantly
(P < 0.05) suppressed from a baseline mean of 4.5 ± 0.7
U/liter to a nadir of 0.2 ± 0.1 U/liter (wk 8), whereas in the
150 pg DSG group mean levels fell from 4.5 ± 1.0 U/liter to
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a nadir of 0.8 ± 0.3 U/liter (wk 4). In the 75 /xg DSG group
LH levels were suppressed from a baseline mean of 4.6 ±1.5
to 0.9 ± 0.7 U/liter (wk 12). Suppression of LH was not fully
maintained during continued treatment. In the 300 /xg DSG
group, LH decreased to below the assay detection limit ini¬
tially in four subjects and to less than 0.3 U/liter by wk 8 in
the other three subjects. Between wk 8 and the end of treat¬
ment, all subjects in this group showed some degree of es¬
cape, mostly transient and below 0.8 U/liter, except for one
which broke through to 1.6 U/liter at wk 16 having had
undetectable LH 4 wk earlier. In the 150 /xg DSG group, LH
suppressed to below assay detection in four of the six sub¬
jects, two of whom escaped while the other two maintained
undetectable LH until the end of treatment. In the 75 |Ug DSG
group, suppression was variable, and no subject had detect¬
able levels.
The pretreatment LH level was significantly higher in sub¬
jects who did not respond compared with those that sup¬
pressed to azoospermia and oligozoospermia (<3 M/ml).
This was largely attributable to one unresponsive subject
with a baseline LH of 9.1 U/liter. Tire mean LH level during
treatment was significantly lower in azoopernric and oligo-
zoospermic responders compared with nonresponders. In all
subjects LH recovered to baseline within 4 wk after cessation
of treatment. There was no significant difference in the rate
of recovery in the three treatment groups.
FSH
FSH levels were significantly (P < 0.05) suppressed during
the treatment phase in all treatment groups. Suppression was
dose dependent, the most effective being in the 300 p.g DSG
group, although the difference between treatment groups
did not achieve statistical significance (Fig. 2). In the 300 /xg
DSG group, FSH was significantly suppressed from a base¬
line mean of 2.7 ± 0.3 U/liter to a nadir of 0.4 ± 0.2 U/liter
(wk 8), whereas in the 150 /xg DSG group, mean levels fell
from a baseline of 4.2 ± 0.5 U/liter to a nadir of 0.5 ± 0.3
U/liter (wk 4). In the 75 /xg group mean FSH levels fell from
a baseline of 3.4 ± 0.4 to a nadir of 0.9 ± 0.4 (wk 8). There
was a consistent pattern of gradual escape from suppression
after wk 8 in all three groups.
In both the 300 and 150 /xg DSG groups, FSH suppressed
to below assay detection limits in three subjects, but only one
in each group maintained the suppression until the end of
treatment. In the 75 /xg DSG group, FSH suppressed to less
than 1.0 U/liter in two subjects, but only transiently.
There was no difference in pretreatment FSH levels in
subjects who suppressed to azoospermia and oligozoosper¬
mia (<3M/ml) compared with those who did not. The mean
FSH level during treatment was significantly lower in
azoopermic and oligozoospermic responders compared with
nonresponders. FSH recovered rapidly on cessation of treat¬
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Fig. 2. Hormone data: group means. The levels of plasma FSH, LH, and total and free T at 4-wk intervals during the 24-wk treatment period
and the subsequent recovery period are shown. Groups received transdermal T (5 mg/d) plus daily oral DSG at a dose of 300, 150, or 75 /xg.
Values are the mean ± SEM. Subjects received transdermal T (5 mg daily) plus oral DSG at a dose of 300 /xg (solid rhomboids), 150 /xg (solid
squares), or 75 /xg (solid triangles).
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treatment assessment. There was no significant difference in
the rate of recovery in the three treatment groups.
T
Mean total T levels were significantly (P < 0.05) decreased
during the treatment phase compared with baseline in all
three groups, although they remained within the normal
physiological range throughout the study. There was no
significant difference in total T between the three groups. In
the 300 /trg DSG group, T levels fell from a baseline of 22.0 ±
2.7 nmol/liter to treatmentmean of 14.2 ± 2.5 (64.5% of basal)
and a nadir of 12.5 ± 2.2 nmol/liter (wk 20), whereas in the
150 ;ug DSG group, levels fell from a baseline of 25.2 ± 3.1
nmol/liter to a mean of 17.8 ± 2.7 (70.6% of basal) and a nadir
of 15.5 ± 3.1 nmol/liter (wk 24). In the 75 /xg DSG group T
levels decreased from a baseline of 21.3 ± 1.8 nmol/liter to
a mean of 16.4 ± 2.4 (76.8% of basal) and a nadir of 11.4 ±
2.8 nmol/liter (wk 8).
Free T levels also decreased significantly (P < 0.05) during
the treatment phase. In the 300 /itg DSG group levels fell from
baseline mean of 0.28 ± 0.03 nmol/liter to a treatment period
mean of 0.17 ± 0.01 nmol/liter (61.6% of basal). In the 150 pg
DSG group free T levels fell from 0.31 ± 0.03 to 0.24 ± 0.04
nmol/liter (78.4%) and in the DSG 75 pg group T levels fell
from 0.30 ± 0.01 to 0.20 ± 0.03 nmol/liter (66.3% of basal).
There was no difference in pretreatment total T levels in
subjects who suppressed to azoospermia and oligozoosper-
mia (<3 m/ml) compared with those who did not. The mean
T during treatment was not significantly different in
azoopermic and oligozoospermic responders compared with
nonresponders. Total and free T levels returned to pretreat¬
ment levels by the end of the recovery period in all groups.
SHBG
SHBG levels were significantly reduced (P < 0.05) in all
treatment groups during the treatment phase, although there
was no significant difference between treatment groups in
this regard. In the 300 pg DSG group, mean levels fell from
a baseline of 31.3 ± 4.8 nmol/liter to a nadir of 20.7 ± 3.9 (wk
12), whereas in the 150 pg DSG group levels fell from baseline
mean of 30.2 ± 6.7 nmol/liter to a nadir of 22.5 ± 5.5 nmol/
liter (wk 24). In the 75 pg DSG group, levels fell from a
baseline mean of 35 ± 8.92 nmol/liter to a nadir of 27.8 ± 6.3
nmol/liter (wk 12). SHBG levels returned to pretreatment
levels by the end of the recovery period in all groups.
Biochemical and hematological parameters
There were no significant changes in plasma urea, creat¬
inine, sodium, potassium, calcium, alkaline phosphatase,
aspartase amino transferase, alanine amino transferase,
y-glutamyl transpeptidase, bilirubin, glucose, HbAlc, hemo¬
globin, hematocrit, white cell count, or platelets during treat¬
ment (data not shown).
Lipids
HDL-C was significantly decreased (P < 0.05)with respect
to baseline during treatment in all groups. In the 300 pg DSG
group, HDL-C fell from a baseline of 1.34 ± 0.10 mmol/liter
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to a nadir of 1.11 ± 0.06 mmol/liter (wk 24), a fall of 17%. In
the 150 pg DSG group, HDL-C fell from a baseline of 1.29 ±
0.15 mmol/liter to a nadir of 0.86 ± 0.06 mmol/liter (wk 16),
representing a fall of 33%. In the 75 pg DSG group, HDL-C
fell from a baseline of 1.18 ± 0.17 mmol/liter to a nadir of
0.90 ± 0.02 mmol/liter (wk 12), a fall of 24%. The differences
in HDL-C suppression between treatment groups did not
achieve statistical significance. Overall, the mean decrease in
HDL-C levels at the end of the treatment period was 12 ±
3.2%.
There were no significant changes in total cholesterol,
LDL-C, triglycerides, or apolipoprotein Al. Total cholesterol
was significantly increased in the recovery period compared
with baseline; this significance disappeared on removing one
outlier from the analysis. All other lipid parameters returned
to pretreatment levels by the end of the recovery phase in all
treatment groups.
Physical changes
There was a small, but significant (P < 0.001), increase of
1.94 ± 0.56 kg (range, -4 to +7kg) in body weight by the end
of the treatment phase. This gain persisted; the average
weight gain at the end of the recovery period was 2.53 ±0.67
kg (range, -3 to +9.5kg). There was no significant difference
between treatment groups in this regard. Testicular volume
decreased by an average of 3.3 ± 1.1 ml (range, 0-7.25 ml)
during treatment and returned to pretreatment values by the
end of the recovery phase. There were no significant changes
in systolic or diastolic blood pressure throughout the study.
Discontinuations, side-effects, and compliance
There were 6 discontinuations; 2 were due to marked and
persistent skin reaction to the T patches, and the remaining
4 subjects were either lost to follow-up before completion of
the study (n = 2) or withdrew for nontreatment-related rea¬
sons, i.e. job relocation or marital discord (n = 2). During the
treatment phase 11 subjects reported side-effects, namely
increased sex drive (n = 4), decreased sex drive (n = 7),
emotional lability (n = 2), irritability (n = 5), and tiredness
(n = 2), although these were transient in nature and unre¬
lated to treatment groupings. In addition, 15 (65%) of the
subjects reported skin reactions of varying degree to the T
patches. In 3 subjects the reaction was classified as mild
(transient erythema), whereas in an additional 8 subjects the
reaction was classified as moderate (marked erythema and
itch requiring treatment with topical hydrocortisone). The
remaining 4 subjects were classified as having severe reac¬
tions, manifest as marked skin erythema and blistering.
Most of our subjects reported full compliance with the
drug regimen. Closer questioning, however, revealed prob¬
lems with the transdermal patches other than the significant
skin reaction. These included patch removal to swim, play
sports, or participate in lovemaking; patch detachment with
excess perspiration or showering; and poor patch adhesion
to hirsute skin and in hot weather. It was therefore difficult
to accurately assess the degree of noncompliance with the T
patch. As daily oral DSG administration was not subject to
the same problems as transdermal application and skin re¬
action, there was no reason to doubt the high degree of
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compliance reported, and this was confirmed by the tablet
counts. This showed that compliance with oral medication
was 90-95%.
Discussion
Previous studies in hormonal male contraception have
overwhelmingly employed im injections of T (enanthate in
particular) in doses (200 mg weekly) that generated supra-
physiological levels in the circulation (13). Consequently, not
only have side-effects been observed, but the minimal effec¬
tive dose for spermatogenesis suppression has remained un¬
defined. In the development of new therapies, it is important
to demonstrate the extent of the safety margin for break¬
through and the tolerance to variable/suboptimal compli¬
ance. This can only be revealed by systematically investi¬
gating the effects of reducing doses and establishing the
minimally effective dose level. In our previous study (8) we
showed that spermatogenesis suppression could be effec¬
tively achieved even when im T enanthate was reduced to the
lowest physiological maintenance dose of 50 mg weekly
(equivalent to 5 mg unesterified T daily) when combined
with the synthetic oral progestin, DSG. However, despite
substantially reducing the total dose, the suboptimal phar¬
macokinetics of T enanthate inevitably produced sharp fluc¬
tuations with supraphysiological postinjection peak T levels
(14). This contributed to demonstrable nonreproductive ef¬
fects and rendered interpretation of minimal effective doses
of drug combinations difficult. At the equivalent dose of 5mg
T daily, transdermal systems can maintain stable physiolog¬
ical levels of T and offer the opportunity to investigate the
minimal dose combination of progestin required to suppress
spermatogenesis effectively.
In the present study a downward dose-ranging designwas
employed to determine the threshold dose of DSG combined
with a fixed daily amount of 5 mg transdermally delivered
T for suppression of spermatogenesis. We have demon¬
strated a trend of progressively declining efficacy in achiev¬
ing the three target levels of sperm density with reducing
doses of DSG. Three hundred and 150 /xg DSG daily induced
azoospermia in 57% and 50% of subjects, respectively. This
is approaching the range of azoospermic suppression ob¬
served with 500 /xg levonorgestrel with 100 mg T enanthate
weekly (67%) (15), 200 mg T enanthate weekly (1) (65%), and
1200 mg T implants (16) (56%) in Caucasian men. Suppres¬
sion to oligozoospermia (either <1 or <3 M/ml) in the
present study (71% and 50% with 300 and 150 /xg DSG,
respectively), however, was clearly inferior to the other reg¬
imens (8, 17, 18), which can achieve the less than 3 M/ml
target in 94-100% of subjects. Below 150 /xg/d DSG, there
was amarked drop in effectiveness, with none of the subjects
achieving azoospermia. Nevertheless, even at this subopti¬
mal dose, one of the four subjects suppressed to less than 1
million/ml consistently, whereas the other three failed to
reach sperm densities less than 10 M/ml. This divergence in
responsiveness was also observed in the 150 /xg, but not the
300 /xg, DSG group. Thus, in contrast to previous studies that
emphasized the resistance to achieving azoospermia in a
minority ofmen receivingmaximal doses (19), we have dem¬
onstrated a marked between-subject variation in sensitivity
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to hormonal suppression by exploring threshold (150 /xg
DSG daily) to subthreshold (75 /xg DSG daily) doses of treat¬
ment. This heterogeneity in suppression suggests that a sub¬
stantial proportion, perhaps up to 50%, of healthy men are
able to respond to much lower doses of exogenous sex ste¬
roids than customarily used in attaining effective contracep¬
tion in previous studies. In common with others (20) we have
not been able to identify these susceptible individuals by any
baseline characteristics, such as sperm density, gonadotro¬
pins, T levels, or body mass index, but they tend to show a
more precipitous decline in sperm density within the first 8
wk after starting treatment.
Suppression of spermatogenesis with daily oral DSG and
transdermal T was also less effective than with similar doses
of DSG combined with weekly im injections of T enanthate
(Table 1), although the speed of decline in sperm density was
not different (8, 21). This was particularly true for the oli-
gospermic targets. In the previous studies using DSG (8, 21)
the least effective combination employing 150 /xg DSG daily
with 50 mg T enanthate weekly produced suppression rates
similar to the best results obtained in the group receiving 300
mg DSG with 5 mg transdermal T. Furthermore, the break¬
through of suppression in three of the seven men who
reached azoospermia and the partial recovery or escape be¬
fore the end of the treatment period in most subjects was not
observed previously with DSG and T enanthate or T enan¬
thate alone. It appears that substituting transdermal T for im
T enanthate has resulted in a loss of efficacy in spermato¬
genesis suppression.
Similarly, inhibition of gonadotropins by DSG and trans¬
dermal T was less effective and less consistent than previous
regimens employing im T enanthate. Suppression of gonad¬
otropins showed the same dose-related trend as spermato¬
genesis suppression, with LH and FSH reaching assay sen¬
sitivity in 57% and 43% of subjects, respectively, in the 300
/xg DSG group and none in the 75 /xg group. In line with
sperm density, very few subjects maintained consistent sup¬
pression of gonadotropin, most showing transient escape or
partial recovery before the end of treatment. Unsurprisingly,
azoospermic and oligozospermic responders achieved sig¬
nificantly lower levels of gonadotropins than nonresponders
during treatment. It is therefore highly probable that the
inadequate suppression of spermatogenesis engendered by
reducing doses of DSG and transdermal T is due to incom¬
plete inhibition of gonadotropins.
The torso transdermal T delivery system has been shown
to produce physiological circulating T levels in hypogonadal
men (9,10,22). In eugonadal men rendered hypogonadal by
exogenous sex steroid in the present study, however, total T
decreased from baseline by about 30% during treatment, but
mean levels at 16.1 ± 2.4 nmol/liter (all three groups com¬
bined; normal, 10-35 nmol/liter) remained within the phys¬
iological range. Equilibrium dialysis-measured free T levels
also decreased significantly by similar extents as total T. A
lower SHBG concentration, associated with DSG and other
oral synthetic progestin treatment, therefore did not correct
for the low total T, and an absolute decline in circulating
bioavailable T levels was extant during treatment. Insuffi¬
cient T may therefore be one explanation for the lower ef¬
ficacy in gonadotropin and spermatogenesis suppression
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compared with other studies using the same doses of oral
DSG (Tables 1 and 2). Nevertheless, this study showed that
improved suppression of spermatogenesis can be obtained
with DSG and transdermal T compared with levonorgestrel
combined with a similar dose but a different transdermal T
preparation (23) and also compared with cyproterone acetate
and oral T undecanoate (24) (Table 2). This may be related to
the varying biopotencies and efficiencies of the different
progestins and/or preparations of noninjection T. Our re¬
sults suggest that self-administration of male hormonal con¬
traceptive steroids is potentially viable, particularly in more
responsive individuals. However, the transdermal systems
are clearly less reliable than injectable T regimens (see be¬
low). The loss of efficacy when weekly im injections of T
enanthate is substituted by daily self-administered nonin¬
jection preparations of T is a consistent finding across all
three paired comparisons (Table 2). This highlights the crit¬
ical role of T in male hormonal contraception.
Tire lower efficacy associated with noninjection delivery of
T merits further consideration. When the supraphysiological
dose of 100 mg T enanthate (14) was coadministered with
LNG or CPA, the higher dose and the higher peak levels of
T compared with the transdermal dose of 5 mg daily and the
T undecanoate dose of 80 mg twice daily may account for the
superior efficacy. However, in our two studies with DSG and
T (Table 2), we deliberately targeted comparisons with a
lower, yet effective, dose of 50 mg T enanthate weekly, im,
which delivers 5 mg unesterified T daily, an amount equiv¬
alent to the daily delivery rates of the transdermal system
studied. The mean T levels, therefore, should not be very
different. The fluctuating T levels giving high postinjection
peaks with T enanthate are probably not required for max¬
imal gonadotropin suppression, as relatively stable T levels
generated by 800-rng T implants combined with depo
medroxyprogesterone acetate was highly effective (25). Scru¬
tiny of individual profiles showed that many subjects in our
study had transient decreases in total and free T levels to the
hypogonadal range with concomitant or subsequent escape
in gonadotropins and sperm density (Table 3, subject 1). In
contrast, the few individuals whose T levels were maintained
in the normal range throughout the treatment phase were
able to sustain suppression of gonadotropins and spermat¬
ogenesis throughout treatment (Table 3, subject 2). Analo¬
gously, the short half-life of oral T undecanoate and its un¬
predictable absorption (26) make it unlikely that twice daily
administration can maintain stable T levels within the phys¬
iological range (27). These observations suggest that the com¬
mon thread that links the low efficacy in the three studies
using noninjectable T preparations is likely to be nonmain-
tenance of adequate T levels, which may have resulted from
pharmacokinetic and delivery problems or noncompliance.
The consequence of these intermittent troughs in circulating
Tmay not be important or clinically evident in hypogonadal
replacement, but is likely to be of critical importance in the
maintenance of spermatogenesis suppression for contracep¬
tion. The cumulative effects of repeated falls in T (probably
underestimated by monthly monitoring) provide the most
likely explanation not only for the lower initial efficacy, but
also the subsequent breakthrough and progressive escape
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TABLE 2. Comparison of efficacy of spermatogenesis suppression between the present study and other progestin and T combinations as








TTS T (5 mg/d)
LNG (250 mg/d)c
TE (100 mg/wk)
CPA (12.5 mg dailyh
Oral TU (80 mg daily)
CPA (25 mg/d)"
TE (100 mg/wk)
Oligo <3 M/ml 71 100 45 89 63 100
Oligo <1 M/ml 71 100 45 89 38 100
Azoospermia 57 100 18 78 13 100
Loss ofefficacy in regimens employing noninjectable T preparations is apparent regardless of the type ofprogestin used in the combinations.
Oligo, Oligozoospermia; DSG, desogestrel; LNG, levonorgestrel; CPA, cyproterone acetate; TTS T, transdermal therapeutic system T; TU, T
undecanoate; TE, im T enanthate; M, million.
° Wu et al. (n = 8; 24-wk treatment).
h Buchter et al. (n = 11; 24-wk treatment).
" Anawalt et al. (n = 18; 24-wk treatment).
d Meriggiola et al. (n = 8; 16-wk treatment).
" Meriggiola et al. (n = 5; 16-wk treatment).
TABLE 3. Individual hormone profiles for two subjects
Wk
-4 -2 4 8 12 16 20 24 28 32
Subject 1
LH" 2.9 3.5 0.05 0.05 0.05 0.05 0.3 0.05 5.2 2.7
FSH 2.8 3.1 0.12 0.09 0.08 0.08 1.6 0.05 3.8 2.8
Free T6 10.1 8.19 7.72 3.99 3.27 0.3 0.29 8.75 6.53 5.7
Sperm 89 184 42 5 0.1 0 2 1.2 4.2 4.4
Density"
Subject 2
LH 1.5 1.1 0.05 0.05 0.05 0.05 0.05 0.05 3.1 4.4
FSH 2.5 1.4 0.05 0.05 0.05 0.05 0.05 0.05 6.3 3.8
Free T 8.78 9.79 9.14 11.17 9.85 8.6 9.12 8.08 9.6 9.6
Sperm 58 65 0.8 0 0 0 0 0 0.1 0.1
Density
" Units for gonadotropins are international units per ml.
h Nanomoles per liter.
c Millions per ml.
seen across all three studies using noninjectable T prep¬
arations.
This study also shows that as we descend to lower thresh¬
old doses of DSG, the safety margin is gradually eroded, and
the tolerance of the combination regimen to fluctuations in
T levels becomes increasingly tested. Themargin of safety for
suppression of spermatogenesis to maintain contraceptive
efficacy is relatively narrow. Doses of T adequate for phys¬
iological replacement (5-6 mg daily) represent the minimum
requirement, but only if drug delivery is strictly reliable. This
raises the important issue of compliance in potential contra¬
ceptive users who are healthy young men unaccustomed to
daily self-medication. There was serious doubt concerning
the efficacy and acceptability of transdermal T delivery due
to the difficulties experienced with patch application and the
high incidence (65% of subjects) of skin reactions in agree¬
ment with recent experience with the same preparation in
hypogonadal men (28). These factors will conspire to dis¬
courage high compliance, and it is our view that the trans¬
dermal route will not be the most satisfactory for drug de¬
livery in male contraception unless the current therapeutic
systems are improved considerably. In our previous study
with daily oral DSG combined with weekly im T enanthate,
high compliance with the oral medication was confirmed by
the well maintained plasma levels of etonogestrel (the active
metabolite of DSG) after 6-month treatment and the persis¬
tent lowering of SHBG levels (8). In the current study with
a similar cohort of men, compliance with daily oral DSG
administration was good. Although etonogestrel levels were
not measured, the consistent suppression of SHBG indirectly
attests to satisfactory compliance. Daily oral drug adminis¬
tration does not appear to be problematical for healthy men
seeking contraception.
We have previously shown that DSG alone decreased lev¬
els of HDL-C as well as apolipoprotein Al, an effect aug¬
mented by coadministration of T enanthate. In the present
study with transdermal T, HDL-C was reduced significantly
in all treatment groups. This confirms that in the absence of
high peak T levels, reduction of HDL-C is due to the action
of oral DSG on hepatic lipid metabolism.
Side-effects during this study were relatively uncommon
apart from skin irritation. Symptoms thatmay be attributable
to androgen deficiency were encountered in seven subjects.
However, these were transient in nature, and temporal cor¬
relation with changes in T levels was inconsistent.
In conclusion, we have shown that oral DSG combined
with a nonscrotal transdermal T delivery system produces
suppression of gonadotropins and spermatogenesis, but is
less effective than regimens incorporating injectable T. The
minimally effective dose of DSG is 150 /rg. Escape from
suppression is seen at all dose levels of DSG, particularly in
those subjects inwhom T replacement is notwell maintained.
These findings serve to further emphasize the critical role of
T delivery and highlight some important practical issues
concerning daily self-administered regimens for hormonal
male contraception. In the current state of patch technology,
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the transdermal route of delivery may not be optimal for
male contraception.
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